Non-human mammals comprising at least two human leukocyte antigen (HLA) class I alleles in their genome, methods of making such mammals and uses thereof
By integrating multiple human HLA class I alleles in non-human mammals and constructing ABab.I transgenic mouse models, the limitations of T cell receptor library broadening and tumor-specific antigen identification in the prior art are solved, and the limitations of T cell receptor library broadening and tumor-specific antigen identification are achieved. The functional expression of multiple HLA alleles and the widening of TCR library have improved the success rate of isolation of tumor target TCR.
Patent Information
- Application Number
- CN202380018155.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-01-21
- Filing Date
- 2023-01-23
- Publication Date
- 2024-11-08
AI Technical Summary
The prior art is difficult to effectively broaden the T cell receptor library in order to isolate non-HLA-A2-restricted TCR, limit the isolation of HLA-A2-restricted TCR, and cannot effectively identify and isolate tumor-specific targeting multiple human HLA alleles. Sexual antigen.
By integrating multiple human HLA class I alleles, such as HLA-A, B, C alleles in non-human mammals, to form functional expression and broaden the TCR library, allowing the isolation of multiple HLA-restricted TCRs, and Six HLA alleles were introduced through the PiggyBac transposon strategy to construct an ABab.I transgenic mouse model for identification and isolation of tumor-specific antigens against multiple HLA alleles.
The functional expression of multiple HLA alleles and the broadening of TCR libraries has been achieved, the identification and isolation ability of tumor-specific antigens targeted by multiple human HLA alleles has been improved, and the success rate of isolation of TCR targeted by tumor targets has been enhanced. .
Smart Images

Figure BDA0004956032600000481 
Figure BDA0004956032600000482 
Figure BDA0004956032600000491
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application refers to European Patent Application No. 22152603.1 filed on January 21, 2022, the contents of which are hereby incorporated by reference in their entirety for all purposes.
[0003] Sequence Listing
[0004] This application contains a Sequence Listing in computer readable form, which is incorporated herein by reference. Technical Field
[0005] The present invention relates to a non-human mammal comprising at least two human leukocyte antigen (HLA) class I alleles in its genome, which can be used as a new tool for isolating human T cell receptors selected on unique human HLA class I haplotypes for adoptive T cell cancer therapy. The present invention further relates to a nucleic acid construct comprising encoding at least two human HLA class I alleles, an expression vector comprising such a nucleic acid construct, and a corresponding host cell comprising such an expression vector. The present invention further relates to a method for modifying endogenous HLA alleles of a non-human mammal, and a method for producing a non-human mammal oocyte carrying a modified target sequence in its genome. The present invention also relates to a method for producing a non-human mammal carrying a modified target sequence in its genome. The present invention also relates to a method for producing one or more T cell receptors capable of binding to a target antigen, and a method for identifying epitopes capable of eliciting an immune response thereto. Background Art
[0006] For effective adoptive T-cell therapy (ATT), appropriate selection of tumor-specific antigens (TSAs) is crucial. Frequent somatic driver mutations generate ideal TSAs for ATT to achieve complete tumor elimination, possibly without relapse. In silico algorithms can predict epitopes as TSAs for ATT, however with low probability. Therefore, the accuracy of prediction algorithms still needs to be validated when describing processed neoepitopes.
[0007] Simultaneous verification of the proteasome processing of predicted TSAs and identification of neoantigen-specific T cell receptors (TCRs) is possible due to transgenic mice. One such model developed by Li et al. (Nature Medicine, Vol. 16, No. 9 (2010), 1029-1034 pages) is the ABabDII mouse, which has a complete human TCR locus, knocks out the mouse TCR and MHC class I loci, and is transgenic for the human HLA class I allele HLA-A*02:01 (also referred to herein as HLA-A2). Although it is possible to isolate human TCRs from ABabDII mice, the model is limited to obtaining only a source of HLA-A2-restricted TCRs, thereby limiting epitope identification to HLA-A2 antigens. Moore et al. “Humanization of T cell–mediated immunity in mice” Sci. Immunol. 6, eabj4026 (2021) also reported transgenic mice, called “VelociT” mice, which had been engineered with one human MHC-I (HLA-A2) and one MHC-II (HLA-DR2) allele while eliminating the respective mouse MHC.
[0008] Therefore, there is a need to expand the TCR repertoire for HLA-restricted TCR isolation. Accordingly, it is an object of the present invention to provide tools and methods that allow broadening the TCR repertoire. Summary of the invention
[0009] This object is achieved in particular by transgenic non-human mammals, nucleic acid constructs, compositions, methods and uses having the features of the respective independent claims.
[0010] In a first aspect, the present invention provides a non-human mammal comprising in its genome at least two human leukocyte antigen (HLA) class I alleles (e.g., at least three HLA class I alleles, at least four HLA class I alleles, at least five HLA class I alleles or more), wherein the at least two human HLA alleles are functionally expressed in that the corresponding MHC I polypeptides are expressed on the surface of cells of the mammal and present MHC antigens to which the non-human mammal provides an antigen-specific CD8+ T cell response. In some embodiments, the at least two human HLA class I alleles comprise: (a) at least one human HLA-A allele; and / or (b) at least one human HLA-B allele; and / or (c) at least one human HLA-C allele; and / or (d) (a) and (b); and / or e) (a) and (c); and / or f) (b) and (c); and / or g) (a), (b) and (c). In one embodiment, the non-human mammal comprises at least three human leukocyte antigen (HLA) class I alleles in its genome, wherein the at least three human HLA class I alleles comprise: at least one human HLA-A allele; at least one human HLA-B allele; and at least one human HLA-C allele.
[0011] In a second aspect, the present invention provides a nucleic acid construct comprising a nucleic acid encoding at least two human HLA class I alleles, wherein the nucleic acid construct is capable of functionally expressing the at least two human HLA alleles, in that the corresponding MHC I polypeptides are expressed on the surface of cells of the mammal and present MHC antigens to which the non-human mammal provides an antigen-specific CD8+ T cell response, and optionally, wherein the at least two human HLA class I alleles comprise: (a) at least one human HLA-A allele; and / or (b) at least one human HLA-B allele; and / or (c) at least one human HLA-C allele; and / or (d) (a) and (b); and / or (e) (a) and (c); and / or (f) (b) and (c); and / or (g) (a), (b) and (c). In one embodiment, the nucleic acid construct comprises a nucleic acid encoding at least three HLA class I alleles, wherein the at least three human HLA class I alleles comprise: at least one human HLA-A allele; at least one human HLA-B allele; and at least one human HLA-C allele.
[0012] In a third aspect, the present invention provides an expression vector comprising the nucleic acid construct as described herein.
[0013] In a fourth aspect, the present invention provides a host cell (eg, an isolated and / or recombinant host cell) comprising a nucleic acid construct as described herein and / or an expression vector as described herein.
[0014] In a fifth aspect, the present invention provides a method for modifying endogenous HLA alleles of a non-human mammal, the method comprising: transducing and / or transplanting the non-human mammal as described herein with the nucleic acid construct and / or expression vector as described herein.
[0015] In a sixth aspect, the present invention provides a method for producing a non-human mammal oocyte carrying a modified target sequence in its genome, the method comprising the step of introducing a nucleic acid construct and / or expression vector as described herein into a non-human mammal oocyte.
[0016] In a seventh aspect, the present invention provides a method for producing a non-human mammal carrying a modified target sequence in its genome, the method comprising:
[0017] (a) producing an oocyte as described herein;
[0018] (b) analyzing the presence of said modification in offspring born by a non-human female host to which said oocyte obtained in (a) has been transferred.
[0019] In an eighth aspect, the present invention provides a non-human mammal produced and / or modified by the method for producing a non-human mammal carrying a modified target sequence in its genome as described herein.
[0020] In a ninth aspect, the present invention provides a method for producing one or more T cell receptors capable of binding a target antigen, the method comprising administering the target antigen and / or a nucleic acid encoding the target antigen to a non-human animal as described herein.
[0021] In a tenth aspect, the invention provides a T cell receptor obtained or obtainable by a corresponding method as described herein.
[0022] In an eleventh aspect, the present invention provides a method for identifying an epitope capable of eliciting an immune response thereto, the method comprising administering to a non-human animal as described herein a target antigen suspected of containing an epitope capable of eliciting an immune response thereto.
[0023] In a twelfth aspect, the present invention provides an epitope to which an immune response can be elicited, the epitope being identified by a corresponding method as described herein. The epitope may be natural or non-natural. The non-natural application of the epitope, such as an in vitro mixture, comprises (i) a peptide having an amino acid sequence of an epitope identified by a method as described herein and (ii) one or more MHC proteins (e.g., one or more MHC class I or class II proteins).
[0024] In a thirteenth aspect, the present invention provides use of a non-human animal as described herein for producing one or more T cell receptors capable of binding an antigen of interest.
[0025] In a fourteenth aspect, the present invention provides use of a non-human animal as described herein for identifying epitopes capable of eliciting an immune response thereto.
[0026] In a fifteenth aspect, the present invention provides use of a non-human animal as described herein for identifying one or more T cell receptors capable of binding an antigen of interest. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] The invention will be better understood with reference to the detailed description when considered in conjunction with the non-limiting examples and the accompanying drawings, in which:
[0028] Figure 1 A schematic diagram of the pMHC-I / HLA-I antigen processing pathway is shown (this simplified form does not show all the codomains and adapter proteins involved as chaperones in the antigen processing pathway). 1. Antigen uptake by proteasomes in the cytoplasm. 2. Proteins are processed by protease activity within the proteasome core. 3. The TAP protein complex promotes transport of peptides into the ER. PLC, Erp57 and CRT proteins direct the loading of the peptide onto MHC / HLA. 4. Peptides are transported to the cell surface via the secretory pathway for presentation to CTLs.
[0029] Figure 2 A diagram of tumor-specific neoantigens that bind different human HLA class I haplotypes is shown. Step A is a schematic diagram describing recurrent neoantigens derived from cancer driver point mutations. Step B illustrates the wild-type and mutant configurations screened for 18 class I alleles using affinity prediction software NetMHCServer-DTU, while step C describes the HLA binding strength of 266 mutants revealing non-HLA-A2 binders. Step D shows a computer screen that provides the basis for the generation of ABAb.I mice, which are described herein as examples of non-human transgenic mammals as described herein with six novel HLA class I human alleles.
[0030] Figure 3 A-3C shows the HLA-A2-restricted TRRAP-S722F neoantigen as a target for ATT. Figure 3 A depicts the TRRAP gene. Asterisks indicate the positions of recurrent mutations in the proline-rich N-terminal domain. Figure 3 B shows the nonamer, mutated epitope-S722F ("aa" change highlighted in red) and wild-type epitope-S722 (in green), with predicted IC50 (relative to HLA-A2) of 29 nM and 55 nM, respectively. TRRAP-S722F mutation as a target for ATT in melanoma could benefit approximately 911 patients / years. Figure 3 C shows the presence of human TRRAP orthologs in mice. The mutation position is underlined. The epitope of the nonamer is highlighted in a red box. TRAP nonamer wild type (SEQ ID NO: 27), TRAP nonamer mutant (SEQ ID NO: 30), TRRAP_Homosap (SEQ ID NO: 28), TRRAP_Musmusc (SEQ ID NO: 29).
[0031] Figure 4 A-4F shows the generation and characterization of TRPAP S722F TCR in ABabDII mice. Figure 4 A depicts a TCR discovery pipeline with an immunization schedule as used in the illustrative example. Figure 4 B depicts CD8+ T cells from ABabDII showing S722F peptide reactivity by IFN-γ production (gated on CD3+ cells, n=3). Controls had wild-type S722 peptide or no (w / o) peptide. One representative flow cytometry plot of three responding mice is shown. Figure 4 C shows that in vitro cultured splenic CD8+ T cells (CD4-depleted) from responding mice generated a -9 M peptide IFN-γ. Figure 4 D shows that IFN-γ capture assay enriched S722F-specific T cells (CD8 + IFN-γ 高 ). Figure 4 E shows that 5'-RACE RT-PCR amplified the clonally dominant and subdominant TCR variable chains. Figure 4 F shows on the left the dominant V transduced in human T cells αβ Chains were loaded with titrated peptide nonamers (concentration: 10 -6 M to 10 -12 M) TAP - / - T2 cells (1×10 5 ) and IFN-γ release was measured by ELISA. Figure 4 F shows on the right an endogenous processing assay performed with a cell line naturally expressing mutant TRRAP. PBMC (1×10 5 ) and A375 cells (mutant-S722F + , NY-ESO + ) or with SK-Mel-37 (wild type-S722 + , NY-ESO + ) After overnight co-culture, IFN-γ levels were measured. TCR-ESO recognizes NY-ESO 157-165 Epitopes. Bar graphs represent mean ± SD (n = 2). One representative of three co-culture experiments is shown.
[0032] Figure 5 A-5D shows the design and construction of the polycistronic ABab.I transgene. Figure 5 A shows an overview of the total number of in silico predicted mutant epitopes across 18 HLA alleles. The first 6 HLA alleles (shown in blue shading) reflect the natural human HLA haplotype (the genes present in the ABab.I transgene). Figure 5 B shows that multiplying the three data sets estimates the number of individuals / year with mutations. Figure 5 C shows the total number of individuals / year with mutations (potential for ATT treatment) calculated for 175 binders of mutations for 18 alleles using data from A. and B. The red asterisk highlights the highest ranked HLA allele. Figure 5 D shows at the top a polycistronic ABab.I transgene designed to encode six HLA alleles driven by a single H-2Db promoter and polyadenylation signal, separated by five different "self-cleaving" viral 2A peptide linkers. Figure 5 D shows the individual single chain construct designs at the bottom. Each HLA is a chimeric human-mouse fusion single chain containing the α1 and α2 heavy chain cDNA regions from the corresponding human HLA alleles, and the α3, transmembrane and cytoplasmic domains from the mouse H-2Db gene, both fused to human β2m via a glycine-serine polylinker.
[0033] Figure 6 A-6B shows HLA protein expression analysis of the polycistronic ABab.I transgene. Figure 6 A shows the ABab.I transgene: primary construct (I) and versions modified from the initial design (II, III). I. Primary transgene in which the viral peptide 2A linker separates those HLAs. II. Modified transgene: H-2D bPromoter driven eGFP gene and CMV promoter driven HLA. III. Modified transgenes with different polyadenylation signal sequences. The dotted box shows modifications to the initial primary construct. Figure 6 B shows surface staining of MCA205 cells transiently transfected with constructs from A-I and II. (III. not shown). 48 hours after transfection, cells were stained with pan HLA-ABC antibody (clone: W6 / 32). Controls: pMP71-eGFP (GFP vector, measured in the same channel) and LCL-BM14 (lymphoblastoid), HLA ABC positive. One representative of multiple flow cytometry experiments is given (n>5).
[0034] Figure 7 A-7B shows the mRNA expression profile of the polycistronic ABab.I transgene. Figure 7 A shows I., top, ABab.I primary transgene. I., bottom, by H-2D b or II. Constructs modified with a polyadenylation (pA) signal driven by a CMV viral promoter. Figure 7 B shows the Figure 7 Quantitative RT-PCR analysis of mRNA transcripts of constructs I. and II. shown in A. 48 hours after transfection, the cDNA region of the ABab.I transgene was amplified from MCA205 cell lysate using primers flanking 2A peptide linkers (P2A, F2A, and C2A). b Percent change of mouse MHC class I genes (red dashed line). Bar graph shows mean ± SD (n = 3). P value: ****, P ≤ 0.0001; ***, P ≤ 0.001; ns, not significant (unpaired two-tailed t test).
[0035] Figure 8 A-8C shows HLA expression analysis of a single monocistronic from the ABab.I transgene. Figure 8 A shows the cloning of individual single chains from the ABab.I primary transgene in I., with or without β2m. Each HLA allele is driven as a monocistronic by its own H-2Db promoter and pA signal. The dashed boxes show additional modifications from the primary construct. II. ABab.I transgene expressing six monocistronic (eg Figure 8 AI) as a single haplotype (5'-to-3') with its own regulatory elements. Figure 8 B and Figure 8 C shows MCA205 cells expressing six single chains, which were surface stained with or without IFN-γ pretreatment. HLA-A2 protein was stained as a reference. 48 hours after transfection, Figure 8In B, cells were stained using pan HLA-ABC antibody (clone: W6 / 32). Figure 8 Human β2 microglobulin antibody (clone: ) were used to stain the cells. One representative flow cytometry plot from three experiments is shown.
[0036] Fig. 9 A-9E shows the HLA haplotype expression profile of the ABab.I transgene in the MCA205 cell line. Fig. 9 A shows staining of MCA205 cells using pan HLA-ABC antibodies. Top, 48 hours after transfection, staining of HLA class I haplotypes expressing six alleles ( Figure 8 Bottom, HLA+ cell populations of transfected MCA205 cells were enriched and stained for HLA alleles in the presence or absence of IFN-γ pretreatment (48 hours prior to staining). Fig. 9 B. Fig. 9 C and Fig. 9 D shows that after enrichment, MCA205 cells were stained with HLA-specific antibodies with or without IFN-γ. Fig. 9 B shows that the HLA-A*03:01 specific antibody (clone: GAP.A3) stains the HLA-A3 allele. Fig. 9 C shows that the HLA-B*07:02 specific antibody (clone: BB7.1) stains the HLA-B7 allele. Fig. 9 D shows that the pan HLA-C antibody (clone: H-5) stains the HLA-C alleles. Fig. 9 E shows staining of the MCA205 / ABab.I stable cell line using pan HLA-ABC antibodies after multi-cell sorting by flow cytometry. A representative example from multiple flow cytometry staining experiments is given (n>5).
[0037] Fig.10 Schematic diagram of the PiggyBac transposon strategy for generating ABAB.I mice using pronuclear microinjection. The PB-targeted ABAB.I targeting transgene (flanked by ITRs for PB transposase catalysis) has six repeat elements (5'- to -3') of chimeric HLA genes constructed sequentially, such as Figure 7 As shown in A.II, each has its own promoter and 3'-UTR components.
[0038] Fig.11 A-11B shows the genotyping profile and breeding scheme of the ABab.I transgenic founder. Fig.11 A shows HLA-PCR reactions on the left: PCR genotyping data of 2 founder mice (F0) Q4115 and Q4118. HLA-A*03, A*11, B*07, B*15, C*04 and C*07 PCR: genomic (g) DNA from MCA205 / ABab.I stable cell line (lane 1), ABab.I transgenic as plasmid DNA (lane 2), control H2O (lane 3), gDNA from C57BL6 / N mice (lane 4), positive ABab.I, 1st generation founder: Q4115 (lane 5), two negative mice (lanes 6 and 7), positive ABab.I, 2nd generation founder: Q4118 (lane 8). Fig.11 A shows internal control PCR on the right: 18s rRNA and human TCRαβ PCR: genomic (g) DNA from C57BL6 / N mice (lane a), gDNA from MCA205 / ABab.I stable cell line (lane b), ABab.I transgene as plasmid DNA (lane c), control H2O (lane d), gDNA from ABabDII mice (lane e), 1st generation founder: Q4115 (lane f), two negative mice (lane g and lane h), positive ABab.I, 2nd generation founder: Q4118 (lane i). Fig.11 B shows a schematic diagram of the breeding scheme of F0 to F4 homozygous mice. F0 is backcrossed to ABabDII for germline transmission. NMRI backcrossing is used for homozygosity testing.
[0039] Fig.12 A-12D shows human HLA class I haplotype expression in ABab.I mice. Fig.12 A shows HLA staining of peripheral blood cells from C57BL6 / N, ABab.I and ABabDII mice using β2 microglobulin (β2m) antibody. Two representative figures (two mice / strain) of multiple experiments are shown (n>10). Fig.12 B shows HLA ABC-positive LCL-BM14 (lymphoblastoid) stained with β2m antibody. Fig.12 C shows a histogram showing the mean fluorescence intensity (MFI) of β2m staining in mouse strains ABabDII and ABab.I and cell line LCL-BM14. One representative staining of multiple mice is given (n>20). Fig.12 D shows β2m MFI compared between ABabDII and ABab.I mice. Bar graphs show mean±SD (n=5). P value: ***, P≤0.001 (unpaired two-tailed t-test).
[0040] Fig.13A-13D shows the phenotypic characterization of peripheral blood T cells in ABab.I mice. Fig.13 A shows the CD8+CD4+ profile (on CD3+ cells) of peripheral blood cells from young (8-12 weeks old) mice by flow cytometry, where the indicated mouse strains were stained with antibodies specific for CD3, CD8, and CD4 chains and analyzed by flow cytometry (on CD3+ cells). + Two representative graphs (two mice / strain) from multiple experiments (n>30) are shown. Fig.13 B and Fig.13 C shows the absolute number of T cells / μl blood, Fig.13 B shows CD3 + CD8 + , Fig.13 C shows CD3 + CD4 + , by flow cytometry using CountBright TM Bead quantification. Each data point represents a single young mouse from the indicated strain. Horizontal intervals on the scatter plot represent mean ± SD. Data from C57BL6 / N (n = 9), HHD (n = 9), ABabDII (n = 32), and ABab.I (n = 60) mice are summarized. Fig.13 D shows the CD8 / CD4 ratio among different mouse strains based on absolute numbers in peripheral blood. The bar graph shows mean ± SD (n = 7). Fig.13 B. Fig.13 C and Fig.13 P values in D indicate: ****, P ≤ 0.0001; ns, not significant (unpaired two-tailed t test).
[0041] Fig.14 A-14D shows the phenotypic characterization of T cells from lymphoid organs in ABab.I mice. Fig.14 A shows spleens and lymph nodes (including whole blood) from young (8-12 weeks old) mice of the indicated strains were stained with antibodies specific for CD3, CD8, and CD4 chains and analyzed by flow cytometry (in CD3 + Two representative graphs (two mice / strain) from multiple experiments (n>10) are shown. Fig.14 B and Fig.14 C shows the absolute number of T cells / mouse, Fig.14 B shows CD3 + CD8 + , Fig.14 C shows CD3 + CD4 + , by flow cytometry using CountBright TMBead quantification. Each data point represents a single juvenile mouse from the indicated strain. The horizontal bars on the scatter plot represent mean ± SD. Data from ABabDII (n = 7) and ABab.I (n = 5) mice are summarized. Fig.14 D shows the CD8 / CD4 ratio based on the absolute numbers in pooled organs among different mouse strains. The bar graph shows mean ± SD (n = 5). Fig.14 B, Fig.14 C, and Fig.14 The P values in D indicate: ****, P ≤ 0.0001; ***, P ≤ 0.001; ns, not significant (unpaired two-tailed t-test).
[0042] Fig.15 A-15C shows a comparison of the TCRβ repertoire among ABabDII, ABab.I, and human donors. Fig.15 A shows the absolute numbers of TCRβ amino acid (aa) clonotypes unique to 3 × 10 5 (mean in mouse strains) or 1.8 × 10 5 human CD8+ T cells. Fig.15 B shows the clonal distribution of TCRβ aa clonotypes of different sizes: rare, 0 < x ≤ 0.001%; small, 0.001% < x ≤ 0.01%; medium, 0.01% < x ≤ 0.1%; large, 0.1% < x < 1%; over-expanded, 1% < x < 10%. Human donors were excluded from this analysis. Fig.15 C shows the TCRβ diversity calculated using the iChao1 estimator (lower bound of richness of the total number of unique templates within an individual population). The horizontal bars on the scatter plot represent mean ± SD. Data are from ABabDII (n = 5); ABab.I (n = 5) mice, and human (for Fig.15 B n = 2; for Fig.15 A and Fig.15 C n = 3). Fig.15 A and Fig.15 The P values in A and C indicate: **, P ≤ 0.01; ns, not significant (unpaired two-tailed t-test).
[0043] Fig.16 A-16B shows the V β and J β gene usage frequencies of TCRβ clonotypes inside and outside the box. Fig.16 A and Fig.16 B show the V + and J β gene usage frequencies of unique TCRβ clonotypes in CD8 β T cells of ABabDII and ABab.I mice and humans. Fig.16 A and Fig.16 B shows the frequencies outside the box at the top and the frequencies inside the box at the bottom. β Gene (A.) and J β (B.) The segments are arranged on the x-axis according to their 5' to 3' positions on human chromosomes. Fig.16 The dashed line in A shows the random V β Frequency of gene usage (TRBV, 2.1%). Bar graphs show mean ± SD. Data from ABabDII (n = 5); ABab.I (n = 5) mice, and humans (n = 3). *V β The expression of the gene was lost in both ABabDII and ABab.I mice.
[0044] Fig.17 A-17B shows analysis of the CDR3β region among ABabDII, ABab.I and human donors. Fig.17 A shows the CDR3 length distribution of TCRβ clonotypes. The bar graph shows the boxed frequency of different CDR3β lengths for ABabDII and ABab.I mice and humans. Fig.17 B shows the average CDR3β length compared between ABabDII and ABab.I mice and humans. The bar graph shows the mean±SD. Data are from ABabDII (n=5); ABab.I (n=5) mice, and humans (n=3). Fig.17 A and Fig.17 P values in B indicate: ****, P ≤ 0.0001 (unpaired two-tailed t test).
[0045] Fig.18 A-18B shows the consensus overall analysis among ABabDII, ABab.I and human donors. Fig.18 A shows the Jaccard index, which represents the score based on the number of shared TCRβ clones within and between groups of ABabDII and ABab.I mice and human overall. The bar graph shows the mean ± SD. Data are from ABabDII (n = 5); ABab.I (n = 5) mice, and humans (n = 3). P values represent: ****, P ≤ 0.0001; ***, P ≤ 0.001; ns, not significant (unpaired two-tailed t test). Fig.18 B shows the total number of unique TCRβ clones in ABabDII and ABab.I from the combined data. Five mice per strain were pooled for analysis.
[0046] Fig.19 A-19C shows the functional characterization of the HLA alleles present in ABab.I mice. Fig.19A shows a list of model TCRs with known peptide binders restricted toward HLA alleles in ABab.I mice. In addition to this list, the HLA-A2-restricted T1367 MAGE-A1 TCR was used as an internal control in all presentation assays. Fig.19 B and Fig.19 C shows the functional activity of the ABab.I HLA allele by surface expression and presentation of a model peptide. Fig.19 B, in the MCA205 cell line stably expressing six HLA alleles, as in ABab.I (except HLA-A2), or Fig.19 In C, cells isolated from peripheral blood or lymphoid organs were co-cultured with T cells transduced with or without model TCRs. Cytokine levels were measured by mouse IFN-γ ELISA assay after overnight co-culture. Fig.19 pHLA-TCR pairing is shown in A. Bar graphs show mean ± SD of replicates within the assay. One representative of multiple co-culture experiments is given (n>5).
[0047] Fig. 20 CD8 in ABab.I mice against a panel of human antigens is shown. + T cell responses. Specific CD8 T cell responses were observed in ABab.I mice after immunization with a panel of model antigens (shown along the x-axis). + T cell responses. Young ABab.I mice were immunized (minimum twice) with an interval of at least 4 weeks between peptide injections. 7 days after injection, peripheral blood cells were stimulated in vitro with the same specific peptide used for immunization (right), or with nonspecific peptide (left), or CD3 / CD28 beads (middle, positive control). Cells were analyzed by flow cytometry for CD3, CD8, and intracellular IFN-γ expression. Dot plots depict CD8 + IFN-γ + T cells (in CD3 + The nonspecific NY-ESO-APRGPHGGAASGL peptide (SEQ ID NO: 172) was used only for in vitro stimulation. A representative flow cytometric plot of multiple responders is shown (out of 6-7 mice / antigen, 6 mice responded to the KRAS peptide, 3 mice responded to the MAGE-A1 and HPV peptides, and 1 mouse responded to the mCALR, CMV, and MAGE-A12 peptides).
[0048] Fig.21A shows the immune response to HLA-A*02 restricted MAGE-A1 in ABab.I mice after immunization. ABab.I mice were immunized with full-length MAGE-A1 mutated (V→D) at position 279 to disrupt the dominant HLA-A*02-restricted epitope KVLEYVIKV (278-286). On day 7 after the third immunization, peripheral blood was stimulated with MAGE-A1 expressing cells and intracellular staining for IFNg was performed. Fig.21 B shows that TCR1 isolated from ABab.I mice recognizes a novel HLA-A*02-restricted MAGE-A1 epitope. TCR1 is isolated from ABab.I mice immunized with full-length MAGE-A1, which is mutated (V→D) at position 279 to destroy the dominant HLA-A*02-restricted epitope KVL 278-286. Human T cells transduced with TCR1 are co-cultured with K562-A2 cells expressing MAGE-A1, fragments of MAGE-A1 (F1-F3) or loaded with KVLEYVIKV (KVL). F1-F3 spans the following fragments of MAGE-A1: F1 1-97, F2 98-222, F3 223-309. Fig.21 C shows that MAGE-A1-reactive TCR1 recognizes the nonamer GTLEEVPTA. Human T cells transduced with TCR1 were co-cultured with K562-A2 cells loaded with predicted nonamer binders (Table 15) or with KVLEYVIKV (KVL).
[0049] Fig. 22 Flow cytometry analysis is shown. In vitro measurement of CD8 + The expression of CD3, CD8 and intracellular IFN-γ in T cells. The dot plots in the figure describe CD8 + IFN-γ + T cells (in CD3 + As a non-specific peptide, NY-ESO peptide (APRGPHGGAASGL) (as a negative control) was used only for in vitro stimulation. One flow cytometry graph of multiple responders is given (6 out of 6-7 mice / epitope, 6 mice responded to KRAS peptide, 3 mice responded to MAGE-A1 and HPV peptides, and 1 mouse responded to mCALR, CMV, and MAGE-A12 peptides).
[0050] Fig.23 The degree of humanization in the HuTCR mice of the present invention is shown. The chimeric HLA in the HuTCR mice promotes the CD8 / CD4 co-receptor, which has been fully validated to function in human T cells.
[0051] Fig.24 Higher CD8 T cell numbers in HuTCR mice of the invention compared to single HLA class I mice are shown. High CD8 T cell numbers in HuTCR mice of the invention increase the possibility of isolating TCRs against any known tumor target and suggest that TCR-HLA interactions are better than in single HLA class I mice.
[0052] Fig.25 Active T cell responses in the blood of multi-HLA HuTCR mice of the present invention are shown, which were immunized several times with DNA encoding full-length MAGE-A1, which was mutated to delete epitopes 278-286. For all eleven mice used in this experiment, T cell responses were examined for the HLA combinations of HLA-A*02:01, HLA-A*03:01, HLA-A*11:01, HLA-B*07:02 and HLA-B*15:01, and for the HLA combination of HLA-C*04:01 and HLA-C*07:02. Mice with positive T cell responses are represented by circles located above the background dashed line, while mice with negative T cell responses are represented by circles located below the background dashed line. For all HLA alleles or HLA allele combinations tested, mice were found to have active T cell responses in the blood against MAGE-A1-derived epitopes. DETAILED DESCRIPTION
[0053] The present invention relates to a novel non-human mammal comprising in its genome at least two or three human leukocyte antigen (HLA) class I alleles. Optionally, the at least two or at least three human HLA class I alleles comprise: at least one human HLA-A allele, at least one human HLA-B allele, and at least one human HLA-C allele. It has been found that such non-human transgenes provide a number of advantages. First, it has been found herein that integration of these multiple human HLA class I alleles into the genome of a non-human mammal allows for the isolation of TCRs, particularly non-HLA-A2-restricted TCRs, from a broad TCR repertoire. For example, transgenic mice carrying two human HLA-A alleles, two HLA-B alleles, and two human HLA-C alleles (HLA-A*03:01, HLA-A*11:01, HLA-B*07:02, HLA-B*15:01, HLA-C*04:01, and HLA-C*07:02, see the Experimental section) represent approximately 80% of the American or European population in terms of their HLA class I gene repertoire. In another example, a transgenic mouse carrying the following two human HLA-A alleles, two HLA-B alleles and two human HLA-C alleles (HLA-A*24:02, HLA-A*33:03, HLA-B*40:01, HLA-B*46:01, HLA-C*01:02 and HLA-C*03:04) represents more than 80% of the Chinese ethnic population in terms of its HLA class I gene spectrum. It should be noted here that such mice are very similar to the class I haplotypes in humans, as each (human) individual has six HLA class I alleles. Therefore, a second advantage of the present invention is that by providing a non-human mammal carrying a variety of human HLA class I alleles in its genome, the present invention allows the TCR repertoire to be specifically adapted to any given human (sub) population to which the TCR should be provided. As also shown in the further examples given herein for sets of HLA class I alleles representing populations of the Japanese or Indian ethnic groups, the class I alleles to be integrated into the genome of the transgenic animal can be selected according to their prevalence in the corresponding population. Thus, the present invention provides for the first time a "universal toolbox" to simulate any population of interest with respect to its TCR repertoire. In this context, the following should also be noted. When a plurality of such non-human mammals (e.g., 5, 10 or even up to 20 transgenic mice) carrying, for example, the same set of six human HLA class I alleles are used for immunization, as a third advantage, the present invention allows a closer representation / simulation of a selected human (sub) population, thereby further increasing the chances of obtaining a suitable TCR for a given antigen.In addition, it has been found herein that, as a fourth advantage, transgenic animals carrying a variety of human HLA class I alleles allow for direct comparison of the intensity of T cell responses associated with each human allele for a given antigen (see Example 4), thereby also being able to identify possible dominant T cell responses. Therefore, the transgenic animals of the present invention allow for direct comparison of the intensity of T cell responses while assessing T cell responses associated with a variety of human HLA alleles. This "multiplexing" is another advantage of the present invention. Finally, as a further advantage, non-human transgenic animals as described herein can be used to discover new antigenic epitopes (also HLA-A2 restricted epitopes) that have not yet been identified or have been theoretically predicted but have so far been unable to produce TCRs experimentally for them (see Example 2 of the present application).
[0054] In this context it should be noted that an illustrative experimental example of such a transgenic animal of the present invention, namely a mouse called "ABab.I mouse" (also referred to herein as "multi-HLA mouse" or "HuTCR mouse"), which contains six (additional) human HLA alleles as a single haplotype, was developed starting from an ABabDII mouse background carrying a single human HLA-A2 allele (Li et al., 2010, Nature Medicine, Vol. 16, No. 9 (2010), pp. 1029-1034). Thus, this "multi-HLA mouse" diversifies the HLA gene set and allows epitope discovery and a wider TCR repertoire for non-HLA-A2 restricted TCR isolation. For this mouse, a computer screening of inferred new antigenic epitopes predicted to bind to highly ranked HLA alleles selected six alleles in the ABAB.I mouse. In the course of the present invention, the computer screen predicted 23 and 152 high affinity TSAs (IC50 < 50 nM) from recurrent point mutations that bind HLA-A2 (n = 266) and other common class I alleles (n = 18), respectively. Specifically, epitope immunogenicity was detected in 4 of the 23 HLA-A2-binders in ABabDII mice. Only 1 of the 4 immunogenic epitopes triggered a CD8+ T cell (CTL) response. However, when tested with TCRs generated from ABabDII mice, it was confirmed that this was not endogenously processed. However, this form of reverse immunology is very laborious. A previous study by Asarsson et al. in 2007 on the identification of epitopes from vaccinia virus is consistent with the computer screen prediction data generated and examined in the course of the present invention. Therefore, the prediction algorithm provides a low probability of selecting immunogenic epitopes. Therefore, in the course of the present invention, the ABab.I mouse model with a new set of chimeric class I fusion alleles (i.e., HLA-A*03:01, A*11:01, B*07:02, B*15:01, C*04:01, and C*07:02) was developed using the PiggyBac transposon strategy. These six HLA alleles were introduced as a single genotype similar to the situation in natural humans, and the TCR repertoire was expanded fourfold by enriching the peripheral pool with five times more unique and rare V(D)J-TCRβ clonotypes than the ABabDII mouse. Finally, in addition to identifying high HLA affinity tumor-specific antigens (ICs) derived from frequent somatic point mutations, 50 In addition to being a valuable tool for developing novel TCRs with Tregs (<50 nM), the ABab.I mice of the present invention can be used as a general in vivo model system for epitope discovery.
[0055] definition
[0056] As used herein, the term "mammal" may refer to a group of vertebrates characterized by the presence of mammary glands which, in females, produce milk to feed (suckle) their young.
[0057] As used herein, the term "non-human mammal" may refer to any mammal that is not a human. Non-limiting examples of non-human mammals of the present invention include, but are not limited to, rodents (e.g., mice or rats), dogs, felids, primates, rabbits, pigs, and ruminants (e.g., rodents, dogs, felids, primates, rabbits, pigs, and ruminants). Non-limiting examples of "rodents" are mice, rats, squirrels, chipmunks, gophers, porcupines, beavers, hamsters, gerbils, guinea pigs, degus, chinchillas, prairie dogs, and marmots. Non-limiting examples of "dogs" include members of the subspecies canis lupus familiaris and wolves, foxes, jackals, and coyotes. Non-limiting examples of "felines" include members of two subfamilies: the subfamily Pantherinae, including lions, tigers, jaguars, and leopards, and the subfamily Feline, including cougars, cheetahs, jaguars, lynxes, caracals, ocelots, and house cats. As used herein, the term "primate" refers to all monkeys, including, for example, macaques (Old World monkeys) or platyrrhines (New World monkeys), as well as lemurs, tarsiers, apes, and marmosets (Jackson's needle-eared monkeys). Other exemplary non-human mammals of the invention are transgenic ABab.I mice generated in the process of the invention, which are also interchangeably referred to as "multi-HLA mice" or "HuTCR mice" elsewhere herein.
[0058] As used herein, the term "genome" can refer to the genetic material of an organism (e.g., a non-human mammal, such as a mouse genome). For example, in the context of the present invention, the term "genome" can refer to a haploid chromosome set with the genes they contain.
[0059] As used herein, the term "human leukocyte antigen" or "HLA" may refer to any of the various (polymorphic) proteins encoded by the genes of the major histocompatibility complex in humans and found on the surface of many cell types (such as leukocytes). HLA class I alleles include HLA-A, HLA-B, and HLA-C alleles (http: / / hla.alleles.org / genes / index.html). The human major histocompatibility complex (MHC) is divided into three regions on chromosome 6p21.3: class II (centromeric), class III, and class I (telomeric), with extended class I and class II regions on either side.
[0060] As used herein, the term "major histocompatibility complex" or "MHC" may refer to a group of genes in mammals that encode polymorphic glycoprotein molecules on the cell surface that display antigenic peptide fragments for T cell recognition and contribute to the ability of the immune system to identify self from non-self. The MHC encodes highly polymorphic proteins, many of which are involved in the immune system. The products of the classic class I polymorphic genes, human leukocyte antigen-A (HLA-A), HLA-B and HLA-C, interact with T cell receptor (TCR) molecules and killer immunoglobulin-like receptors (KIR) expressed on natural killer cells and some T cells.
[0061] As used herein, the term "allele" may refer to any alternative form of a gene (e.g., human HLA gene) that may occur at a given locus. Each HLA allele name has a unique number, corresponding to up to four groups of numbers separated by colons. The length of the allele designation depends on the sequence of the allele and the sequence of its nearest related object. Typically, the HLA allele name comprises the following elements: an "HLA" prefix, a hyphen ("-") for separating the gene name from the HLA prefix, a gene name (e.g., "A", "B", "C"), a separator "*", field 1 describing an allele group (e.g., 03, 11, 01, 26, 24, 32, 02, 07, 15, 58, 40, 35, 08, 04, 07, 16, 03, 07, or 06, etc.), a separator "*", field 2 describing a specific HLA protein (e.g., 01 or 02, etc.). Exemplary human class I HLA genes of the invention include HLA-A (class I α-chain), HLA-B (class I α-chain), and HLA-C (class I α-chain). Other human class I HLA alleles of the invention include HLA-E, HLA-F, HLA-G alleles and pseudogenes HLA-H, HLA-J, HLA-K, HLA-L, HLA-N, HLA-P, HLA-S, HLA-T, HLA-U, HLA-V, HLA-W, and HLA-Y (http: / / hla.alleles.org / alleles / class1.html). Exemplary alleles of the invention include any human class I and class II HLA alleles, for example selected from class I HLA-A, HLA-B, and HLA-C alleles. These alleles can be selected from the following exemplary human HLA allele groups: HLA-A*01, HLA-A*02, HLA-A*03, HLA-A*11, HLA-A*24, HLA-A*26 and HLA-A*32; HLA-B*07, HLA-B*08, HLA-B*15, HLA-B*27, HLA-B*35, HLA-B*40 and HLA-B*58; HLA-C*03, HLA-C*04, HLA-C*06, HLA-C*07 and HLA-C*16 alleles. Exemplary human HLA alleles of the invention include, but are not limited to, HLA-A*01:03, HLA-A*03:01, HLA-A*24:02, HLA-A*11:01, HLA-B*07:02, HLA-B*08:01, HLA-B*15:01, HLA-B*27:05, HLA-B*35:01, HLA-B*44:02, HLA-C*04:01, HLA-C*07:01, HLA-C*07:02, and HLA-A*02:01 alleles.According to http: / / hla.alleles.org / alleles / index.html, there are currently 32,330 HLA and related alleles described by the HLA nomenclature and included in the IPD-IMGT / HLA database version 3.46 (2021-10) Build2d19adf (https: / / www.ebi.ac.uk / ipd / imgt / hla / ). Any human class I HLA allele (e.g., HLA-A, HLA-B, or HLA-C allele) is within the meaning of the present invention. Any human class II HLA allele (e.g., any allele selected from the HLA-DRB1*13 allele group, such as HLA-DRB1*13:01) is within the meaning of the present invention. Exemplary class II HLA alleles of the present invention further include, but are not limited to, alleles of HLA-DRA, HLA-DRB1, HLA-DRB2-9, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DPAl, HLA-DPBl, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB proteins (e.g., http: / / hla.alleles.org / alleles / class2.html). As described above, other human class I and class II HLA alleles can also be queried using the "Allele Query Tool" in the IPD-IMGT / HLA Database.
[0062] In this context, it should also be noted that one advantage of the present invention is that it allows modeling of any given human (sub)population by integrating into the genome of a non-human animal any desired set of class I HLA alleles (e.g. class I HLA alleles with a high prevalence in a given population or geographic region).
[0063] In one such illustrative example, a transgenic animal of the invention comprises the following HLA class I alleles integrated into its genome: HLA-A*03:01, HLA-A*11:01, HLA-B*07:02, HLA-B*15:01, HLA-C*04:01, HLA-C*07:02, and HLA-A*02:01. As described above, such transgenic animals represent approximately 80% of the U.S. or European population in terms of their HLA class I genetic profile.
[0064] In another illustrative example, the transgenic animal of the present invention may include a selection of HLA class I alleles representative of the Chinese (ethnic) population integrated into its genome. Such a transgenic animal may include two or more of the following human HLA class I allele sets: HLA-A*11:01 having a carrier frequency of 47.5% (i.e., the percentage of individuals with the allele) in the Chinese ethnic population and / or HLA-A*24:02 having a carrier frequency of 28.1% in the Chinese ethnic population and / or HLA-A*33:03 having a carrier frequency of 19.2% in the Chinese ethnic population and / or HLA-B*40:01 having a carrier frequency of 28.4% in the Chinese ethnic population and / or HLA-B*40:01 having a carrier frequency of 25.1% in the Chinese ethnic population. HLA-B*46:01 with a carrier frequency of 16.7% in the Chinese ethnic population and / or HLA-B*58:01 with a carrier frequency of 16.7% in the Chinese ethnic population and / or HLA-B*15:02 with a carrier frequency of 12.5% in the Chinese ethnic population and / or HLA-C*07:02 with a carrier frequency of 35.1% in the Chinese ethnic population and / or HLA-C*01:02 with a carrier frequency of 34.6% in the Chinese ethnic population and / or HLA-C*03:04 with a carrier frequency of 21.9% in the Chinese ethnic population. In this illustrative example, the transgenic animal can contain two of the human HLA-A alleles described above, two of the human HLA-B alleles described above, and two of these human HLA-C alleles, e.g., HLA-A*11:01, HLA-A*24:02, HLA-B*40:01, HLA-B*46:01, HLA-C*01:02, and HLA-C*03:04.
[0065] In another illustrative example, a transgenic animal of the invention may contain integrated into its genome a selection of HLA class I alleles representative of the Japanese (ethnic) population. Such transgenic animals may include two or more of the following specific HLA class I alleles: HLA-A*24:02 (58.1% frequency in the Japanese population) and / or HLA-A*02:01 (27.4%) and / or HLA-B*52:01 (18.8%) and / or HLA-B*51:01 (17.0%) and / or HLA-B*35:01 (16.6%) and / or HLA-B*15:01 (14.8%) and / or HLA-B*40:02 (14.7%) and / or HLA-C*01:02 (31.6%) and / or HLA-C*03:03 (27.5%) and / or HLA-C*03:04 (23.8%). Also in this illustrative example, the transgenic animal can comprise two of the human HLA-A alleles described above, two of the human HLA-B alleles described above, and two of these human HLA-C alleles, e.g., HLA-A*24:02, HLA-A*02:01, HLA-B*52:01, HLA-B*51:01, HLA-C*01:02, and HLA-C*03:03.
[0066] In yet another illustrative example, the transgenic animal of the present invention may comprise integrated into its genome a selection of HLA class I alleles representative of the Indian population. Such transgenic animals may include two or more of the following HLA class I alleles: HLA-A*01:01 (28.5%) and / or HLA-A*11:01 (26.0%) and / or HLA-A*24:02 (25.4%) and / or HLA-B*40:06 (17.4%) and / or HLA-B*51:01 (14.4%) and / or HLA-B*52:01 (14.3%) and / or HLA-B*44:03 (14.3%) and / or HLA-C*06:02 (25.9%) and / or HLA-C*04:01 (25.4%) and / or HLA-C*07:02 (20.4%). Also in this illustrative example, the transgenic animal can comprise two of the human HLA-A alleles described above, two of the human HLA-B alleles described above, and two of these human HLA-C alleles, e.g., HLA-A*01:01, HLA-A*24:02, HLA-B*40:06, HLA-B*51:01, HLA-C*06:02, and HLA-C*04:01.
[0067] As used herein, the term "functionally expressed" may refer to an HLA allele that is expressed (e.g., on the surface of a cell) and functions as an HLA protein, such as presenting peptides derived from an endogenous protein (e.g., from the interior of a cell). The term "functionally expressed" may particularly refer to an HLA allele that is expressed (e.g., on the surface of a cell of, e.g., a mammal of the present invention) and functions as an HLA protein, such as presenting peptides derived from an endogenous protein (e.g., from the interior of a cell of, e.g., a mammal of the present invention), because the corresponding MHC I polypeptide is expressed on the surface of a cell of, e.g., a mammal of the present invention and presents an MHC antigen to which the non-human mammal provides an antigen-specific CD8+ T cell response and optionally an antigen-specific CD4+ T cell response.
[0068] As used herein, the term "monocistron" can refer to a nucleic acid (eg, RNA, eg, fully processed) encoding a single protein (eg, an HLA allele).
[0069] As used herein, the term "promoter" can refer to a regulatory region of DNA (e.g., located upstream of a gene) that provides a control point for regulated gene transcription. An exemplary promoter of the present invention is the mammalian H-2Db promoter. Another exemplary promoter of the present invention is the viral CMV promoter. Other suitable promoters that can drive expression of the MHC I transgene and can be used herein include, but are not limited to, the H-2Kb promoter (see Kimura et al., "Detailed analysis of the mouse H-2Kb promoter: enhancer-like sequences and their role in the regulation of class I gene expression Cell 1986 Jan 31; 44(2): 261-72), the pROSA-26 promoter (see Zambrowicz et al. 'Disruption of Overlapping Transcripts in the RosaBeta Geo 26 Gene Trap Strain Leads to Widespread Expression of Beta-Galactosidase in Mouse Embryos and Hematopoietic Cells', Proc Natl Acad Sci USA, 94 (1997), 3789-94), the viral SV40 promoter or the mouse β2m promoter.
[0070] As used herein, the term "2A peptide linker" may refer to a class of 18-22 amino acid long peptides that can induce ribosome jumping during protein translation in cells. An exemplary non-limiting 2A peptide linker of the present invention is the E2A peptide linker derived from equine rhinitis A virus (e.g., SEQ ID NO: 229).
[0071] As used herein, the term "epitope" may refer to a portion of an antigen that is recognized by the immune system, particularly by antibodies, B cells or T cells. An epitope is a specific piece of an antigen to which an antibody binds.
[0072] In the context of the present invention, the term "antigen" may refer to any substance that can be specifically bound by components of the immune system. Only antigens that are able to elicit (or evoke or induce) an immune response are considered immunogenic and are referred to as "immunogens."
[0073] The term "polypeptide" can be used equivalently with the term "protein (quality)" in this article. Protein (including its fragments, preferably biologically active fragments, and peptides, usually have less than 30 amino acids, such as 10 or more amino acids at the most, such as 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25 or 30 amino acids) contains one or more amino acids (producing amino acid chains) coupled to each other by covalent peptide bonds. The term "polypeptide" as used herein describes a group of molecules, which is, for example, composed of more than 30 amino acids. Polypeptide can further form polymers, such as dimers, trimers and higher oligomers, i.e., composed of more than one polypeptide molecule. The polypeptide molecules forming such dimers, trimers, etc. can be the same or different. Therefore, the corresponding higher-order structures of this polymer are referred to as homodimers or heterodimers, homotrimers or heterotrimers, etc. An example of a heteromultimer is an antibody molecule, which, in its naturally occurring form, consists of two identical light polypeptide chains and two identical heavy polypeptide chains. The terms "polypeptide" and "protein" also refer to naturally modified polypeptides / proteins, wherein the modifications are, for example, affected by post-translational modifications such as glycosylation, acetylation, phosphorylation, etc. Such modifications are well known in the art.
[0074] The term "amino acid" or "amino acid residue" generally refers to an amino acid having its art-recognized definition, such as an amino acid selected from the group consisting of alanine (Ala or A); arginine (Arg or R); asparagine (Asn or N); aspartic acid (Asp or D); cysteine (Cys or C); glutamine (GIn or Q); glutamic acid (Glu or E); glycine (GIy or G); histidine (His or H); isoleucine (He or I); leucine (Leu or L); lysine (Lys or K); methionine (Met or M); phenylalanine (Phe or F); proline (Pro or P); serine (Ser or S); threonine (Thr or T); tryptophan (Trp or W); tyrosine (Tyr or Y); and valine (Val or V), although modified, synthetic or rare amino acids may be used as desired. Generally, amino acids can be grouped as having nonpolar side chains (e.g., Ala, Cys, He, Leu, Met, Phe, Pro, Val); negatively charged side chains (e.g., Asp, Glu); positively charged side chains (e.g., Arg, His, Lys); or uncharged polar side chains (e.g., Asn, Cys, Gln, Gly, His, Met, Phe, Ser, Thr, Trp, and Tyr).
[0075] For ease of reference, polypeptide variants (or mutants) of the present invention can be referred to by using the following nomenclature: original amino acid: position: substituted amino acid. According to this nomenclature, for example, the substitution of S (serine) at position 722 to F (phenylalanine) can be shown as "S722F".
[0076] Generally, as used herein, the terms "polynucleotide" and "nucleic acid" or "nucleic acid molecule" should be interpreted synonymously. Generally, nucleic acid molecules can include DNA molecules, RNA molecules, oligonucleotide thiophosphates, substituted ribonucleotides-oligonucleotides or PNA molecules, etc. In addition, the term "nucleic acid molecule" can refer to DNA or RNA or its hybrid or any modification thereof known in the art (for example, see US5525711, US 471 1955, US 5792608 or EP 302175). The polynucleotide sequence can be single-stranded or double-stranded, linear or circular, natural or synthetic, and without any size restrictions. For example, the polynucleotide sequence can be genomic DNA, cDNA, mRNA, antisense RNA, ribozyme RNA or DNA encoding these RNAs or chimeroplasts (Gamper et al., Nucleic Acids Res (2000), 28 (21): 4332-4339). The polynucleotide sequence can be in the form of a vector, a plasmid or viral DNA or RNA.
[0077] The term "nucleic acid construct" may refer to a single-stranded or double-stranded nucleic acid molecule that is isolated from a naturally occurring gene or modified to contain a nucleic acid segment in a manner that does not otherwise exist in nature, or that is synthetic, including one or more control sequences.
[0078] The term "control sequence" may refer to nucleic acid sequences necessary for the expression of a polynucleotide encoding an HLA allele of the present invention. Such control sequences may include, but are not limited to, a leader sequence, a polyadenylation signal, a promoter, and a transcription terminator.
[0079] The term "expression" may refer to any step involved in the production of an HLA protein of the invention, for example by a non-human mammal of the invention, including but not limited to transcription, post-transcriptional modification, translation, post-translational modification.
[0080] The term "polyadenylation signal" (or "pA") may refer to a poly(A) tail added to a nucleic acid (eg, RNA) at the end of transcription. Exemplary pAs of the invention are bGH pA (bovine growth hormone polyadenylation signal) and full-length H-2Db pA.
[0081] The term "expression vector" may refer to a linear or circular nucleic acid molecule (eg, DNA) comprising a polynucleotide encoding an HLA allele of the invention and operably linked to control sequences that provide for its expression.
[0082] The term "host cell" can refer to any cell type (e.g., bacterial cells) that is susceptible to transformation, transfection, transduction, etc. with a nucleic acid construct or expression vector comprising an HLA allele of the invention. The term "host cell" encompasses any progeny of a parent cell that is not identical to the parent cell due to mutations that occur during replication.
[0083] As used herein, the term "oocyte" can refer to the female reproductive cell involved in reproduction, i.e., egg or egg cell. According to the present invention, the term "oocyte" includes both the oocyte before fertilization and the fertilized oocyte also referred to as a zygote. Therefore, the oocyte before fertilization only comprises maternal chromosomes, and the oocyte after fertilization comprises maternal and paternal chromosomes. After fertilization, the oocyte maintains a double haploid state for several hours, such as in mice, after fertilization, maintaining up to 18 hours. For example, the oocyte of the present invention can be a fertilized oocyte.
[0084] As used herein, the term "fertilized oocyte" can refer to the oocyte after fusion with the sperm of insemination. After fertilization for many hours (such as up to 18 hours in mice), the oocyte is in a double haploid state, comprising a maternal haploid pronucleus and a paternal haploid pronucleus. After the two pronuclei migrate together, their membrane decomposes, and two genomes condense into chromosomes, thus rebuilding a diploid organism. The fertilized oocyte, also referred to as a single cell zygote and 2 cells and 4 cell stage zygotes, is also covered by the term "fertilized oocyte" as used herein.
[0085] The term "fragment" may refer to a polypeptide lacking one or more (eg, several, such as up to 10-20) amino acids from the amino and / or carboxyl terminus of a mature polypeptide.
[0086] As used herein, the term "TCR" may refer to a T cell receptor.
[0087] As used herein, the term "TCR" may refer to a T cell receptor.
[0088] As used herein, the term "pMHC" may refer to a peptide-binding major histocompatibility complex.
[0089] As used herein, the term "pHLA" may refer to peptide-binding human leukocyte antigen.
[0090] As used herein, the term "CDR" may refer to complementarity determining region.
[0091] As used herein, the term "ATT" may refer to adoptive transfer therapy.
[0092] As used herein, the term "TSA" may refer to a tumor-specific antigen.
[0093] As used herein, the term "TAA" may refer to a tumor-associated antigen.
[0094] As used herein, the term "BCR" may refer to B cell receptor.
[0095] As used herein, the term “PD-1” may refer to programmed cell death protein-1.
[0096] As used herein, the term "MAGE-1" may refer to melanoma associated antigen-1.
[0097] As used herein, the term "NY-ESO-1" may refer to New York ESOphageal squamous cell carcinoma-1.
[0098] As used herein, the term "APC" may refer to an antigen presenting cell.
[0099] As used herein, the term "mIL-2 / 15" may refer to murine interleukin-2 / 15.
[0100] The adaptive arm of the immune system
[0101] The immune system provides a protective barrier for the body by using innate and adaptive defense mechanisms to fight foreign invaders such as bacteria, viruses and parasites. Innate immunity is the body's nonspecific first line of defense in detecting and destroying pathogens. Toll-like receptors (TLRs) sense pathogens and recruit immune cells to the site for elimination by creating an inflammatory environment together with macrophage-induced phagocytosis. Dendritic cells (DCs) are professional antigen presenting cells (APCs) that present endogenous and exogenous antigens to major histocompatibility molecules (MHC) I and II and act as a bridge in the recruitment of the adaptive immune system. Several pro-inflammatory signals with multiple pathways of activation such as nuclear factor-κB (NF-κB), interferon (IFN)-regulatory factor (IRF) and activator protein-1 (AP-1) recruit cells of the adaptive immune system. Although innate immune mechanisms act rapidly with the release of pro-inflammatory cytokines such as IFN-α, -β (type I) and -γ (type II), cell-mediated adaptive immunity is the most effective way for the immune system to eliminate pathogens. The adaptive arm of the immune system consists of two types of cell-mediated responses, T and B cell-mediated immunity. T and B lymphocytes differ in their specificity and mechanism of action. B cells, which are precursors of antibody-secreting cells, recognize pathogenic antigens through the B cell receptor (BCR) and support helper CD4 + T cells are recruited to the site of infection through MHC class II proteins. + T cell activation occurs via the classical MHC class I presentation pathway by antigen-presenting DCs. CD4 + T cells provide strong signals to antigen-presenting DCs via CD40L-CD40 interactions, independently of the cytotoxic CD8 + In addition, CD4 + T cells help cytotoxic CD8 + T cell memory formation.
[0102] CD8 + and CD4 + Conventional naive T cells all interact with their cognate antigens presented on polymorphic MHC class I and class II proteins through αβT cell receptors (TCRs). The naive TCR repertoire formed in the thymus primarily determines the precursor frequency and distribution of different T cell clones. Quantification of the TCR repertoire can provide an understanding of the diversity of T cell-mediated responses that an organism can establish.
[0103] T cell receptors (TCRs) and their diverse repertoire shape T cell-mediated immunity
[0104] ΑβTCRs may be generated through random but abundant variable (V), diversity (D), and junction (J) recombination events in the thymus, with up to 10 20 (theoretical) combinations. TCRαβ + T cells undergo both positive and negative selection, with thymocytes undergoing positive selection for appropriate self-MHC interactions and negative selection for excessive affinity for any self-peptide MHC (pMHC). About 7.5% of thymocytes produce thymic signaling, from which about 3-5% of the survivors that migrate to the periphery are selected as naive T cells. These T cells, which have a variety of αβ TCRs, inherently interact with pMHC (under costimulation via CD3-γ, -δ, -ε, -ζ, CD4, and CD8 chains), allowing naive CD8 + / CD4 + The repertoire is shaped to face foreign cognate antigens for T cell-mediated responses. MHC reactivity to about 5-20% of the preselected pool and about 10% of the peripheral T cell pool explains its intrinsic affinity for the TCR. Other factors such as TCRV α and V β The encoded (germline-encoded) complementarity determining regions (CDR) 1 and CDR2 further direct the germline bias of the TCR toward the MHC.
[0105] There are some exceptions where CDR1 and 2 are not the major contact domains on the MHC. The crystallographic structure shows an unconventional diagonal topology on the MHC, where the TCRV α and V β CDR1 and 2 dock with the α2 and α1 helices of MHC class I or the β and α helices of MHC class II. α and V β The hypervariable CDR3 loop is the major docking point for peptide binding to MHC (pMHC). Although some existing evidence has shown that TCR and MHC genes have co-evolved to interact with each other, the different antigenic peptides processed and presented through the class I / II antigen presentation pathway strictly define the potential T cell effector functions through their CDR3α and CDR3β interactions.
[0106] Therefore, a large number of recombinant CDR3-V α and -V β Clonotypes form a diverse TCR repertoire that enables unique pMHC interactions, driving T cell-mediated immunity.
[0107] pMHC-I / HLA-I restricted antigen presentation pathway
[0108] MHC glycoproteins, known in humans as human leukocyte antigens (HLA), process antigens and present 8-15 amino acids (aa) (in the case of class I peptides) or 12-25 aa (8-10 aa core motif) (in the case of class II peptides) on their surface. Two antigen presentation pathways facilitate surface presentation of processed epitopes, peptide-loaded HLA-I (pHLA-I) and pHLA-II. HLA class I presents endogenously processed epitopes such as somatic point mutants, virally derived and aberrantly frameshifted proteins to cytotoxic CD8 + T cells (CTL). HLA class II alleles present exogenous engulfed and processed epitopes on their β1 and α1 helices, such as extracellular matrix proteins from the stroma and fragmented viral proteins, to helper CD4 T cells (T H Cells). Professional APCs can take up exogenous antigens into the endogenous HLA I pathway through cross-presentation. The co-receptor interaction of CD8 with the α3 domain of HLA I and CD4 with the β2 helix of HLA II is critical for T cell function.
[0109] Cells, viruses, abnormal mutations and misfolded post-translational proteins in the cytoplasm undergo proteasomal degradation. After proteasomal processing, fragmented peptides enter the endoplasmic reticulum (ER) through peptide-loading complex (PLC) proteins such as transporter-associated protein (TAP) and chaperone tapasin. ER aminopeptidase (ERAAP) proteins associated with antigen processing trim the amino termini of ER-resident peptides before loading on MHC. Calreticulin (CRT), Erp57 and PLC load processed peptides onto MHC / HLA. The pMHC-I / HLA-I complex is released into the early endosome and then transferred to the cell surface through the late endosomal compartment so that CD8 + T cell recognition by T cells (CTL).
[0110] Tumor Immunology
[0111] The immune system and cancer
[0112] Cancer is a widely recognized genetic disease, as oncogenic mutations, chromosomal rearrangements, and abnormal gene expression are the most common causes detected in nearly a million cases. Complete sequencing studies of primary lung tumor samples identified more than 50,000 point mutations (with adjacent non-tumor tissue as a control), including several mutation hotspots, such as Gly in the RAS gene 12loci. Emerging evidence demonstrates that all cancers evolve by accumulating a small number of driver mutations that provide fitness and a large number of passenger mutations that do not provide a growth advantage. For decades, research into understanding the nature of cancer has focused primarily on individual tumor cells. Oncogenic driver mutations allow cancer to thrive but not independently in the absence of additional factors that support growth. Research has demonstrated the heterogeneity of tumor tissue, which makes the interaction with the surrounding microenvironment that generally regulates cancer progression dynamic. The tumor microenvironment with fibroblasts, inflammatory cells, vascular endothelial cells, and extracellular matrix comprises the so-called "stroma". Chronic inflammatory states in the stroma have been described in the literature to promote cancer development with accumulation of inflammatory cells. An example is stromal fibroblasts, in which abrogation of transforming growth factor β (TGF-β) signaling induces gastric and prostate tumors. In the inflammatory state of progressive tumors, similar to wound healing, fibroblasts, macrophages, and endothelial cells actively participate in assisting the formation of new blood vessels (as part of the stroma) to nourish the tumor; this is a process known as "neoangiogenesis".
[0113] CD8 + and CD4 + T cells require HLA-I (pHLA-I) and pHLA-II recognition of tumor-restricted peptides for tumor rejection. + T cells (CTLs) can in most cases elicit cytotoxic activity alone, but in some models, CD4 +T cells reject tumors in the absence of CTLs. CTLs release cytokines such as interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) to reject tumors by attacking the tumor stroma, and in some cases release cytotoxic molecules such as perforin to eliminate tumors, especially in virally transformed tumors. In studies from many analyzed models, T cells use IFN-γ as a key effector molecule for tumor rejection. A report by Kammertones et al. in 2017 inferred the mechanism of IFN-γ on tumor stroma, especially endothelial cells. T cells induce tumor ischemia that exhibits a physiological state of vascular regression through IFN-γ induction, thereby inhibiting angiogenesis. Another theme that links the immune system to cancer is the concept of "immune surveillance"; however, this remains a controversial topic that requires more evidence. In 2002, a study by Dunn et al. based on a spontaneous tumor model induced by methylcholanthrene (MCA) claimed that cancer immune surveillance of T cells for tumor rejection and growth control had been demonstrated. However, subsequent studies refuted the concept that surveillance of tumor rejection is mediated by T cells. The first report proposed several other reasons for the altered tumor development, such as tissue repair at the MCA site, differences in steady-state IFN-γ concentrations between the control and experimental groups, and biases in IFN-γ protection due to different housing conditions in the animal facilities. In addition, tumor development in these models is considered problematic because either chemically induced chronic inflammation or opportunistic infections may be responsible for spontaneous growth, which is not similar to naturally growing tumors in humans. In 2005, Willimsky et al. developed a sporadic tumor model induced by a viral transgenic dormant oncogene (reflecting physiological tumors) to study the impact of T cell recognition of tumor cells in the context of immune surveillance. This study demonstrated that immunogenic sporadic tumors do not escape T cell recognition, but avoid T cell destruction by inducing tolerance, thus proposing that tumor immune surveillance against virus-related cancers is possible. In addition to the SV40 model, EBV- and HPV-related tumors can be monitored by T cells, while immune surveillance of non-viral tumors requires more solid experimental evidence. In addition, for reports showing the concept of immune surveillance in non-viral related cancers, careful data interpretation is required.
[0114] In summary, the role of T cells in attacking tumor cells is clear. Regardless of T cell immune surveillance and its control of growing tumors, TCR-engineered CD8 + and CD4 + T Cells Treatment options using adoptive T cell therapy may give the best possible chance for tumor rejection.
[0115] Adoptive T cell therapy (ATT) for cancer
[0116] In the past, many immunologists have focused on using therapeutic vaccination to target non-tumor-specific self-antigens, however, there are notable exceptions. Therapeutic vaccines against tumor-associated shared antigens by active and passive cancer immunotherapy have not yielded the expected success due to established tolerance mechanisms, suppression, and tumor microenvironmental factors. In contrast to cancer vaccination, adoptive T cell therapy (ATT) has the potential to reject large established tumors, especially TCR-engineered CTLs that release effector molecules such as IFN-γ instead of perforin (FasL * ), with the potential to destroy the surrounding matrix with complete eradication efficiency. In addition to TCR-modified CTLs, the application of chimeric antigen receptor (CAR)-engaged T cells (CART cells) in non-solid tumor clinical studies has shown success. Early clinical studies were conducted with CART cells targeting CD19 surface antigens in hematological malignancies. Although the initial results of targeting surface antigens in liquid tumors have attracted attention, there are still challenges in achieving similar success by targeting solid tumors.
[0117] There are several obstacles that CART cells need to overcome to show efficacy without causing toxicity in solid cancers. These include single-chain variable fragments (scFv) on CART cells to target unique tumor-associated antigens (TAA) on the surface of tumor cells without antigen loss. Next, CAR-engaged T cells should migrate to distant tumor sites to effectively home. In addition, T cells circumvent the immunosuppressive tumor microenvironment and pose additional difficulties. Clinical studies targeting folate receptor-α in ovarian cancer have reported limited T cell homing to solid tumor sites, which can be enhanced by co-expressing chemokine receptor 2 (CXCR2) for Gro-α chemokines in CART cells. Blocking TGF-β signaling in CART cells targeting prostate-specific membrane antigen by co-expression of dominant negative RII receptors increases their ability to infiltrate tumor stroma. In another clinically relevant pleural mesothelioma study in mice, CD28 CAR T cells restored their effector function by cotransduction of a dominant-negative programmed death-1 (PD-1) receptor or by >60% knockdown of PD-1 expression by short hairpin RNA (shRNA).
[0118] Although the lessons learned from clinical studies on improving antigen selection, T cell migration, homing, and efficacy can be applied to CAR-based and TCR-modified adoptive T cell therapies, the most critical concern is always "safety". TCR-modified T cells are outstanding in terms of safety because such T cells can accurately recognize endogenously processed antigens on tumor cells or stroma in an HLA-I or HLA-II restricted manner. In ATT, in order to avoid adverse autoimmune effects by reducing the chance of cross-reaction to unintended self-targets, the use of TCR-modified T cells provides us with the superior advantage of targeting tumor-specific antigens. This unique class of truly tumor-specific antigens may come from non-synonymous somatic point mutations.
[0119] Somatic point mutations can generate tumor-specific neoantigens
[0120] Carcinogenesis is a multi-stage process in evolution that develops through a series of genomic instability events. Instability in the genome can cause uncontrolled cell growth, invasion and metastasis. Such genomic changes include gene amplification, chromosomal translocation, deletion and collectively any somatic mutation.
[0121] Most tumor cells produce and process antigenic peptides, and these antigenic peptides are expressed on the cell surface or released into the extracellular matrix (matrix), stroma. Studies have reported that a variety of peptide antigens are associated with or shared in several cancer types, such as colon cancer and prostate cancer, malignant melanoma, kidney cancer, breast cancer and lung cancer. In all cancer entities, tumor antigens are mainly divided into two categories, tumor-specific antigens (TSA) and tumor-associated antigens (TAA). TSA is a class of antigens expressed only on tumor cells, which includes all abnormal protein structures derived from somatic mutations, which may be the main cause of malignant transformation. On the other hand, TAA is an overexpressed abnormal protein-derived antigen, which is expressed not only on tumor cells, but also on normal cell subpopulations.
[0122] With the recent progress of next generation sequencing of whole genome and exome (all protein coding regions), mutation identification and TSA screening have become easier and highly important. Such TSAs are considered to be ideal and truly tumor-specific (called new antigens) targets for adoptive T cell therapy (ATT). The properties of TSAs derived from mutations vary from cancer to cancer and from individual to individual, due to inter-tumor and intra-tumor heterogeneity, respectively. Adult solid tumor entities have about 50 mutations during the first diagnosis, while pediatric cancers and leukemias acquire fewer mutations (an average of 10). UV-related skin melanoma carries 100-200 mutations. However, genomic instability of colorectal cancer can contain more than 1000 mutations. Most importantly, most mutations that often change coded proteins are non-synonymous somatic point mutations, which are caused by single amino acid substitutions, such as R175H and R248Q in the TP53 gene, and G12V and G13D in the RAS gene.
[0123] Regardless of the total number of somatic mutations in a tumor or the frequency of its specific mutations (hotspots), the aberrant protein generated by a driver mutation may or may not generate epitopes and induce immunogenicity. Many factors contribute to the generation of epitopes, such as antigen expression levels, proteasomal peptide processing, transport (e.g. Figure 1 ) and its binding affinity to MHC / HLA determine whether the mutant peptide is likely to be a suitable epitope. The probability that a nonsynonymous somatic mutation will pass through these stages to generate a new tumor-specific antigen is very low. In a vaccinia virus study, the likelihood speculation proved to be correct, and the study reported that only 1 of 14 predicted epitopes was truly immunogenic. In detail, among the approximately 100 predicted IC 50 Among vaccinia-encoded epitopes that bind HLA-A*02:01 (HLA-A2) at <100 nM, only 50% elicited CD8 + T cell responses, and from these only 15% were shown to be endogenously processed. 11% of the 15% processed epitopes elicited a CTL response, which explains that 1 in 14 predicted epitopes is immunogenic. Comparing vaccinia virus to physiological cancers with somatic mutations, that is, with similar probability, about 4-5 mutated epitopes per cancer can be an estimate of 50 mutations. Since each individual has six HLA alleles, 20-25 epitopes can be expected for each individual.
[0124] Immunodominance also plays a role in dominant vs. recessive mutant epitopes. Recessive epitopes can only be targetable if dominant epitopes are lost. One factor in the lack of immunodominance of recessive epitopes may be their affinity for HLA; dominant epitopes may show strong affinity for HLA alleles. On the other hand, some HLA alleles show predictions of binding more epitopes than other HLA alleles, making estimation difficult. In addition to point mutations, frameshift mutations that result in new reading frames may increase the chances of each individual generating potential epitopes.
[0125] Supportively, in cancer patients, various forms of TSA have been identified as CD8 + T cell targets and have also been examined in preclinical trials. There is ample evidence that cytotoxic T lymphocytes can effectively recognize tumor antigens caused by mutations in various forms of cancer such as colorectal cancer, head and neck cancer (CASP-8), melanoma (β-catenin), squamous cell lung cancer (NFYC) and leukemia. According to all of the above common understandings, somatic mutations can generate potential new antigenic epitopes for cancer ATT; if it is proven to be naturally processed and presented.
[0126] Recurrent somatic driver mutations as targets for ATT in cancer
[0127] The adoptive transfer of tumor antigen-specific T cells is one of the most promising and advanced medicinal products (ATMPs) in the field of cancer immunotherapy. However, the selection of appropriate antigens for potent ATT remains problematic.
[0128] In the past two decades, several preclinical studies that appear to be tumor specific have enabled the development of various biological agents that block or inhibit various molecular targets derived from genetic abnormalities in cancer. Targeted cancer therapies, such as monoclonal antibodies (mAbs), small molecule drugs (SMDs), and cancer vaccines, use tumor-associated and self-antigens as their targets.
[0129] These therapies exhibit high toxicity, frequent drug resistance, and relapse due to on-target attack by cells expressing self-antigens, thereby weakening the overall therapeutic benefit. Therefore, careful selection of appropriate tumor antigens still seems to pose a critical challenge for effective ATT. Therefore, using TCR-engaged T cells to target recurrent somatic driver mutations (TSAs) may become a more precise strategy compared with SMDs and mAbs.
[0130] Anders et al. demonstrated that monospecific CD8 + T cells can completely reject large established tumors (≥500 mm 3). This complete tumor rejection may be made possible by eliminating escape variants. Targeting driver mutations that generate homogeneously expressed epitopes (the ancestors from which cancer cells evolved) may also avoid the generation of antigen-losing variants.
[0131] Not every mutation is a driver mutation and can generate an epitope. Driver mutations confer tumor growth advantages. Regarding tumor heterogeneity, driver mutations can occur repeatedly across tumors (inter-tumor) and between tumors (intra-tumor). Recurrent new antigen epitopes are often derivatives of driver mutations (ancestral mutations) shared by all cancer cells and are ideal target antigens that will not be lost. However, selecting and validating the most promising new antigen epitope candidates for ATT is a cumbersome task.
[0132] Recently, in silico identification of neoantigens from tumor whole genome or exome sequencing datasets appears to aid neoantigen epitope selection. In 2019, our bioinformatics study published a predictive screen that identified and ranked putative neoantigen epitopes for binding affinity to HLA complexes using the TCGA dataset. We used a machine learning-based affinity prediction algorithm as an opportunity to design off-the-shelf T-cell therapies for subsets of cancer patients sharing recurrent neoantigen epitopes. For all predicted recurrently mutated epitopes, immunogenicity validation with respect to efficient processing and presentation is inevitable. To this end, humanized TCR-HLA mouse models can be used as a valuable tool not only for validating the immunogenicity of predicted epitopes but also for discovering novel epitopes by full-length protein-encoding genetic immunization.
[0133] Humanized mammalian models
[0134] Frequently occurring new antigenic epitopes are ideal targets, as they are uniformly expressed on all cancer cells, which has led to an emerging approach to isolate TCRs for cancer ATT. New antigen-specific TCRs can be identified from humans or from transgenic mammals such as transgenic mice, rats, or pigs, to name just a few.
[0135] In humans, TCR alpha and beta chains can be isolated by in vitro priming from HLA-matched healthy individuals or candidates immunized with mutant peptides. In any case, in the former case, the TCR repertoire precursors against neoantigen epitopes in healthy donors are not subject to central tolerance mechanisms; depletion of T cells that only bind wild-type self counterparts with high affinity. In principle, TCR isolation can therefore be performed by autologous priming, although the percentage of neoantigen-specific T cells is low, as shown in patients with melanoma, gastrointestinal cancer, lung cancer, and ovarian cancer; only about 1.2% of mutations are recognized spontaneously. In addition, the expression level of neoantigens in the periphery is a decisive factor in whether T cells are exhausted or become anergic.
[0136] In transgenic animals, as experimentally exemplified herein by transgenic mice, isolation of TCRs from the naive repertoire can be performed after multiple immunizations; to generate memory responses in vivo. In addition, TCRs are derived from tumor-free hosts, which provides the possibility of selecting high-affinity T cells from the naive precursor pool, which may undergo exhaustion in tumor-bearing human individuals due to chronic antigen stimulation.
[0137] Transgenic HLA-I mice with human HLA antigen presentation
[0138] An example of a tumor-free human HLA host is HLA-A2 / D b Transgenic mouse model used as a model for monitoring human immune responses for TCR isolation and epitope identification. b / K b Models are often used to understand heterologous immunity between viruses and humans. Although chimeric MHC / HLA transgenic models have existed for some time, there is still much research on chimeric single human HLA alleles, the full TCR repertoire, and certain V genes gained or lost during thymic selection. αβ The problem of specifically educating mouse TCRs remains. In addition, severe on-target toxicity and lethality have been reported in cancer patients treated with affinity-matured (in the CDR3α region) anti-MAGE-A3 TCRs derived from HLA-A2 transgenic mice that cross-react with other shared epitopes of MAGE-A9 and -A12 antigens. Since mouse TCRs are not thymically negatively selected on patient HLA alleles and the human proteome, a thorough on- and off-toxicity evaluation of such mouse-derived TCRs that may cross-react with normal human proteins is necessary. In addition, partially humanized mouse TCRs are indeed immunogenic when transferred to humans.
[0139] Therefore, in order to carefully predict and translate murine therapeutics into human systems, comprehensive humanization of mouse models expressing diverse human HLA with human TCR loci seems inevitable. Despite the latter, transgenic HLA-A2 / K2 mice with intact human TCR loci have been generated and established for efficient isolation of the best affinity TCR. b Mice (Li, L.-P. et al., Transgenic mice with a diverse human T cell antigen receptor repertoire. Nat. Med. 16, 1029 (2010)).
[0140] Human TCR transgenic mice as an ideal tool for isolating TCRs for cancer ATT
[0141] The necessity of humanization has triggered the development of a new humanized transgenic mouse named ABabDII. ABabDII mice have a complete human TCR locus, which knocks out the mouse TCR and MHC I locus, and it is transgenic for human class I allele HLA-A2 (Li, L.-P. et al., Transgenic mice with a diverse human T cellantigen receptor repertoire. Nat. Med. 16, 1029 (2010)). Therefore, this model becomes a valuable tool for TCR separation for TAAs and TSAs including viral epitopes. Although its advanced humanization produces functional CD8 + T cell populations, the ABabDII model is limited as a source for obtaining only HLA-A2-restricted TCRs. Therefore, the inability of ABabDII mice to be obtained with other HLA alleles is indeed a bottleneck. Therefore, this makes humanized TCR mice expressing other class I alleles a necessity for epitope discovery, which will be beneficial for TCR isolation for a large number of non-HLA-A2 individuals.
[0142] Aim and target
[0143] One of the main goals is to broaden allele diversity to study the enrichment of the human TCR repertoire against complete human HLA haplotypes in mice. The PiggyBac transposon (or PB, a mobile genetic element that effectively transposes between a vector and a chromosome by a "cut and paste" mechanism) strategy introduces six HLA alleles into transcriptionally active sites as a single haplotype like in humans (each individual carries six HLA class I alleles). Another purpose is to ensure the surface expression of the newly introduced HLA alleles to analyze their presentation capabilities. Finally, the novel mouse model of the present invention can become an in vivo epitope discovery system for identifying a series of tumor antigens that are restricted to high-frequency (allele-wise) HLA genes, thereby isolating T cell receptors for cancer ATT.
[0144] The ABab.I transgenic mouse model of the present invention is a new tool for isolating TCRs restricted toward a broad spectrum of HLA.
[0145] So far, the ABabDII transgenic mouse model described by Li et al. is a valuable system for separating human TCR because it contains all human T cell receptor loci. However, the model shows the limitation of separating only HLA-A2-restricted TCR. In order to target diverse non-HLA-A2 binding antigens, and in parallel, to broaden the HLA repertoire of the existing system for epitope discovery, multiple human ABDII mice must be included. In this regard, one of the purposes of the present invention is to construct "ABab.I transgenic mice" by introducing new chimeric class I fusion allele sets (HLA-A*03:01, A*11:01, B*07:02, B*15:01, C*04:01, C*07:02) as a single genotype into existing ABabDII mice (HLA-A2). In addition, the use of ABab.I mice is to find immunogenic epitopes not previously described, which are selected for presentation on any one of the six HLA alleles after processing.
[0146] In the course of the present invention, the goal was to develop a new transgenic ABab.I mouse line as an in vivo model system for epitope discovery and, in addition, to identify high HLA affinity tumor-specific antigens (ICs) derived from recurrent somatic point mutations. 50 A valuable tool for novel TCRs with T cell proliferation and invasion (<50 nM).
[0147] In one embodiment, the present invention provides a non-human mammal (e.g., a transgenic ABab.I mouse of the present invention), which comprises in its genome at least two or at least three human leukocyte antigen (HLA) class I alleles, wherein the at least two or at least three human HLA alleles are functionally expressed, in that the corresponding MHC I polypeptides are expressed on the surface of cells of the mammal and present the non-human mammal with antigen-specific CD8 + The invention relates to an MHC antigen to which T cells respond, and wherein the at least two or at least three human HLA class I alleles comprise: a) at least one human HLA-A allele; and / or b) at least one human HLA-B allele; and / or c) at least one human HLA-C allele; and / or d) (a) and (b); and / or e) (a) and (c); and / or f) (b) and (c); and / or g) (a), (b) and (c). For the sake of clarity, possibility g) means that the transgenic mammal comprises in its genome at least one human HLA-A allele, at least one human HLA-B allele and at least one human HLA-C allele.
[0148] In a further embodiment, the present invention provides a nucleic acid construct comprising a nucleic acid encoding at least two or at least three human HLA class I alleles, wherein the nucleic acid construct is capable of functionally expressing the at least two or at least three human HLA alleles, in that the corresponding MHC I polypeptides are expressed on the surface of cells of the mammal and present MHC antigens to which the non-human mammal provides an antigen-specific CD8+ T cell response, and optionally, wherein the at least two or at least three human HLA class I alleles comprise: a) at least one human HLA-A allele; and / or b) at least one human HLA-B allele; and / or c) at least one human HLA-C allele; and / or d) (a) and (b); and / or e) (a) and (c); and / or f) (b) and (c); and / or g) (a), (b) and (c). For the sake of clarity, possibility g) indicates that the nucleic acid construct comprises a nucleic acid encoding a transgenic mammal comprising in its genome at least one human HLA-A allele, at least one human HLA-B allele and at least one human HLA-C allele.
[0149] In a further embodiment, the present invention provides an expression vector comprising the nucleic acid construct as described herein.
[0150] In a further embodiment, the present invention provides a host cell (eg, an isolated and / or recombinant host cell) comprising a nucleic acid construct as described herein and / or an expression vector as described herein.
[0151] In a further embodiment, the present invention provides a method for modifying endogenous HLA alleles of a non-human mammal, the method comprising: transducing and / or transplanting the non-human mammal as described herein with the nucleic acid construct and / or expression vector as described herein.
[0152] In a further embodiment, the present invention provides a method for producing a non-human mammal oocyte carrying a modified target sequence in its genome, the method comprising the step of introducing a nucleic acid construct and / or expression vector as described herein into a non-human mammal oocyte.
[0153] In a further embodiment, the present invention provides a method for producing a non-human mammal carrying a modified target sequence in its genome, the method comprising: (a) producing an oocyte as described herein; (b) analyzing the presence of the modification in offspring born by a non-human female host to which the oocyte obtained in (a) has been transferred.
[0154] In a further embodiment, the invention provides a non-human mammal produced and / or modified by a method of producing a non-human mammal carrying in its genome a modified target sequence as described herein. In a further embodiment, the invention provides a method of producing one or more T cell receptors capable of binding to a target antigen, the method comprising administering a target antigen to a non-human animal as described herein.
[0155] In a further embodiment, the invention provides a T cell receptor obtained or obtainable by a corresponding method as described herein.
[0156] In a further embodiment, the invention provides a method of identifying an epitope capable of eliciting an immune response, the method comprising administering to a non-human animal as described herein a target antigen suspected of containing an epitope capable of eliciting an immune response.
[0157] In a further embodiment, the present invention provides an epitope to which an immune response is elicited, the epitope being identified by a corresponding method as described herein.
[0158] In a further embodiment, the present invention provides the use of a non-human animal as described herein for producing one or more T cell receptors capable of binding an antigen of interest.
[0159] In a further embodiment, the present invention provides the use of a non-human animal as described herein for identifying epitopes against which an immune response is elicited.
[0160] In a further embodiment, the present invention provides the use of a non-human animal as described herein for identifying one or more T cell receptors capable of binding an antigen of interest.
[0161] The present invention as described herein, in particular the non-human mammal of the present invention (i.e. the transgenic ABab.I mouse of the present invention, which may also be interchangeably referred to herein as a "multi-HLA mouse" or a "HuTCR mouse") and the TCR isolation method based thereon, has / provides one or more of the following advantages with respect to TCR isolation:
[0162] - Wider TCR diversity and therefore higher chance of success in isolating TCRs against any known tumor target;
[0163] - Broader HLA coverage, and thus the non-human mammals of the present invention (also referred to as poly-
[0164] HLA mouse) covers approximately 80% of the EU / US population;
[0165] - Improved and / or more extensive methods for TCR generation based thereon;
[0166] -PoC to generate high affinity TCR.
[0167] In addition, in some aspects / embodiments of the present invention, the non-human mammals of the present invention (i.e., the transgenic ABab.I mice of the present invention, which are also interchangeably referred to herein as "multi-HLA mice" or "HuTCR mice") and / or methods based thereon include / provide one or more of the following features / advantages:
[0168] - The degree of humanization (e.g. in mice) includes HLA and TCR;
[0169] -CD8 and CD4 interaction, which is facilitated by a chimeric HLA as described herein; for example, a chimeric HLA in a non-human mammal of the invention facilitates CD8 / CD4 co-receptor interaction.
[0170] The non-human mammals of the invention are extensively demonstrated to function in human T cells;
[0171] - Gene editing based on random integration (e.g., by HLA allele integration as described herein)
[0172] combine);
[0173] - the non-human mammals of the present invention and methods based thereon may be collectively referred to as the "platform" of the present invention, which has been validated in the course of the present invention for the isolation of TCRs against tumor targets;
[0174] - Broad HLA coverage, e.g., 7 class I alleles as described herein (represented in EU / US
[0175] Table 80% coverage) and 1 class II allele;
[0176] - Higher (about 40%) T cell numbers (e.g. CD8) compared to mice with a single HLA class I allele;
[0177] - Wider and / or higher TCR diversity (e.g. very wide TCR repertoire);
[0178] - Potential for isolating high affinity TCRs, which have been demonstrated in the course of the present invention for a variety of
[0179] Tumor targets;
[0180] -Fully human TCR genes.
[0181] The present invention is also characterized by the following items (e.g., embodiments):
[0182] 1. A non-human mammal comprising in its genome at least two (e.g., at least three, at least four, at least five, at least six or at least seven, etc.) human leukocyte antigen (HLA) class I alleles, wherein the at least two human HLA alleles are functionally expressed in that the corresponding MHC I polypeptides are expressed on the surface of cells of the mammal and present MHC antigens to which the non-human mammal provides an antigen-specific CD8+ T cell response, and optionally wherein the at least two human HLA class I alleles comprise: a) at least one (e.g., at least two or at least three) human HLA-A allele; and / or b) at least one (e.g., at least two) human HLA-B alleles; c) and / or at least one (e.g., at least two) human HLA-C alleles; d) (a) and (b); and / or e) (a) and (c); and / or f) (b) and (c); and / or g) (a), (b) and (c).
[0183] 2. A non-human mammal according to any of the preceding items, wherein the mammal further comprises at least one human HLA class II allele in its genome.
[0184] 3. A non-human mammal according to any of the preceding items, wherein the mammal comprises at least 4, 5, 6 or 7 human HLA class I alleles in its genome.
[0185] 4. A non-human mammal according to any one of the preceding items, wherein the mammal comprises in its genome:
[0186] a) at least two different human HLA-A alleles, preferably at least three different human HLA-A alleles; and / or
[0187] b) at least two different human HLA-B alleles; and / or
[0188] c) at least two different human HLA-C alleles.
[0189] 5. A non-human mammal according to any of the preceding items, wherein the at least two human HLA class I alleles comprise one or more HLA-A class I alleles selected from the group consisting of (European / American): HLA-A*03 (e.g., HLA-A*03:01), HLA-A*11 (e.g., HLA-A*11:01), HLA-A*01 (e.g., HLA-A*01:01), HLA-A*26 (e.g., HLA-A*26:01), HLA-A*24 (e.g., HLA-A*24:02), HLA-A*32 (e.g., HLA-A*32:01) and HLA-A*02 (e.g., HLA-A*02:01), preferably, the three HLA-A class I alleles are selected from the group of human HLA alleles consisting of: HLA-A*03, HLA-A*11 and HLA-A*02.
[0190] 6. A non-human mammal according to any of the preceding items, wherein the at least two human HLA class I alleles comprise one or more HLA-A class I alleles selected from (China): HLA-A*11 (e.g., HLA-A*11:01), HLA-A*24 (e.g., HLA-A*24:02) and HLA-A*33 (e.g., HLA-A*33:03), preferably HLA-A*24 (e.g., HLA-A*24:02) and HLA-A*33 (e.g., HLA-A*33:03).
[0191] 7. A non-human mammal according to any of the preceding items, wherein the at least two human HLA class I alleles comprise one or more HLA-A class I alleles selected from the group consisting of (Japan): HLA-A*24 (e.g., HLA-A*24:02), HLA-A*02 (e.g., HLA-A*02:01), HLA-A*11 (e.g., HLA-A*11:01), and HLA-A*31 (e.g., HLA-A*31:01), preferably HLA-A*24 (e.g., HLA-A*24:02) and HLA-A*31 (e.g., HLA-A*31:01).
[0192] 8. A non-human mammal according to any of the preceding items, wherein the at least two human HLA class I alleles comprise one or more HLA-A class I alleles selected from the group consisting of HLA-A*01 (e.g., HLA-A*01:01), HLA-A*11 (e.g., HLA-A*11:01), and HLA-A*24 (e.g., HLA-A*24:02), preferably HLA-A*01 (e.g., HLA-A*01:01) and HLA-A*24 (e.g., HLA-A*24:02).
[0193] 9. A non-human mammal according to any of the preceding items, wherein the at least three HLA-A I class alleles are selected from a human HLA allele group consisting of: HLA-A*03 (e.g., HLA-A*03:01), HLA-A*11 (e.g., HLA-A*11:01), HLA-A*01 (e.g., HLA-A*01:01), HLA-A*26 (e.g., HLA-A*26:01), HLA-A*24 (e.g., HLA-A*24:02), HLA-A*32 (e.g., HLA-A*32:01) and HLA-A*02 (e.g., HLA-A*02:01), preferably, the three HLA-A I class alleles are selected from a human HLA allele group consisting of: HLA-A*03, HLA-A*11 and HLA-A*02.
[0194] 10. A non-human mammal according to any of the preceding items, wherein the at least two HLA class I alleles comprise one or more HLA-B class I alleles selected from the group consisting of (European / American): HLA-B*07 (e.g. HLA-B*07:02), HLA-B*15 (e.g. HLA-B*15:01), HLA-B*58 (e.g. HLA-B*58:01), HLA-B*40 (e.g. HLA-B*40:01), HLA-B*35 (e.g. HLA-B*35:01) and HLA-B*08 (e.g. HLA-B*08:01), preferably, the at least two HLA-B class I alleles are selected from the group of human HLA alleles consisting of: HLA-B*07 and HLA-B*15.
[0195] 11. A non-human mammal according to any of the preceding items, wherein the at least two HLA class I alleles comprise one or more HLA-B class I alleles selected from (China): HLA-B*40 (e.g., HLA-B*40:01), HLA-B*46 (e.g., HLA-B*46:01), HLA-B*58 (e.g., HLA-B*58:01), and HLA-B*15 (e.g., HLA-B*15:02), preferably HLA-B*40 (e.g., HLA-B*40:01) and HLA-B*46 (e.g., HLA-B*46:01).
[0196] 12. A non-human mammal according to any of the preceding items, wherein the at least two HLA class I alleles comprise one or more HLA-B class I alleles selected from the group consisting of (Japan): HLA-B*52 (e.g., HLA-B*52:01), HLA-B*51 (e.g., HLA-B*51:01), HLA-B*35 (e.g., HLA-B*35:01), HLA-B*15 (e.g., HLA-B*15:01) and HLA-B*40 (e.g., HLA-B*40:02), preferably HLA-B*52 (e.g., HLA-B*52:01) and HLA-B*51 (e.g., HLA-B*51:01).
[0197] 13. A non-human mammal according to any of the preceding items, wherein the at least two HLA class I alleles comprise one or more HLA-B class I alleles selected from the group consisting of HLA-B*40 (e.g. HLA-B*40:06), HLA-B*51 (e.g. HLA-B*51:01), HLA-B*52 (e.g. HLA-B*52:01) and HLA-B*44 (e.g. HLA-B*44:03), preferably HLA-B*40 (e.g. HLA-B*40:06) and HLA-B*51 (e.g. HLA-B*51:01).
[0198] 14. A non-human mammal according to any of the preceding items, wherein the at least two HLA-B class I alleles are selected from a human HLA allele group consisting of: HLA-B*07 (e.g., HLA-B*07:02), HLA-B*15 (e.g., HLA-B*15:01), HLA-B*58 (e.g., HLA-B*58:01), HLA-B*40 (e.g., HLA-B*40:01), HLA-B*35 (e.g., HLA-B*35:01), and HLA-B*08 (e.g., HLA-B*08:01. Preferably, the at least two HLA-B class I alleles are selected from a human HLA allele group consisting of: HLA-B*07 and HLA-B*15.
[0199] 15. A non-human mammal according to any of the preceding items, wherein the at least two HLA class I alleles comprise one or more HLA-C class I alleles selected from the group consisting of (European / American): HLA-C*04 (e.g., HLA-C*04:01), HLA-C*07 (e.g., HLA-C*07:02), HLA-C*16 (e.g., HLA-C*16:01), HLA-C*03 (e.g., HLA-C*03:04), HLA-C*07 (e.g., HLA-C*07:01) and HLA-C*06 (e.g., HLA-C*06:02), preferably, the two HLA-C class I alleles are selected from the group of human HLA alleles consisting of: HLA-C*04 and HLA-C*07.
[0200] 16. A non-human mammal according to any of the preceding items, wherein the at least two HLA class I alleles comprise one or more HLA-C class I alleles selected from (China): HLA-C*07 (e.g., HLA-C*07:02), HLA-C*01 (e.g., HLA-C*01:02) and HLA-C*03 (e.g., HLA-C*03:04), preferably HLA-C*01 (e.g., HLA-C*01:02) and HLA-C*03 (e.g., HLA-C*03:04).
[0201] 17. A non-human mammal according to any of the preceding items, wherein the at least two HLA class I alleles comprise one or more HLA-C class I alleles selected from the group consisting of (Japan): HLA-C*01 (e.g., HLA-C*01:02), HLA-C*03 (e.g., HLA-C*03:03) and HLA-C*03 (e.g., HLA-C*03:04), preferably HLA-C*01 (e.g., HLA-C*01:02) and HLA-C*03 (e.g., HLA-C*03:03).
[0202] 18. A non-human mammal according to any of the preceding items, wherein the at least two HLA class I alleles comprise one or more HLA-C class I alleles selected from the group consisting of (India): HLA-C*06 (e.g. HLA-C*06:02), HLA-C*04 (e.g. HLA-C*04:01), HLA-C*07 (e.g. HLA-C*07:02) and HLA-C*15 (e.g. HLA-C*15:02), preferably HLA-C*06 (e.g. HLA-C*06:02) and HLA-C*15 (e.g. HLA-C*15:02).
[0203] 19. A non-human mammal according to any of the preceding items, wherein the at least two HLA-C class I alleles are selected from a human HLA allele group consisting of: HLA-C*04 (e.g., HLA-C*04:01), HLA-C*07 (e.g., HLA-C*07:02), HLA-C*16 (e.g., HLA-C*16:01), HLA-C*03 (e.g., HLA-C*03:04), HLA-C*07 (e.g., HLA-C*07:01) and HLA-C*06 (e.g., HLA-C*06:02), preferably, the two HLA-C class I alleles are selected from a human HLA allele group consisting of: HLA-C*04 and HLA-C*07.
[0204] 20. A non-human mammal according to any of the preceding items, wherein the mammal comprises in its genome six or seven human leukocyte antigen (HLA) class I alleles, the HLA class I alleles being selected from the group of human HLA alleles comprising or consisting of:
[0205] a) HLA-A*03,
[0206] b) HLA-A*11,
[0207] c) HLA-B*07,
[0208] d) HLA-B*15,
[0209] e) HLA-C*04,
[0210] f) HLA-C*07 and
[0211] g) HLA-A*02.
[0212] 21. A non-human mammal according to any of the preceding items, wherein the seven human HLA alleles include or consist of:
[0213] a) HLA-A*03:01,
[0214] b) HLA-A*11:01,
[0215] c) HLA-B*07:02,
[0216] d) HLA-B*15:01,
[0217] e) HLA-C*04:01,
[0218] f) HLA-C*07:02 and
[0219] g) HLA-A*02:01.
[0220] 22. A non-human mammal according to any one of the preceding items, wherein the at least two human HLA alleles are functionally expressed in that the corresponding MHC I polypeptides are expressed on the surface of cells of the mammal.
[0221] 23. The non-human mammal according to any one of the preceding items, wherein the corresponding MHC I polypeptide is expressed on the surface of peripheral blood cells of said mammal.
[0222] 24. A non-human mammal according to any of the preceding items, wherein the corresponding MHC I polypeptide expressed on the surface of cells of the mammal presents an MHC antigen to which the non-human mammal provides an antigen-specific CD8+ T cell response (e.g., wherein the antigen-specific CD8+ T cell response is measured by any suitable means such as FACS).
[0223] 25. A non-human mammal according to any of the preceding items, wherein the at least two human HLA alleles encode chimeric human / non-human mammal MHC molecules.
[0224] 26. A non-human mammal according to any of the preceding items, wherein the at least two HLA alleles encode a chimeric human / non-human mammal MHC I polypeptide, wherein the human portion of the chimeric polypeptide comprises the α1 and α2 domains of a human MHC I polypeptide, wherein the non-human mammal portion of the chimeric polypeptide comprises the α3 domain, transmembrane and cytoplasmic domains of an endogenous non-human mammal MHC I polypeptide, and wherein the non-human mammal expresses the chimeric human / non-human mammal MHC I polypeptide.
[0225] 27. A non-human mammal according to any of the preceding items, wherein the at least two HLA alleles encode a chimeric human / non-human MHC I polypeptide, wherein the human portion of the chimeric polypeptide comprises the α1, α2, and α3 domains of a human MHC I polypeptide, wherein the non-human mammal portion of the chimeric polypeptide comprises the transmembrane and cytoplasmic domains of an endogenous non-human mammal MHC I polypeptide, and wherein the non-human mammal expresses the chimeric human / non-human mammal MHC I polypeptide.
[0226] 28. A non-human mammal according to any one of the preceding items, wherein each of the at least two HLA alleles is encoded as a monocistronic, preferably, each of the at least two HLA alleles encoded as a monocistronic is selected from the group of human HLA alleles comprising or consisting of:
[0227] a) HLA-A*03,
[0228] b) HLA-A*11,
[0229] c) HLA-B*07,
[0230] d) HLA-B*15,
[0231] e)HLA-C*04 and
[0232] f)HLA-C*07.
[0233] 29. A non-human mammal according to any one of the preceding items, wherein each HLA allele is equipped with its mouse endogenous self H-2Db promoter (e.g., having or comprising SEQ ID NO: 227) and polyadenylation signal (e.g., having or comprising SEQ ID NO: 228).
[0234] 30. A non-human mammal according to any of the preceding items, wherein the mammal comprises a complete human T cell receptor (TCR) locus in its genome.
[0235] 31. A non-human mammal according to any of the preceding items, wherein the mammal is defective in its endogenous T cell receptor (TCR) locus.
[0236] 32. A non-human mammal according to any one of the preceding items, wherein the non-human mammal is selected from the group consisting of rodents, dogs, cats, primates, rabbits, pigs and ruminants.
[0237] 33. A non-human mammal according to any of the preceding items, wherein the rodent is a mouse or a rat.
[0238] 34. A nucleic acid construct comprising a nucleic acid encoding at least two (e.g., at least three, at least four, at least five, at least six, or at least seven, etc.) human HLA class I alleles, wherein the nucleic acid construct is capable of functionally expressing the at least two human HLA alleles (e.g., in a non-human mammal, e.g., as described herein) in that the corresponding MHC I polypeptides are expressed on the surface of a cell of the non-human mammal comprising the nucleic acid construct and present an MHC antigen to which the non-human mammal provides an antigen-specific CD8+ T cell response, and optionally wherein the at least two human HLA class I alleles comprise:
[0239] a) at least one (e.g., at least two or at least three) human HLA-A alleles; and / or
[0240] b) at least one (e.g., at least two) human HLA-B alleles; and / or
[0241] c) at least one (e.g., at least two) human HLA-C alleles; and / or
[0242] d)(a) and (b); and / or
[0243] e)(a) and (c); and / or
[0244] f)(a) and (c); and / or
[0245] g) (a), (b) and (c).
[0246] 35. The nucleic acid construct according to any of the preceding items, wherein the nucleic acid further encodes at least one human HLA class II allele.
[0247] 36. The nucleic acid construct according to any one of the preceding items, wherein the nucleic acid construct comprises 4, 5, 6 or 7 human HLA class I alleles.
[0248] 37. A nucleic acid construct according to any one of the preceding items, wherein the nucleic acid construct comprises
[0249] a) at least two different human HLA-A alleles, preferably at least three different human HLA-A alleles; and / or
[0250] b) at least two different human HLA-B alleles; and / or
[0251] c) at least two different human HLA-C alleles.
[0252] 38. The nucleic acid construct of any one of the preceding items, wherein the at least two human HLA class I alleles comprise one or more HLA-A class I alleles selected from the group consisting of HLA-A*03 (e.g., HLA-A*03:01), HLA-A*11 (e.g., HLA-A*11:01), HLA-A*01 (e.g., HLA-A*01:01), HLA-A*26 (e.g., HLA-A*26:01), HLA-A*24 (e.g., HLA-A*24:02), HLA-A*32 (e.g., HLA-A*32:01) and HLA-A*02 (e.g., HLA-A*02:01), preferably, the three HLA-A class I alleles are selected from the group of human HLA alleles consisting of: HLA-A*03, HLA-A*11 and HLA-A*02.
[0253] 39. The nucleic acid construct of any one of the preceding items, wherein the at least two human HLA class I alleles comprise one or more HLA-A class I alleles selected from the group consisting of: HLA-A*11 (e.g., HLA-A*11:01), HLA-A*24 (e.g., HLA-A*24:02), and HLA-A*33 (e.g., HLA-A*33:03), preferably HLA-A*24 (e.g., HLA-A*24:02) and HLA-A*33 (e.g., HLA-A*33:03).
[0254] 40. The nucleic acid construct of any one of the preceding items, wherein the at least two human HLA class I alleles comprise one or more HLA-A class I alleles selected from the group consisting of: HLA-A*24 (e.g., HLA-A*24:02), HLA-A*02 (e.g., HLA-A*02:01), HLA-A*11 (e.g., HLA-A*11:01), and HLA-A*31 (e.g., HLA-A*31:01), preferably HLA-A*24 (e.g., HLA-A*24:02) and HLA-A*31 (e.g., HLA-A*31:01).
[0255] 41. The nucleic acid construct of any one of the preceding items, wherein the at least two human HLA class I alleles comprise one or more HLA-A class I alleles selected from the group consisting of: HLA-A*01 (e.g., HLA-A*01:01), HLA-A*11 (e.g., HLA-A*11:01), and HLA-A*24 (e.g., HLA-A*24:02), preferably HLA-A*01 (e.g., HLA-A*01:01) and HLA-A*24 (e.g., HLA-A*24:02).
[0256] 42. The nucleic acid construct according to any one of the preceding items, wherein the at least two HLA-A class I alleles are selected from a human HLA allele group consisting of: HLA-A*03 (e.g., HLA-A*03:01), HLA-A*11 (e.g., HLA-A*11:01), HLA-A*01 (e.g., HLA-A*01:01), HLA-A*26 (e.g., HLA-A*26:01), HLA-A*24 (e.g., HLA-A*24:02), HLA-A*32 (e.g., HLA-A*32:01) and HLA-A*02 (e.g., HLA-A*02:01), preferably, the at least three HLA-A class I alleles are selected from a human HLA allele group consisting of: HLA-A*03, HLA-A*11 and HLA-A*02.
[0257] 43. The nucleic acid construct according to any of the preceding items, wherein the at least two HLA class I alleles comprise one or more HLA-B class I alleles selected from the group consisting of: HLA-B*07 (e.g., HLA-B*07:02), HLA-B*15 (e.g., HLA-B*15:01), HLA-B*58 (e.g., HLA-B*58:01), HLA-B*40 (e.g., HLA-B*40:01), HLA-B*35 (e.g., HLA-B*35:01) and HLA-B*08 (e.g., HLA-B*08:01), preferably, the at least two HLA-B I class alleles are selected from the group of human HLA alleles consisting of: HLA-B*07 and HLA-B*15.
[0258] 44. A nucleic acid construct according to any one of the preceding items, wherein the at least two HLA class I alleles comprise one or more HLA-B class I alleles selected from the group consisting of (China): HLA-B*40 (e.g., HLA-B*40:01), HLA-B*46 (e.g., HLA-B*46:01), HLA-B*58 (e.g., HLA-B*58:01) and HLA-B*15 (e.g., HLA-B*15:02), preferably HLA-B*40 (e.g., HLA-B*40:01) and HLA-B*46 (e.g., HLA-B*46:01).
[0259] 45. The nucleic acid construct according to any one of the preceding items, wherein the at least two HLA class I alleles comprise one or more HLA-B class I alleles selected from the group consisting of (Japan): HLA-B*52 (e.g., HLA-B*52:01), HLA-B*51 (e.g., HLA-B*51:01), HLA-B*35 (e.g., HLA-B*35:01), HLA-B*15 (e.g., HLA-B*15:01) and HLA-B*40 (e.g., HLA-B*40:02), preferably HLA-B*52 (e.g., HLA-B*52:01) and HLA-B*51 (e.g., HLA-B*51:01).
[0260] 46. The nucleic acid construct according to any of the preceding items, wherein the at least two HLA class I alleles comprise one or more HLA-B class I alleles selected from the group consisting of HLA-B*40 (e.g. HLA-B*40:06), HLA-B*51 (e.g. HLA-B*51:01), HLA-B*52 (e.g. HLA-B*52:01) and HLA-B*44 (e.g. HLA-B*44:03), preferably HLA-B*40 (e.g. HLA-B*40:06) and HLA-B*51 (e.g. HLA-B*51:01).
[0261] 47. The nucleic acid construct according to any of the preceding items, wherein the at least two HLA-B class I alleles are selected from the human HLA allele group consisting of: HLA-B*07 (e.g., HLA-B*07:02), HLA-B*15 (e.g., HLA-B*15:01), HLA-B*58 (e.g., HLA-B*58:01), HLA-B*40 (e.g., HLA-B*40:01), HLA-B*35 (e.g., HLA-B*35:01) and HLA-B*08 (e.g., HLA-B*08:01), preferably, the two HLA-B class I alleles are selected from HLA-B*07 and HLA-B*15.
[0262] 48. The nucleic acid construct according to any one of the preceding items, wherein the at least two HLA class I alleles comprise one or more HLA-C class I alleles selected from the group consisting of: HLA-C*04 (e.g., HLA-C*04:01), HLA-C*07 (e.g., HLA-C*07:02), HLA-C*16 (e.g., HLA-C*16:01), HLA-C*03 (e.g., HLA-C*03:04), HLA-C*07 (e.g., HLA-C*07:01) and HLA-C*06 (e.g., HLA-C*06:02), preferably, the two HLA-C class I alleles are selected from the group of human HLA alleles consisting of: HLA-C*04 and HLA-C*07.
[0263] 49. A nucleic acid construct according to any one of the preceding items, wherein the at least two HLA class I alleles comprise one or more HLA-C class I alleles selected from (China): HLA-C*07 (e.g., HLA-C*07:02), HLA-C*01 (e.g., HLA-C*01:02), and HLA-C*03 (e.g., HLA-C*03:04), preferably HLA-C*01 (e.g., HLA-C*01:02) and HLA-C*03 (e.g., HLA-C*03:04).
[0264] 50. The nucleic acid construct of any one of the preceding items, wherein the at least two HLA class I alleles comprise one or more HLA-C class I alleles selected from the group consisting of HLA-C*01 (e.g., HLA-C*01:02), HLA-C*03 (e.g., HLA-C*03:03) and HLA-C*03 (e.g., HLA-C*03:04), preferably HLA-C*01 (e.g., HLA-C*01:02) and HLA-C*03 (e.g., HLA-C*03:03).
[0265] 51. The nucleic acid construct according to any of the preceding items, wherein the at least two HLA class I alleles comprise one or more HLA-C class I alleles selected from the group consisting of HLA-C*06 (e.g. HLA-C*06:02), HLA-C*04 (e.g. HLA-C*04:01), HLA-C*07 (e.g. HLA-C*07:02) and HLA-C*15 (e.g. HLA-C*15:02), preferably HLA-C*06 (e.g. HLA-C*06:02) and HLA-C*15 (e.g. HLA-C*15:02).
[0266] 52. A nucleic acid construct according to any one of the preceding items, wherein the at least two HLA-C class I alleles are selected from a human HLA allele group consisting of: HLA-C*04 (e.g., HLA-C*04:01), HLA-C*07 (e.g., HLA-C*07:02), HLA-C*16 (e.g., HLA-C*16:01), HLA-C*03 (e.g., HLA-C*03:04), HLA-C*07 (e.g., HLA-C*07:01) and HLA-C*06 (e.g., HLA-C*06:02), preferably, the at least two HLA-C class I alleles are selected from a human HLA allele group consisting of: HLA-C*04 and HLA-C*07.
[0267] 53. The nucleic acid construct according to any one of the preceding items, wherein the mammal comprises seven human leukocyte antigen (HLA) class I alleles in its genome, wherein the seven human HLAs are selected from a human HLA allele group comprising or consisting of:
[0268] a) HLA-A*03,
[0269] b) HLA-A*11,
[0270] c) HLA-B*07,
[0271] d) HLA-B*15,
[0272] e) HLA-C*04,
[0273] f) HLA-C*07 and
[0274] g) HLA-A*02.
[0275] 54. The nucleic acid construct according to any one of the preceding items, wherein the seven human HLA alleles comprise or consist of:
[0276] a) HLA-A*03:01,
[0277] b) HLA-A*11:01,
[0278] c) HLA-B*07:02,
[0279] d) HLA-B*15:01,
[0280] e) HLA-C*04:01,
[0281] f) HLA-C*07:02 and
[0282] g) HLA-A*02:01.
[0283] 55. The nucleic acid construct according to any one of the preceding items, wherein the HLA allele encodes a chimeric human / non-human mammal MHC molecule.
[0284] 56. The nucleic acid construct of any one of the preceding items, wherein the at least two HLA alleles encode a chimeric human / non-human mammal MHC I polypeptide, wherein the human portion of the chimeric polypeptide comprises the α1 and α2 domains of a human MHC I polypeptide, and wherein the non-human mammal portion of the chimeric polypeptide comprises the α3 domain, transmembrane and cytoplasmic domains of an endogenous non-human mammal MHC I polypeptide.
[0285] 57. The nucleic acid construct according to any one of the preceding items, wherein the at least two HLA alleles encode a chimeric human / non-human MHC I polypeptide, wherein the human portion of the chimeric polypeptide comprises the α1, α2 and α3 domains of a human MHC I polypeptide, and wherein the non-human mammal portion of the chimeric polypeptide comprises the transmembrane and cytoplasmic domains of an endogenous non-human mammal MHC I polypeptide.
[0286] 58. The nucleic acid construct according to any one of the preceding items, wherein each of the at least two HLA alleles is encoded as a monocistronic, preferably, each of the at least three HLA alleles encoded as a monocistronic is selected from the group of human HLA alleles comprising or consisting of:
[0287] a) HLA-A*03,
[0288] b) HLA-A*11,
[0289] c) HLA-B*07,
[0290] d) HLA-B*15,
[0291] e)HLA-C*04 and
[0292] f)HLA-C*07.
[0293] 59. The nucleic acid construct according to any of the preceding items, wherein each HLA allele is equipped with its endogenous own H-2Db promoter and polyadenylation signal, preferably, the at least two HLA alleles are selected from the group of human HLA alleles comprising or consisting of:
[0294] a) HLA-A*03,
[0295] b) HLA-A*11,
[0296] c) HLA-B*07,
[0297] d) HLA-B*15,
[0298] e)HLA-C*04 and
[0299] f)HLA-C*07.
[0300] 60. The nucleic acid construct according to any one of the preceding items, wherein the endogenous self H-2Db promoter is an MHC H-2 type I promoter (eg having or comprising SEQ ID NO: 227).
[0301] 61. The nucleic acid construct according to any one of the preceding items, wherein the polyadenylation signal (pA) is a bovine growth hormone (bGH) polyadenylation signal (e.g. having or comprising SEQ ID NO: 228), preferably, the at least two HLA alleles are selected from a human HLA allele group comprising or consisting of:
[0302] a) HLA-A*03,
[0303] b) HLA-A*11,
[0304] c) HLA-B*07,
[0305] d) HLA-B*15,
[0306] e)HLA-C*04 and
[0307] f)HLA-C*07.
[0308] 62. The nucleic acid construct according to any one of the preceding items, wherein the nucleic acid construct encodes a 2A peptide linker (eg, having or comprising SEQ ID NO: 229), such that the encoded at least two human MHC class I molecules are separated by a 2A peptide linker, preferably, the at least two HLA alleles are two or more selected from the following:
[0309] a) HLA-A*03,
[0310] b) HLA-A*11,
[0311] c) HLA-B*07,
[0312] d) HLA-B*15,
[0313] e)HLA-C*04 and
[0314] f)HLA-C*07.
[0315] 63. The nucleic acid construct according to any one of the preceding items, further encoding a leader sequence (eg, having or comprising SEQ ID NO: 230).
[0316] 64. A nucleic acid construct according to any one of the preceding items, wherein the nucleic acid construct is according to the method disclosed herein. Figures 1 to 22 (eg, the nucleic acid construct is ITR-flanked, such as with 5'-PiggyBac-ITRs, such as having or comprising SEQ ID NO: 231, and is flanked by 3'-PiggyBac-ITRs, such as having or comprising SEQ ID NO: 232).
[0317] 65. The nucleic acid construct according to any one of the preceding items, wherein the leader sequence is a human β2-microglobulin (β2m) leader sequence (eg, having or comprising SEQ ID NO: 233)
[0318] 66. The nucleic acid construct of any one of the preceding items, wherein the nucleic acid construct is codon-optimized for expression in the non-human mammal.
[0319] 67. An expression vector comprising the nucleic acid construct according to any one of the preceding items.
[0320] 68. A host cell (eg, a recombinant and / or isolated and / or non-human host cell) comprising a nucleic acid construct according to any one of the preceding items and / or an expression vector according to any one of the preceding items.
[0321] 69. A method for modifying endogenous HLA alleles of a non-human mammal, the method comprising: transducing and / or transplanting the non-human mammal with a nucleic acid construct according to any one of the preceding items and / or an expression vector according to any one of the preceding items.
[0322] 70. The method according to any of the preceding items, wherein transduction is performed by pronuclear microinjection.
[0323] 71. A method for producing a non-human mammalian oocyte carrying a modified target sequence in its genome (e.g., by transposon-mediated targeting, e.g., as described in the experimental part of this article), the method comprising the step of introducing a nucleic acid construct according to any of the preceding items (e.g., an ITR-flanked targeting vector (e.g., a cassette carrying HLA)) and / or an expression vector according to any of the preceding items into a non-human mammalian oocyte.
[0324] 72. The method according to any one of the preceding items, wherein the nucleic acid construct according to any one of the preceding items and / or the expression vector according to any one of the preceding items is injected into the nucleus / pronucleus of the oocyte or introduced into the oocyte by electroporation.
[0325] 73. A method for producing a non-human mammal carrying a modified target sequence in its genome, the method comprising: (a) producing an oocyte as described in any of the preceding items; (b) analyzing the presence of the modification in offspring born by a non-human female host to which the oocyte obtained in (a) has been transferred.
[0326] 74. The method according to any of the preceding items, wherein the method comprises a transposon-mediated targeting step.
[0327] 75. The method according to any of the preceding items, wherein the non-human mammal is selected from the group consisting of rodents, dogs, cats, primates, rabbits, pigs and ruminants.
[0328] 76. The method according to any of the preceding items, wherein the rodent is a mouse or a rat.
[0329] 77. A non-human mammal produced and / or modified by a method according to any one of the preceding items.
[0330] 78. A method of producing one or more T cell receptors capable of binding a target antigen, the method comprising administering the target antigen to a non-human animal as defined in any one of the preceding items.
[0331] 79. The method according to any one of the preceding items, wherein the target antigen is a full-length polypeptide or a fragment of the full-length polypeptide.
[0332] 80. The method according to any one of the preceding items, wherein the antigen is a tumor-specific antigen (TSA) or a tumor-associated antigen.
[0333] 81. A method according to any one of the preceding items, further comprising isolating T cells that bind to the target antigen from cells of the non-human animal.
[0334] 82. The method according to any one of the preceding items, further comprising isolating a nucleic acid encoding the T cell receptor that binds the target antigen from cells of the non-human animal.
[0335] 83. A method according to any of the preceding items, wherein the T cell receptor is a human T cell receptor.
[0336] 84. A T cell receptor obtained or obtainable by a method according to any one of the preceding items.
[0337] 85. A method for identifying an epitope capable of eliciting an immune response, the method comprising administering to a non-human animal as defined in any one of the preceding items a target antigen suspected of containing an epitope capable of eliciting an immune response.
[0338] 86. The method according to any one of the preceding items, wherein the target antigen is a full-length polypeptide or a fragment of the full-length polypeptide.
[0339] 87. A method according to any one of the preceding items, wherein the epitope is selected from a tumor-specific epitope, a viral epitope, a neoantigen epitope and a human autoepitope.
[0340] 88. The method according to any one of the preceding items, further comprising isolating T cells that bind to the target antigen from cells of the non-human animal.
[0341] 89. The method according to any one of the preceding items, further comprising isolating a nucleic acid encoding the T cell receptor that binds the target antigen from cells of the non-human animal.
[0342] 90. The method according to any of the preceding items, further comprising recombinantly producing the T cell receptor and determining the epitope to which the T cell receptor binds.
[0343] 91. A method according to any of the preceding items, wherein the method is an unbiased epitope discovery method.
[0344] 92. The method according to any of the preceding items, wherein the epitope is an MHC I restricted epitope.
[0345] 93. An epitope for identifying an epitope capable of eliciting an immune response, the epitope being identified or identifiable by the method according to any one of the preceding items, preferably, the epitope is the MAGE-A1 epitope GTLEEVPTA (SEQ ID NO: 200).
[0346] 94. Use of a non-human animal according to any of the preceding items for producing one or more T cell receptors capable of binding a target antigen.
[0347] 95. Use of a non-human animal according to any of the preceding items for identifying one or more T cell receptors capable of binding a target antigen.
[0348] 96. The use according to any one of the preceding items, wherein the antigen is selected from tumor-specific antigens, viral antigens, new antigenic epitopes and human autoantigens.
[0349] 97. Use of a non-human animal according to any of the preceding items for identifying epitopes capable of eliciting an immune response thereto.
[0350] Embodiments of the present invention
[0351] In order that the present invention may be easily understood and put into practical application, some aspects of the present invention are described by the following non-limiting examples.
[0352] Embodiment 1:
[0353] Materials and methods
[0354] Material
[0355] Computer software algorithms
[0356] Table 1: List of web-based resources for T cell epitope prediction screening
[0357]
[0358] Databases and Datasets
[0359] Table 2. List of datasets for retrieving HLA frequency, ranking, and cancer incidence
[0360]
[0361]
[0362] Cell culture media, flasks, tubes and plates
[0363] Table 3: List of cell culture media. * Standard culture medium preparation: DMEM / RPMI + 10% (ie 50 ml / 500 ml) heat-inactivated, sterile-filtered fetal bovine serum + 100 IU / ml penicillin and 100 μg / ml streptomycin. # Mouse T Cell Culture Medium (mTCM): * Standard RPMI medium + 1 mM sodium pyruvate + 0.1 mM non-essential amino acid solution + 2 mM HEPES buffer + 50 μM β-mercaptoethanol.
[0364] Culture medium Manufacturer <![CDATA[DMEM,GlutaMAX TM Supplementary*]]> Thermo Fisher Scientific,Rockford(USA) <![CDATA[RPMI 1640,GlutaMAX TM Supplemented* # ]]> Thermo Fisher Scientific,Rockford(USA)
[0365] Table 4: List of consumables
[0366]
[0367] Chemical reagents
[0368] Table 5: List of chemical reagents
[0369]
[0370]
[0371] Buffer
[0372] Table 6: Buffer list
[0373]
[0374] Cell lines
[0375] Table 7: Cell series
[0376]
[0377] Cytokines
[0378] Table 8: List of cytokines
[0379] Cytokines Manufacturer Recombinant mouse FN-γ PeproTech, Hamburg (Germany) Recombinant human / mouse IL-2 Novartis Pharma AG, Basel (Switzerland) Recombinant mouse IL-15 PeproTech, Hamburg (Germany)
[0380] Antibodies and primers
[0381] Table 9: Antibody list
[0382]
[0383] Table 10: Primer list
[0384]
[0385]
[0386]
[0387]
[0388] Mouse
[0389] Table 11: List of transgenic and wild-type mice with relevant TCR loci and HLA genotypes
[0390]
[0391] Laboratory Equipment
[0392] Table 12: Equipment List
[0393]
[0394]
[0395] software
[0396] Table 13: List of commercial software
[0397]
[0398]
[0399] method
[0400] Computational design and construction of chimeric HLA class I alleles
[0401] The ABab.I polycistronic transgene encoding six HLA alleles separated by 2A peptide linkers was designed in silico and cloned by GeneArt TM , synthesized by Thermo Fisher Scientific. The HLA alleles in this transgene are chimeric human-mouse fusion proteins. The α1 and α2 domains are human cDNAs from the respective HLA alleles, and the α3 to cytoplasmic domains are murine cDNAs from the H-2Db gene. Human β2m is linked to the N-terminus via a 15 amino acid glycine-serine peptide linker. Modified HLA constructs with H-2Db or CMV promoters, 3'-bGH polyadenylation signal variants, and HLA single chains with or without β2m are custom cloned in-house. DNA polymerase was combined with the HLA amplicon by overhang extension (SOE) PCR splicing. The six HLA alleles were cloned sequentially as a single haplotype into the pre-integrated multiple cloning site using unique restriction enzyme sites. The ABab.I transgene flanked by PiggyBac ITRs was generated using 5'-AscI and 3'-PacI sites. Stbl3 TM The long HLA plasmid containing the repetitive sequence was propagated in Escherichia coli (Thermo Fisher Scientific, Rockford, USA).
[0402] In vitro characterization of the HLA-ABab.I transgene by flow cytometric analysis
[0403] Surface HLA class I expression was analyzed by flow cytometry 48 hours after each transient transfection. MCA205 cells were treated with or without recombinant IFN-γ (100 ng / ml) in transfection experiments. 10 μl Lipofectamine TM 2000 delivered the primary polycistronic ABab.I transgene and all modified HLA constructs. Two days after transfection in each case, cells were stained using fluorescent dye-conjugated antibodies against human pan HLA-ABC and β2 microglobulin. MCA205 cells were transfected with linearized DNA constructs digested with AscI-PacI, followed by multiple enrichment of HLA by flow cytometry-based cell sorting using pan HLA-ABC antibodies. + Cell population, MCA205 / ABab.I stable cell line was prepared.
[0404] Quantification of transgenic mRNA using quantitative RT-PCR analysis
[0405] As described above, H-2D b MCA205 cells were transiently transfected with constructs modified with polyadenylation signals driven by the CMV promoter. Two days later, total RNA in cell lysates was reverse transcribed using anchored oligo(dT) and random hexamers. RNA was used in quantitative RT-PCR (qRT-PCR) reactions. Green dye was used to quantify cDNA amplification with HLA-specific primers. As controls, 18S rRNA (housekeeping) and constitutive H-2D b Based on the Ct value, the expression difference was estimated as ΔCt = Ct (HLA / H-2D b )–Ct(18s rRNA). By targeting it to the reference gene mouse H-2D b (set to 100%), the percent change in expression was measured.
[0406] Construction of genome targeting vector
[0407] Six chimeric HLA alleles, HLA-A*03:01, A*11:01, B*07:02, B*15:01, C*04:01 and C*07:02, were cloned into the mammalian minimal expression vector pMA plasmid as natural HLA haplotypes identical to humans. For mouse genome targeting, the 5'-AscI and 3'-PacI sites were sequentially digested and blunted to insert the highly active PiggyBac restriction inverted terminal repeats (ITRs) to generate an oocyte targeting vector.
[0408] Generation of ABAB.I transgenic mice using pronuclear injection
[0409] In vitro transcribed (ivt) PiggyBac (PB) transposase mRNA targets the ABab.I transgenic cassette flanked by ITRs into recipient oocytes. 10-12 week old ABabDII male mice are mating partners. 6-10 week old ABabDII female mice are superovulated to collect oocytes before mating. NMRI mice serve as pseudopregnant foster mothers. Donor HLA plasmid (ABab.I transgenic) and PB transposase (ivt mRNA) are co-prepared at a molar ratio of 2:1. As described, a mixed sample of DNA and ivtmRNA is pronuclearly microinjected into fertilized ABabDII oocytes. All mouse experiments are performed in accordance with standard guidelines approved by Landesamt für Arbeitsschutz, Gesundheitsschutz und technische Sicherheit.
[0410] Genotyping of HLA I haplotypes in ABab.I.Tg mice
[0411] Genomic DNA was extracted from ear biopsies of transgenic mice at 95°C in the presence of 0.05 M NaOH. HLA-specific primers for amplified fragments of all six chimeric fusion alleles were used for conventional PCR using Taq DNA polymerase. 18s rRNA and human TCRαβ were control reactions. PCR amplicons were electrophoresed on a 1.5% gel at 100 V for 45 minutes using an agarose gel electrophoresis system. PCR primers were:
[0412]
[0413]
[0414] Estimation of absolute numbers of CD3+CD8+ / CD4+ in blood and lymphoid organs
[0415] Preparation of blood: Block Fc receptor III / II of 50 μl blood from each mouse (from each strain) with anti-CD16 / 32 antibody. Lyse erythrocytes with erythrocyte lysis buffer (ACK buffer) prior to staining and flow cytometry. Preparation of lymphoid organs: Spleens and lymph nodes (axillary, brachial, mediastinal, inguinal, and mesenteric) from 8-12 week old mice were mashed and filtered through a 70 μm cell strainer. Combine the ACK-lysed spleen and lymph nodes by passing them through a 40 μm filter. Staining of blood and lymphoid organs for T cell counting: Samples were stained with fluorescent dye-conjugated CD3, CD8, and CD4 antibodies. Each sample was stained with CountBright in an 11 μl volume (11,880 beads). TM Beads were counted and T cells were quantified by flow cytometry.
[0416]
[0417] Enrichment of T cell population (CD3+CD8+) using non-contact FACS sorting
[0418] Lymphoid cells and whole blood from young ABabDII or ABab.I mice (8-12 weeks old) were prepared and pooled using the previously described protocol (see 2.2.7, Preparation of Blood and Lymphoid Organs). TM Mouse T Cell Non-Contact Isolation Kit (Stemcell Technologies GmbH, Cologne, Germany) was used to enrich CD3 from pooled cell suspensions by bead-based magnetic separation (without the use of columns). + Briefly, cell suspensions (2 × 10 8 cells / ml). - ) were used to stain the pooled cells from spleen, lymph nodes, and blood. Streptavidin-coated magnetic beads (75 μl / ml) were used to bind these CD3 - Cell capture with EasySep TM On the magnet, CD3 + The cells are then collected by passing them through a magnetic field into the flow-through solution. + Cell populations were surface stained with fluorescent antibodies specific for CD3, CD8 and CD4 markers. Flow cytometry-based sorting enriched CD3+CD8+ T cells (purity > 97%) were used for organic DNA (genomic) extraction using the phenol-chloroform method.
[0419] use Deep sequencing of the TCRβ repertoire of ABab.I. mice using a novel technology
[0420] Deep sequencing of the TCRβ immune repertoire was performed in Adaptive Biotechnologies (Seattle, USA). The platform accurately quantifies the full VJ gene set in a cell population using a multiplex PCR-based assay, in which a bias correction is performed in the first step to minimize amplification bias. The assay also provides quantitative abundance data with a sensitivity of 1 in 200,000 T cells. 5 2-4 μg genomic DNA / sample (average in mice) from 1.8×10 5 Personal CD8 + 1.5 μg genomic DNA / sample obtained from T cells was subjected to deep sequencing. Three healthy human donors (age: 30, 48 and 60 years old) donated blood with informed consent. Blood collection and processing were performed under license EA4 / 046 / 10 (Ethics Committee) according to the human experimental guidelines. Computational analysis of sequencing data was performed by Adaptive Biotechnologies. ImmunoSEQ TM The analyzer portal provides access. TCR sequences are named based on the immunogenetics (IMGT) nomenclature. For example, for CD4 + Statistical analysis was performed using the R program as described for T cells.
[0421] Retroviral transduction of mouse splenocytes
[0422] Ecotropic retrovirus (infects mouse / rat cells only) packaging cell line, Platinum-E 188 (Plat-E) Lipofectamine was used to transfect with pMP71 retroviral plasmid (3 μg / construct) encoding T cell receptor genes (configuration: TCRβ-mCβ-P2A-TCRα-mCα) at 80% cell fusion rate. At different time points, 3 ml of viral supernatant was harvested twice using a 0.45 μm membrane filter and used to infect mouse ABabDII spleen cells. Spleen and lymph nodes were prepared and combined using the previous protocol (refer to 2.2.7, preparation of lymphoid organs). In the presence of 40 IU / ml recombinant mouse IL-2 (cell concentration adjusted to 2×10 6 Splenocytes were preactivated with anti-CD3 (1 μg / ml) and anti-CD28 (0.1 μg / ml) antibodies in the presence of 2×10 cells / ml. Two transductions were performed 48 hours and 72 hours after transfection. In the first transduction, the supernatant containing viral particles was first centrifuged (3000 g, 4°C for 90 minutes) onto a non-tissue culture 24-well plate coated with fibronectin. 2×106 Pre-activated splenocytes were supplemented with 8 μg / ml protamine sulfate (PS), 10 μl CD3 / CD28 Dynabeads TM , 40IU / ml IL-2 in mTCM medium, added to the virus-captured plate, and centrifuged at 32°C 800g for 30 minutes. At the second transduction, 1ml of supernatant was removed from the top layer of the 24-well plate and replaced with a batch of fresh virus harvested at the 72-hour time point (supplemented with 8μg / ml ps, 40IU / ml IL-2) and centrifuged at 32°C 800g for 90 minutes. After the second transduction, the transduced splenocytes were adjusted to have 2×10 6 The cells were cultured at a concentration of 10 cells / ml and supplemented with 50 ng / ml murine IL-15.
[0423] In vitro functional characterization of HLA alleles expressed in ABab.I.Tg mice
[0424] IFN-γ production in the supernatant of the co-culture assay was monitored by enzyme-linked immunosorbent assay (ELISA). 4 TCR-transduced effector T cells and 5×10 4 Target cells (MCA205 / ABab.I tumor cells or peripheral blood cells / lymphoid organs from ABab.I mice) were co-cultured overnight (16 hours). Target cells were pulsed with peptides (1 μM / peptide) or with phorbol myristate acetate (PMA) and ionomycin (1 μM each) as positive controls.
[0425] In vivo characterization of the HLA-ABab.I transgene by peptide immunization
[0426] 200 μl of injection suspension containing 100 μg of short peptide in PBS, 100 μl of incomplete Freund's adjuvant and 50 μg of CpG oligonucleotide were injected subcutaneously in both lateral sides of the hind legs. Young ABabDII or ABab.I mice (6-7 mice / group) aged 10 to 20 weeks were immunized with a 4-week interval between primary immunization and boost. A similar peptide mixture was prepared and injected for a further boosting regimen of all peptides. As a standard control, 100 μg of MAGE-A1 278 KVLEYVIKV (SEQ ID NO: 26) peptide and similar injection mixture immunization ABabDII 1and ABab.I mice. 7-10 days after each booster injection, peripheral blood cells from immunized mice were ACK lysed and cultured for 5-6 hours with 1 μM of each specific or nonspecific peptide in the presence of a protein transport inhibitor. After cell fixation, intracellular IFN-γ staining, surface CD3, CD8 marker staining, and analysis by flow cytometry.
[0427] Statistical analysis
[0428] GraphPad Prism software was used to generate standard curves, plot graphs, and calculate statistical significance levels using mean and standard deviation (P value). FlowJo TM Raw flow cytometry data (.fcs files) were statistically analyzed by means of mean fluorescence intensity values.
[0429] result
[0430] Cancer mutagenesis screening generates potential neoantigens for adoptive T cell therapy
[0431] In silico screening of frequent hotspot mutations that generate putative tumor-specific antigens (TSAs) using an open-source server Figure 2 , Tables 1 and 2). Using literature research, 266 “non-synonymous somatic point mutations” previously described in 40 different genes were selected as TSAs ( Figure 2 A). Selected point mutations (occurring in ≥2 patients) were detected primarily by whole-exome sequencing analysis in 21 different human cancer entities; mutation frequencies ranged from 0.1% to 39%. The NetMHC program predicted the affinity of mutated and wild-type epitopes to HLA alleles under the applied selection criteria ( Figure 2 B) Of these 266 mutants, 175 epitopes showed in silico strong binding affinity (IC 50 :<50nM)( Figure 2 C). The ABabDII mouse model expressing HLA-A2 provides a platform for analyzing the immunogenicity of 23 HLA-A2-restricted binders ( Figure 2 D, left). Among 152 non-HLA-A2 binders, 68 putative epitopes bind to "HLA-A*0301-A*11:01, B*07:02-B*15:01, C*04:01-C*07:02", a novel class I haplotype similar to humans. The restriction status of these six HLA alleles to multiple (>5) mutated epitopes provides a rationale for generating ABab.I mice ( Figure 2 D, right).
[0432] Human T cell receptors (TCRs) isolated from ABabDII and ABab.I mice can be clinically applied for adoptive T cell therapy (ATT) of cancers targeting endogenously processed mutant antigens.
[0433] The ABabDII mouse model elicits HLA-A2-restricted neoantigen-specific T cell responses
[0434] To address the restriction of neoantigen-specific CD8 + For T cell responses, we selected the mutation S722F that frequently occurs in the N-terminus of the transformation / transcription domain-associated protein (TRRAP) gene. In our prediction screen, the serine to phenylalanine mutation at position 722 produced an IC 50 55nM HLA-A2 epitope ( Figure 3 A and 3B). TRRAP proteins are transcriptional cofactors involved in cellular transformation through MYC activation. 4% of melanoma cases, totaling 86,000 incidences / year, express the S722F driver mutation. Considering that these 4% with S722F express HLA-A2, with an allele frequency of 26.5% in Europe, it is estimated that (theoretically) approximately 911 individuals per year could undergo ATT after a previous line of treatment ( Figure 3 B). Similarly, a worldwide estimate of individuals / year with the TRRAP-S722F mutation was calculated using data sets from various continents such as the United States, South America, and Asia (data not shown). Mice have TRRAP orthologs to ensure thymic deletion of wild-type epitope-restricted T cells ( Figure 3 C).
[0435] To discover TCR candidates, the cells were challenged with mutant 9-mer peptides ( Figure 3 B, KLVFGSV F L, SEQ ID NO: 30) to immunize young ABabDII mice (n=7, 12-16 weeks old). One week after each booster immunization, CD8 + T cell responses, followed by culture of T cells and IFN-γ capture assay to isolate peptide-specific T cells ( Figure 4 A). One week after the 4th injection (3rd boost) regimen, approximately 0.8% of T cells responded in the blood ( Figure 4 B), in low peptide (10 -9 M) and IL-2 (20 IU / ml) for 10 days, it expanded up to about 17% in the spleen ( Figure 4 C) After T cell culture, -6 After 2 h of stimulation with M peptide concentration, 12,000 IFN-γ specific for S722F were captured.+ CD8 + cell( Figure 4 D). No wild-type specific T cell responses were observed after in vitro restimulation ( Figure 4 B, 4C and 4D). 5'-RACEPCR generated a dominant TCRαβ pairing ( Figure 4 E) 5'-RACE amplification method using primers annealing to the constant TCR αβ and the anchored 5'-adapter region as described previously.
[0436] In the figure ( Figure 4 E), the following SEQ ID NOs are applied to the listed CDR3 regions:
[0437]
[0438]
[0439] Transduced T cells were incubated with peptide-titrated T2 (TAP - / - ) cells to ensure TCR interaction and its affinity for S722F. Dominant TCRV α 17-V β The 27 pair recognized S722F by producing IFN-γ in the absence of wild-type epitope recognition, which was sensitive enough to reach 10 -11 M peptide concentration ( Figure 4 F, left). TRRAP + Human cell lines were co-cultured with transduced T cells to verify proteasomal processing of epitope S722F. Transduced T cells recognized neither A375 cells nor SK-Mel-37 cells; they were positive for mutant and wild-type TRRAP, respectively. NY-ESO 157-165 , this HLA-A2 epitope is expressed on melanoma cells A375 and SK-Mel-37. TCR-ESO (control TCR) recognized NY-ESO by producing IFN-γ 157-165 Epitope ( Figure 4 F, right).
[0440] Therefore, we demonstrated that the TRRAP mutation-derived neoantigen S722F 715-723 The 9mer is not endogenously processed and is not presented on HLA-A2.
[0441] ABab.I transgene designed to reflect natural human HLA haplotype
[0442] Epitopes from 23 mutations in TRRAP, C-KIT, XPO1, FOXA1, RAC1, RAC2, RHOT1, TP53, MAP2K1, EGFR, TRAF7, SMO, SF3B1, FBXW7, SPOP, EZH2, FLT3, NFE2L2, TSHR, PTPN11, and NOTCH1 were predicted to bind to HLA-A2 ( Figure 2 C, pie chart). Similar to TRRAP-S772F ( Figure 4 A), Immunogenicity analysis of mutant peptides from the first four genes. ABabDII mice do not produce CD8 after immunization with C-KIT (K642E), XPO1 (E571K), and FOXA1 (D226N) epitopes. + T cell responses (data not shown). ABabDII mice provided the opportunity to isolate TCRs restricted to only these 23 HLA-A2-binders.
[0443] 8 / 152 non-HLA-A2 binders were predicted ( Figure 2 C, pie chart) combined with at least one allele of a novel HLA haplotype, which is A*0301-A*11:01, B*07:02-B*15:01 and C*04:01-C*07:02, similar to the HLA situation in humans (six genes per individual). To understand the biology of the complete human haplotype in mice and target the other 68 high-affinity mutants (Table 14), we designed the ABab.I transgene based on the computer screening results to reflect the human HLA haplotype ( Figure 5 ).
[0444] Table 14: Computer predicted mutant epitopes binding to ABab.I HLA haplotype.
[0445]
[0446]
[0447]
[0448]
[0449]
[0450]
[0451]
[0452]
[0453]
[0454] The prediction program suggests that HLA-A*03:01 binds to a total of 8 mutated epitopes, A*11:01 binds to a maximum of 21 epitopes. B*07:02 binds to 6 epitopes, B*15:01 binds to 12 epitopes, C*04:01 binds to 13 epitopes, and C*07:02 is limited to 8 epitopes on the computer ( Figure 5 A and Table 14).
[0455] Total number of individuals / year with mutations based on three factors predicts likelihood of ATT treatment worldwide ( Figure 5 B). Estimated to be about 11,220 A*03:01 + Individuals / year carry mutations that generate targeted epitopes. Similarly, theoretically, this would be about 70,389 A*11:01 per year. + 、About 1,381 B*07:02 + 、About 2,651 B*15:01 + 、About 21,532 C*04:01 + 、About 10,451 C*07:02 + As a possible individual carrying a mutation ( Figure 5 C). A total of approximately 117,624 individuals / year are estimated to carry these 68 recurrent point mutations in their cancers worldwide; the predicted epitopes listed (Table 14) bind to at least one allele in this new class I haplotype. In the ABab.I transgenic design, six highly expressed HLA alleles similar to human HLA structure are encoded as a polycistronic expression cassette ( Figure 5 D).
[0456] Polycistronic HLA transgenes are transcribed to produce mRNA but are not translated to express protein
[0457] Polycistronic primary ABab.I and fully modified constructs ( Figure 6 A) No HLA allele expression after staining with pan HLA ABC antibody ( Figure 6 B) HLA expression was measured 48 hours after transient transfection. Polycistronic, H-2D b The ABab.I driven MCA205 cells showed no surface HLA expression. 39% of cells expressed GFP. 98% of LCL-BM14 cells showed endogenous HLA expression ( Figure 6 B, I). LCL-BM14 is an EBV-transformed lymphoblastoid B cell.
[0458] Six HLA were converted by enhanced GFP (eGFP) gene or CMV promoter converted H-2D b To obtain promoter activity ( Figure 6 A, II). 13% of MCA205 cells expressed H-2D b 53% of cells expressed GFP from the control pMP71-eGFP retroviral plasmid ( Figure 6 B, II). However, H-2D was converted by CMV b The promoter could not rescue the expression of the six HLAs ( Figure 6 B, II).
[0459] Next, 1 kb full-length (FL) H-2D b or synthetic 350bp bovine growth hormone (bGH) pA replacing 500bp H-2D b Polyadenylation (pA) sequences to analyze defects in transcription termination. H-2D b or CMV promoter-driven pA-modified constructs, and their surface expression was analyzed by flow cytometry staining ( Figure 6 A, III). None of the pA-modified constructs showed significant HLA surface expression following transient transfection (data not shown).
[0460] H-2D b The primary ABab.I construct with all respective pA modifications driven by the promoter and the CMV promoter ( Figure 7 A) mRNA production in MCA205 cells ( Figure 7 B). HLA mRNA was detected using cDNA amplification with specific primers for the three viral peptide linkers P2A (pro-region), F2A (middle region) and C2A (terminal region). After transient transfection, HLA mRNA was expressed in mice (endogenous D in MCA205 cells). b gene) compared to H-2D b The promoter-driven bGH pA construct produced up to 7% HLA expression. b The promoter-driven FL pA and primary ABab.I constructs resulted in 6% and 2% HLA expression, respectively ( Figure 7 B, I). Significantly increased mRNA production in the CMV-driven bGH pA construct relative to endogenous D b The relative change in expression was 193%. The FL pA and CMV-primary ABab.I constructs did show a relative increase in expression relative to the basal H-2D b 138% and 75% relative changes ( Figure 7 B, II).
[0461] HLA alleles are stably expressed when driven by their own 5' and 3' regulatory elements
[0462] H-2D driving six HLA alleles in a polycistronic configuration with bGH pA b The promoter does produce HLA mRNA, but not protein ( Figure 6 and 7 ).
[0463] The six HLA alleles were cloned as monocistronic clones with or without β2 microglobulin (β2m) Figure 8 A, I) to test their expression before they were placed together into a single class I haplotype, each with its regulatory elements ( Figure 8 A, II). The single chain without (linked) β2m is co-transfected with the β2m plasmid exogenously. Each leader sequence guides HLA translocation in the β2m non-linked single chain, for example, the A*03 leader peptide is cloned in the HLA-A*03:01 construct instead of the β2m leader sequence.
[0464] MCA205 cells were transfected with or without β2m-linked single chains in the presence or absence of IFN-γ ( Figure 8 A, I). HLA single chains without β2m transfection (β2m co-transfected) did not show any significant differences in surface expression of HLA alleles (data not shown). Here, all six monocistrons (as β2m-linked single chains) were stained with pan HLA ABC and anti-human β2m antibodies and measured by flow cytometry in transiently transfected MCA205 cells ( Figure 8 B).
[0465] Pan HLA ABC antibody staining of transiently transfected MCA205 cells treated with 100 ng / ml IFN-γ for 48 h during transfection increased HLA expression of single chains ranging from 9- to 23-fold for A*03 (5.4% to 52%), A*11 (6% to 59%), B*07 (5.6% to 57%), B*15 (5.6% to 56%), C*04 (2.3% to 52%), and C*07 (2.6% to 48%). Figure 8 Similarly, transiently transfected MCA205 cells stained with anti-human β2m and treated with 100 ng / ml IFN-γ for 48 h during transfection increased HLA expression of A*03 (8.6% to 15%), A*11 (9.3% to 22%), B*07 (5.4% to 20%), B*15 (3.9% to 18%), C*04 (1.6% to 12%), and C*07 (3.7% to 14.6%) single chains in the range of 1.5- to 8-fold ( Figure 8 C).
[0466] The ABab.I transgene encoding six chimeric monocistronic genes was transfected into the MCA205 cell line for HLA expression analysis. The ABab.I HLA haplotype encodes six alleles back to back in a head-to-tail configuration. All six genes contain their own promoters and polyadenylation signals ( Figure 8 A, II).
[0467] Two days after transfection, 16% of cells were HLA allele positive ( Fig. 9 A, top). Flow cytometry sorting enriched HLA in transfected cells. + Two days after sorting and in vitro culture, cells were pretreated with or without IFN-γ and stained with pan HLA ABC antibodies. 41% of cells stained for HLA in the absence of IFN-γ, while 77% of MCA205 cells stained for HLA alleles after 48 hours of enrichment in the presence of IFN-γ in culture ( Fig. 9 A, lower panel). At the same time, HLA-specific antibodies were used to sort the cells (HLA + After 48 hours of 100 ng / ml IFN-γ treatment, HLA expression increased in the range of 2- to 4-fold after staining with A*03-specific (19% to 73%), B*07-specific (17% to 69%), and pan HLA-C (32% to 69%) antibodies ( Fig. 9 B, 9C and 9D). AscI-PacI digested and linearized ABab.I DNA was used for MCA205 transfection to generate the stable cell line MCA205 / ABab.I. HLA was sorted by flow cytometry at different time points + After multiple enrichment of cells, 92% of the cells expressed the ABab.I transgene ( Fig. 9 E).
[0468] PiggyBac transposon-mediated targeting generates ABab.I founder mice with six HLAs as a single haplotype
[0469] The ABab.I HLA cassette was transiently expressed on the surface of murine MCA205 cells in vitro ( Fig. 9 A and 9B) and stable ( Figure 8 C) expression.
[0470] In vivo integration of HLA haplotypes was achieved using the highly active PiggyBac (PB) transposon system. The PB transposase acts on the ITR-flanked targeting vector (HLA-carrying cassette) by a cut-and-paste mechanism. The enzyme is co-transfected with the mRNA and excises (cleaves) the 5' and 3' ITR regions to release the insert (HLA) for integration (pasting) into the transcriptionally active site of the mouse genome ( Fig.10).
[0471] After successful rounds of pronuclear injection, allele-specific PCR confirmed the presence of six HLA alleles in two founder animals ( Fig.11 A). Using genotyping PCR, ear biopsy sample DNA confirmed genomic integration of the F0_Q4115 and F0_Q4118 alleles ( Fig.11 A, left). As controls, the 18s rRNA housekeeping gene and the human TCRαβ gene ( Fig.11 A, right). Three additional founders: F0_Q6844, F0_Q8552 and F0_Q8556 were genotype positive (data not shown). According to the standard breeding model, a stable homozygous ABab.I mouse strain was established from the Q6844 line ( Fig.11 B).
[0472] Using anti-human β2m antibody, LCL-BM14 cells (99% β2m + ) was used as a control, and HLA expression was stained and quantified in peripheral blood cells of C57BL6 / N, ABabDII and ABab.I mice ( Fig.12 A and 12B). 3% and 7% of lymphocytes from ABabDII mice, and 35% and 40% of lymphocytes from ABab.I mice, were stained with β2m antibody for HLA expression ( Fig.12 A). Two ABab.I mice from founder line Q6844 are shown here. Other founders including Q4115, Q4118, Q8552, and Q8556 were tested for HLA expression (data not shown). Mouse-to-mouse variability was analyzed by staining multiple mice per line. Comparison of mean fluorescence intensity (MFI) of β2m revealed that HLA expression in ABab.I was 4 times higher than that in ABabDII. A 120-fold higher MFI ( Fig.12 C and 12D). One possible explanation could be that the folding characteristics of human HLA proteins are different from those of the chimeric fusion molecule, which could hinder the access of the epitope to the β2m antibody, which requires further analysis.
[0473] ABab.I mice have higher CD8+ T cell counts compared to single HLA-bearing ABabDII mice
[0474] Phenotypic T cell characterization describes increased thymic output / peripheral survival in ABab.I mice (founder F0_Q6844 lineage) compared to ABabDII and HHD mice ( Fig.13). HHD mice have a mouse TCR repertoire selected on human HLA-A2. CD8 + CD4 + Spectral analysis (in CD3 + Cells) showed that 13% and 14% of CD8 + T cells, about 6% in both HHD mice, 36% and 45% in ABab.I, and 36% and 41% in C57BL6 / N mice ( Fig.13 A) Two mice / strains are shown here. CD8 in ABab.I mice + T cell fractions (%) were comparable to those in C57BL6 / N mice. + T cells in HHD mice are 90% CD4 + , in AB ab In DII, it was 64%, in ABab.I, it was 45%, and in C57BL6 / N mice, it was 55% ( Fig.13 A) A significant number of ABab.I mice accumulated 4-fold more CD8 + T cell count ( Fig.13 B) With high CD8 + ABab.I mice with T cell counts were crossed in F2 to generate stable mouse lines ( Fig.11 B) No CD4 was observed + There were significant differences in T cell numbers ( Fig.13 C). The CD8 / CD4 ratio was higher in ABab.I mice, similar to that in C57BL6 / N mice and 3-fold higher than that in ABabDII mice ( Fig.13 D).
[0475] CD8 + and CD4 + Comparison of T cell populations (in CD3 + Cells) showed 14% and 12% of CD8 + T cells, and 62% and 67% of CD4 + T cells, and 47% and 44% CD8 in ABab.I + T cells, and 39% of CD4 + T cells ( Fig.14 A) On average, AB ab .I mice were estimated to have 3.5-fold more absolute CD8 + T cell count ( Fig.14 B) and absolute CD4+ There was no significant difference in T cell numbers ( Fig.14 C). Similar to peripheral blood, the CD8 / CD4 ratio was higher in ABabDII mice, 2.5 times higher than that in ABabDII mice ( Fig.14 D).
[0476] Wider CD8+ T cell repertoire in ABab.I mice compared with ABabDII mice
[0477] Deep sequencing of the TCRβ repertoire quantified CD8 + The number of unique in-frame amino acid (aa) clonotypes in T cells was 11.2±2.7×10 4 and 4.8±0.80×10 4 indivual( Fig.15 A). Among three age-mismatched individuals, the 30-year-old donor had a similar number of clonotypes compared to ABab.I mice, 11.4 ± 4.1 × 10 4 indivual( Fig.15 A). The total number of unique aa clonotypes in human donors had high variability. Given the large variability in age (30, 50, and 65 years), we excluded human data from clone size analysis. ABab.I mice had 8.5% rare clones, while ABabDII had 5.7% rare clones ( Fig.15 B). However, ABabDII mice had three times more small clones (4.1%) than ABab.I mice, which had 1.4% small clones ( Fig.15 B) Using ImmunoSEQ TM Deep sequencing does not allow for complete coverage of the entire repertoire. Therefore, computational statistics were used to determine the CD8 + An estimate of the total TCR repertoire in T cells. The iChao1 estimator calculates the total number of clonotypes (observed and undetected) for each mouse using information from clones that occur only once or twice. iChao1 uses a lower bound of rare occurrences to estimate true species richness. The first human donor, a 30-year-old individual, had up to 2 × 10 6 clones, with an average of 1×10 6 After humans, ABab.I mice had an average of 0.66×10 6 ABabDII has 1.8×10 5 The lowest estimate of clonotypes ( Fig.15 C) Analysis of V present in out-of-frame and in-frame TCRβ clonotypes β ( Fig.16 A) and J β( Fig.16 B) Gene usage. The latter represents the preselection pool, which is an unbiased measure of the diversity of all possible V(D)J recombination events that may occur before positive selection. In ABabDII mice, and therefore in ABab.I mice, most of the detected V β The fragments were rearranged, except for TRBV5-1 and TRBV6-1, which were previously reported to be absent or lack expression ( Fig.16 A). ABabDII and ABab.I mice in the pre-selected library in any preferred V β No differences were shown in the use. Similarly, in humans, the outside V β Gene usage patterns were comparable, without any selection bias.
[0478] In the pre- and post-selection libraries, some V β Genes are over- or under-expressed in mice. Over-expressed V β The genes include TRBV20, TRBV21, TRBV23, TRBV27, and TRBV28. β The genes include TRBV6-2 / 6-3, TRBV6-4, TRBV7-9, TRBV9-1, and TRBV10-1, most of which are closer to the 5' end ( Fig.16 A, top). Single nucleotide polymorphisms may account for this difference in performance. Compared with humans, two V β Genes such as TRPV7-3 and TRPV12-3 / 12-4 are preferentially over-expressed ( Fig.16 A, upper figure).
[0479] V in the frame β The genes represent the post-selection repertoire with similar frequencies, except for some genes in the 5' region, such as TRBV2-1, TRBV4-1, and TRBV7-9, which were highly selected-in by positive selection, while V β Genes such as TRBV7-3, TRBV20 / 21 / 23 / 24 and TRBV25 are selected-out in the thymus ( Fig.16 A, bottom). In the post-selection pool of one or the other mouse, only one V β Gene, AB ab .V in I β 4-1 and AB ab V in DII mice β 12-3 / 12-4 appear to be primarily expressed ( Fig.16 A, lower figure).
[0480] Between transgenic mice and humans β Gene usage is also non-random and similar ( Fig.16 B) Although some J β Segments are more frequently used in mice than in humans: TRBJ1-2, TRBJ2-1, and TRBJ2-3 ( Fig.16 B, upper panel). It is noteworthy that in mice, compared with humans, the J β 2-07 performed well, with a total usage of ∼30% in the post-selection pool ( Fig.16 B, lower figure).
[0481] ABab.I mice are enriched for T cell receptors containing longer CDR3s
[0482] V(D)J recombination events in the TCRβ chain generate CDR3 diversity and, in combination with VJ events in the TCRα chain, are responsible for antigen recognition. ABab.I mice are enriched with significantly longer CDR3β regions than ABabDII mice.
[0483] Taking into account the shorter CDR3 length, in ABabDII, 5.5% of the clones expressed TCRs with 33bp CDR3 sequences, 11.5% of the clones expressed TCRs with 36bp CDR3 sequences, and 21% of the clones expressed TCRs with 39bp CDR3 sequences. In ABab.I, the lengths were equivalent to 4.9% of the clones expressing TCRs with 33bp CDR3 sequences, 10% of the clones expressing TCRs with 36bp CDR3 sequences, and 19% of the clones expressing TCRs with 39bp CDR3 sequences. In ABab.I mice, a higher percentage of clones expressed longer CDR3 sequences than in ABabDII mice, with 48bp CDR3 sequences at 23% vs. 21%, 51bp CDR3 sequences at 10% vs. 8.3%, and 54bp CDR3 sequences at 3.7% vs. 3.4% ( Fig.17 A). However, humans produce the longest CDR3β sequence compared to mice ( Fig.17 A). On average, ABab.I mice have TCRs with a CDR3 length of 42 ± 0.1 bp, while the CDR3 length in ABabDII mice is 41.5 ± 0.06 bp, but not longer than the average CDR3 of 43.5 ± 0.18 bp in humans ( Fig.17 B).
[0484] The natural human HLA haplotype in ABab.I mice generates a large number of unique clones
[0485] Common clones were compared between mouse strains and between humans using the Jaccard similarity index estimate. The Jaccard index (J) evaluates the shared immune repertoire between samples. The J index ranges from 0 to 1, and the score is calculated based on the following formula: the total number of shared clones between two samples divided by the total number of unique clones J(A, B) = A∩B / A∪B. Compared with cross-strains (ABab.I with ABabDII, or vice versa), high shared clonality within strains (ABab.I with ABab.I, or ABabDII with ABabDII) was detected. ABab.I mice share ~6.4% of clones with each other, Jaccard index: 0.0636±0.003, and ABabDII mice share ~5% of clones within their group, Jaccard index: 0.0498±0.004 ( Fig.18 A). Humans shared more clones with ABab.I mice (Jaccard index: 0.006±0.001) than with ABabDII mice (Jaccard index: 0.005±0.001), or there was no statistically significant difference between them ( Fig.18 A).
[0486] Both ABabDII and ABab.I generated more common TCRβ clones between each other than they did with humans, presumably due to the likelihood of a genetic background similar to the human TCR loci. Notably, ABab.I mice shared fewer clones with ABabDII than within their group (0.0636±0.003), Jaccard index: 0.04±0.003 ( Fig.18 A).
[0487] ABab.I mice generated more unique clones than ABabDII mice. Pooled analysis from 5 mice per strain determined the total number of shared and unique clones. ABabDII and ABab.I mice shared less than 100,000 clones with each other (0.8 × 10 5 Compared with 2×10 in ABabDII mice 5 TCRβ clones, ABab.I mice produced almost 4 times more unique and rare clones (ABab.I: 7.5×10 5 indivual)( Fig.18 B).
[0488] HLA alleles in ABab.I mice efficiently present epitopes and elicit ex vivo T cell responses
[0489] To determine epitope presentation of HLA alleles in newly generated ABab.I mice, peripheral blood or lymphoid organ cells isolated from mice were co-cultured with T cells transduced with TCRs that recognize model epitopes. TCRs (A3-, A11-, B7-, B15-, and C7-restricted) or in-house generated (C4-restricted) were used in the co-culture assays against a panel of model antigens obtained from literature sources. Fig.19 A). The following SEQ ID NOs apply to Fig.19 A:
[0490]
[0491]
[0492] The mouse IFN-γ of co-culture supernatant was analyzed to evaluate the HLA allele recognition of effector T cells for binding to their respective model epitopes. As a positive control, MCA205 / ABab.I cells expressing six HLA alleles as in ABab.I mice were used as target cells to present the model epitopes to transduced T cells. After 16 hours of co-culture, IFN-γ was measured in the supernatant to confirm functional activity. All five model TCRs recognized their respective peptide HLA combinations (pHLA-TCR) and produced IFN-γ (range 9437 ± 863pg / ml-11,877 ± 299pg / ml). Fig.19 B).
[0493] Peripheral blood and lymphoid organ cells were used as target cells to measure pHLA-TCR interactions in ABab.I mice ex vivo. After blood pHLA recognition, all TCR-transduced T cells produced IFN-γ, with a minimum release of 4168±308 pg / ml and a maximum release of 7873±212 pg / ml ( Fig.19 C), demonstrating functional activity. Similarly, recognizing pHLA from secondary lymphoid organs (spleen, lymph nodes as target cells), all T cells transduced with the model TCR released IFN-γ ranging from 5540±216pg / ml–8054±270pg / ml ( Fig.19 C).
[0494] PMA / ionomycin activated protein kinase C and turned on calcium (Ca) in transduced T cells. 2+ ) channel to maximize IFN-γ release. In untransduced T cells, no IFN-γ release was measured (only low background) ( Fig.19A and 19B). HLA-A2 (present in ABab.I mice) restricted TCR, T1367 transduced T cells were used in co-culture as an internal reference control in all presentation assays. Model TCRs against the CMV pp65 epitope were isolated from immunized HuTCR mice expressing HLA-C*04:01 as a single chain (see Discussion Section 4.5). All model epitopes used in co-culture assays ( Fig.19 A) CD8 T cells were used for in vivo immunization of ABab.I mice to analyze IFN-γ release using intracellular staining + T cell response.
[0495] ABab.I mice mount immune response against peptide antigens
[0496] We used peptide immunization ( Fig. 20 ) analyzed the antigen-specific CD8 + T cell response ( Fig.19 A). All six model antigens were predicted in silico to be strong binders of their respective HLA alleles. Approximately 1.8% of CD8 + T cells produced IFN-γ against the mutant calreticulin (mCALR) protein-derived epitope KMRMRRMRR (SEQ ID NO: 173). Approximately 6.9% of CD8 + T cells released IFN-γ against the mutant KRAS protein derived G12V epitope VVGAVGVGK (SEQ ID NO: 174), about 1.4% against the CMV epitope TPRVTGGGAM (SEQ ID NO: 175) bound by B*07:02, about 0.2% against the HPV epitope SAFRCFIVY (SEQ ID NO: 176) bound by B*15:01, about 0.3% against the CMV epitope QYDPVAALF (SEQ ID NO: 177) bound by C*04:01, and about 0.23% against the MAGE-A12 epitope VRIGHLYIL (SEQ ID NO: 178). Fig. 20 ). The MAGE-A1 epitope, KVLEYVIKV (SEQ ID NO: 179), bound HLA-A2 triggered ~1% of CD8 + T cell responses. The nonspecific peptide used in the in vitro restimulation was the NY-ESO epitope APRGPHGGAASGL (SEQ ID NO: 180). No T cell responses were observed against the nonspecific peptide in any case, demonstrating a specific response against the immunizing peptide. CD8 + T cell responses ranged from 1.7% to 14% ( Fig. 20 ). Therefore, CD8 + T cell responses characterize the in vivo functionality of human HLA haplotypes.
[0497] discuss
[0498] In the course of the present invention, we generated an "ABab.I transgenic mouse model" with six HLA class I alleles on a "humanized TCR" mouse background using the piggyBac transposon strategy. We confirmed the human HLA haplotype in the mouse by genotyping the six HLAs using allele-specific PCR. We confirmed the phenotype by staining with as many pan- and HLA-specific antibodies as available using flow cytometric analysis. We provided evidence by analyzing CD8 + and CD4 + T cells support the increased thymic output in ABab.I mice. We used ImmunoSEQ TM Deep sequencing characterized the immune repertoire and observed that ABab.I mice had a four-fold broader T cell receptor repertoire than ABabDII mice. We used an IFN-γ release assay to measure the expression of effector CD8 + T cells demonstrated antigen presentation efficiency for all six HLA alleles present in ABab.I mice both ex vivo and in vivo.
[0499] Computational neoantigen prediction and the need for epitope immunogenicity validation - the mutated neoantigenic epitope S722F is not endogenously processed
[0500] We predicted that 175 of the 266 mutations had epitopes for class I mutations that bound 18 highly ranked (population-wise) HLA alleles. All 266 mutations were somatic point mutations that occurred more than twice in different cancer entities. We focused only on recurrent driver mutations because they are present in every cancer cell throughout the disease and produce true tumor-specific antigens. Early evidence compared chemotherapy with drug-inactivated cancer driver oncogenes with tumor-specific CD8+ATT treatment and demonstrated that relapse-free tumor elimination occurred by eradication of escape variants together with tumor matrix destruction. Based on this, we inferred that in our study, complete eradication of tumors without antigen loss and relapse may be possible by improving TCRs against recurrent new antigens derived from driver mutations.
[0501] In our in silico screening, we marked epitopes as strong binders, IC 50 <50nM is the standard. The pMHC affinity range is IC 50Engels et al. studied pMHC affinity and the outcome of treatment was tumor rejection versus recurrence. The study reported that IC 50 Strong pMHC affinities <10 nM caused tumor rejection in every case if IC 50 Subsequently, two reviews highlighted the importance of selecting for CD8 in the context of a triple interaction between peptide-bound MHC and TCR. + ATT treatment with high affinity (IC 50 Based on these studies, we used ABabDII and ABab.I (generated as part of this invention) to select IC 50 The predicted neoantigens are less than 50 nM to generate TCRs against these frequently occurring antigens. Not all predicted neoantigens generate immunogenic epitopes. Epitope immunogenicity combines natural endogenous processing of pMHC presentation with triggering of CD8 + The ability of T cells to respond is combined. In silico determined epitopes must be evaluated with caution as they may generate false positives. In our study, we predicted that the TRRAP-S722F driver mutation contains a putative neoantigen, a 9-mer epitope. The S722F mutant epitope elicits an immune response in ABabDII mice. TCRs isolated from mice are specific for S722F and recognize small amounts of exogenously loaded peptides. However, they do not react with melanoma cell lines that naturally express the mutated gene, confirming that the 9-mer epitope is not endogenously processed and presented. By this reverse immunological approach, we demonstrated that the S722F predicted epitope is not endogenously processed. In addition to the TRRAP mutant (S722F), predicted neoantigen epitopes from the genes C-KIT (K642E), XPO1 (E571K) and FOXA1 (D226N) do not elicit CD8 in ABabDII mice. + T cell responses (own data not shown, not published).
[0502] Several other findings confirm our observation that reverse immunology (predict epitopes first and study endogenous processing last) is not the best way to select target antigens for adoptive T cell therapy. In epitope immunogenicity studies of vaccinia virus, ~100 epitopes showed well predicted binding affinity for HLA-A2, IC 50 <100nM. Only 50% of them elicited CD8 after immunization of HLA-A2 transgenic mice + T cell responses. 15% of responses triggered peptides to be further processed by the proteasome. Of these, 11% triggered spontaneous CD8 +response, demonstrating that only 1 / 14 of the predicted fraction produced immunogenic epitopes 126 In another melanoma RNA vaccination trial, CD8 + T cell response and CD4 + T cell responses were relatively low, likely due to the more promiscuous presentation of peptides by MHC class II. In another long peptide melanoma vaccination trial, only 16% of the predicted neoepitopes elicited CD8 + T cell response.
[0503] Software programs cannot correctly predict endogenous epitope modifications in the antigen presentation pathway using their algorithms. These alterations within the proteasome, post-proteasome, and peptide transport compartments are decisive factors in determining whether an epitope is immunogenic and targetable. One study showed proteasomal epitope destruction of a proposed epitope. Another example reported that ERAP-trimmed epitopes escape more easily than uncleaved epitopes. In a third study, although human subjects showed CD8 + T cell responses, but were later shown to be relatively poor targets for T cell therapy in experimental cancer models.
[0504] Therefore, artificial network algorithms cannot accurately predict proteasomal processing, peptide transport, N-terminal trimming of ERAP enzymes, or splicing mechanisms to identify human neoantigens for ATT in cancer.
[0505] Polycistronic transgene design requires mRNA stability and protein misfolding considerations - lessons learned
[0506] The polycistronic primary ABab.I transgene separated by the viral 2A linker element showed no surface protein expression from any of the six HLA alleles. Therefore, we manipulated the H-2D with three polyadenylation signals. b Promoter driven primary construct (short D b , full length D b and bGH pA). At the same time, we replaced the promoter sequence in these three constructs with the viral CMV promoter. In all six constructs, although we detected b Significant amounts of HLA mRNA were quantified in the primary construct, 30-fold more in the CMV primary construct, but we did not detect cell surface protein expression by flow cytometry. Multiple reasons may have contributed to this non-translatable situation of HLA mRNA affecting its cell surface presentation. These considerations may be mRNA instability of long HLA transcripts, inefficient excision of the viral 2A linker, and unfavorable post-translational modifications that lead to misfolding of the nascent polypeptide chain.
[0507] We consider that mRNA stability is influenced by a single common 3'-UTR region that regulates all six HLA alleles. Furthermore, recent evidence confirms that the native 2A linker functions inefficiently because it does not self-cleave to release the protein; notably, our primary transgene contains a native 2A peptide linker. Studies of sequence divergence versus homology report that transient misfolding does occur in proteins derived from polycistronic mRNAs, whereas they disappear in the presence of low sequence identity; HLA class I chimeric chains retain 90-98% homology. Consistent with this, a recent review posits that there are open questions about how nascent polypeptides from polycistronic mRNAs fold without forming aggregates for cellular clearance.
[0508] Based on these factors, we decided to clone and express all six HLA alleles as a monocistron driven by their own 5'- and 3' regulatory elements (DNA sequence of the ABab.I transgenic construct in the founder mouse - SEQ ID NO: 208).
[0509] Protein characterization of chimeric HLA and the requirement for single-chain specific antibodies in ABab.I mice - a human lymphoblastoid cell line expressing high levels of HLA proteins
[0510] Individual HLA alleles were cloned from the primary polycistronic transgene and recloned as monocistronic for successful surface expression. To confirm cell surface expression of HLA, pan antibodies or antibodies against the human β2m chain (present in all chimeric alleles) were always stained. There were no specific antibodies for unique HLA alleles in the ABab.I mouse that could be used for flow cytometry analysis, except for HLA-A*03:01 and HLA-B*07:02, making verification of HLA proteins difficult.
[0511] It is noteworthy that the pan HLA and β2m antibodies stain different HLA chains with different intensities, especially the β2m antibody stains the HLA genes in the lymphoblastoid cell line (LCL) with a high fluorescence intensity distribution (MFI) compared to the chimeric alleles in the ABab.I mouse. It is noteworthy that the HLA genes in the LCL line are fully human; pHLA stabilization occurs through human proteome-derived antigens. The HLA alleles in the ABab.I mouse are chimeric; pHLA stabilization occurs here through mouse proteome-derived antigens. This difference in expression pattern raises the question of whether it is a result of peptide stabilization of the HLA that causes the β2m antibody to better stain fully human HLA with an increased shift in mean fluorescence intensity.
[0512] Interestingly, studies using HLA antibodies from multiparous women demonstrated an effect of peptides on HLA reactivity via antibodies. Based on this, we speculate that the more stable the pHLAs are on the surface, the better they will be detected by antibody staining. Therefore, we can relate the difference in alloantibody staining between LCL and ABab.I mice to our β2m staining differences. Another possible explanation could be that the chimeric HLAs in ABab.I mice are folded differently in a non-native manner, which could hinder the accessibility of the epitope to the β2m antibody, which requires further analysis.
[0513] On a different note, expression of fully human HLA in transgenic mice without the β2m linkage as a fusion protein can enhance surface stability, thereby improving detection. However, maintenance of the interaction of mouse CD8α with the α3 domain of the chimeric mouse-human HLA heavy chain is critical for CD8 + T cell co-activation is critical.
[0514] Generation of ABab.I transgenic mice using pronuclear injection
[0515] We prepared two versions of the ABab.I transgenic targeting vector for injection into ABabDII donor oocytes. The first vector was flanked by the Rosa26 guide RNA sequence for CRISPR-Cas9 recognition, and the second vector was flanked by inverted terminal repeat sequences for high-activity PiggyBac recognition at the 5' and 3' ends, respectively.
[0516] Our exploratory attempts to use CRISPR-Cas9 technology through homology-independent targeted integration (HITI) failed even after several trials. Injection for random integration of naked DNA transgenes without a vector backbone was also unsuccessful. For HITI with CRISPR-Cas9, we reasoned that a better strategy might be to use homology arms flanking the transgene cassette for efficient integration into the Rosa26 locus. To date, the HITI method has only shown high integration efficiency in postmitotic neurons rather than in oocytes, so it requires in-depth optimization to be successfully attempted in mouse embryos. DNA strand breaks in the mouse genome during pronuclear microinjection are the main cause of random transgene integration (multiple copies) in a head-to-tail manner. During chromosome end joining, the ends of the breakpoints absorb the available DNA transgene as a donor template to connect the adapter. We speculate that the large size (~17kb) of the ABab.I transgene with homologous sequences may be the reason for the failure of naked transgene integration as a concatemer. The use of the PiggyBac transposon strategy enables us to target one copy per locus.
[0517] Therefore, we utilize the highly active PiggyBac transposase to catalyze the ABab.I transgenic box with ITR to integrate into the mouse genome at the same time. We have successfully produced five founders, Q4115, Q4118, Q6844, Q8552 and Q8556. The first founder Q4115 does not pass the HLA allele germline in its genome to the F1 generation in nearly 250 genotyping mice. We believe that PiggyBac catalyzes the integration of the transgene into the genome after multiple cell divisions or late integration of the embryo, which causes the chimeric founder mouse to be unable to be passed to the F1 generation germline like Mendelian genetics. Nevertheless, we try to achieve germline transmission in all other founders Q4118, Q6844, Q8552 and Q8556.
[0518] We based our analysis on CD8 + and CD4 + The absolute number of T cells was investigated for the phenotypes of the different founder mice (except for the Q6844 line, data for other founders are not shown). The Q6844 line showed the highest and consistent CD8 T cell population in each generation from F1 to F4. + T cell numbers provide indirect evidence for HLA expression in the thymus and possibly the periphery. Significant HLA expression is required for positive selection in T cell maintenance in the thymus and the periphery. Therefore, we hypothesize that high CD8 + The number of T cells (Q6844 lineage) reflects effective positive thymic selection and increased TCR repertoire diversity. In addition, the effect on T cell homeostasis proliferation is another interesting issue to be addressed. For this reason, it is critical to consider CD44 staining as an activation marker to understand the homeostasis in the periphery based on the number of thymic output and precursor T cells entering the circulation.
[0519] However, using next-generation ImmunoSEQ repertoire sequencing, we managed to characterize the CD8 + The TCRβ immune repertoire of T cells was deeply sequenced in comparison with ABabDII mice.
[0520] Next-generation deep sequencing of ABab.I and ABabDII mice - CD8 + TCRβ immunosequencing
[0521] Absolute CD8 + We performed deep sequencing of the TCRβ repertoires in these lines to understand the differences in CD8 + Whether the increase in T cell numbers results in a broader TCR repertoire. In this case, we can exclude the possibility that CD8 +The possibility that the increased number of T cells is the result of increased homeostatic expansion. Of note, ABabDII mice have a single HLA-A2, while ABab.I mice additionally have a complete human HLA haplotype of six alleles. Therefore, we investigated whether the introduction of multiple class I alleles into humanized TCR mice made the repertoire broader, and how broader compared to ABabDII mice.
[0522] We used iChao1 estimation to demonstrate that ABab.I mice have a diverse repertoire that is, on average, four times broader than that of ABabDII mice. Although we deep sequenced approximately twice as many in-frame amino acid clonotypes in ABab.I mice compared with ABabDII mice (11.2 ± 2.7 × 10 4 4.8±0.80×10 4 ), but the iChao1 estimator theoretically extrapolates the repertoire to be four times wider; it is back-calculated to the full mouse repertoire by including clones that occur only once or twice (low binding events). By theoretical extrapolation, we show that ABab.I mice use diverse V and J genes and produce nearly 1×10 6 clonotypes, while ABabDII only produced a maximum of 2.57×10 5 clonotypes (~ four times lower). The greater diversity in ABab.I mice reflects a higher percentage of rare and unique clones, and thymic selection does select new V(D)J TCRβ combinations on multiple HLA alleles. Therefore, the expression of six HLA alleles in ABab.I mice selects a highly diverse human TCR repertoire, probably because of enhanced positive selection and total thymic output, which is reduced in ABabDII mice. The out-of-frame TCR repertoire represents the pre-selected library before positive selection and gives an accurate estimate of the frequency of individual V and J segment rearrangements in ABabDII and ABab.I mice. As expected, the pre-selected (out-of-frame) TCR repertoire is almost identical between ABabDII and ABab.I mice because the human TCR loci and recombinases are the same. After positive selection, the (in-frame) repertoire reflects the frequency of single V and J segment rearrangements on the one hand, and reveals some V β Gene segments are over-expressed in ABab.I mice, such as TRBV4-1, while they are under-expressed in ABabDII mice. Similarly, TRBV12-3 / 12-4 are over-expressed in ABabDII mice, but not in ABab.I mice.
[0523] We have established a clear link between multiple HLA expression and their impact on repertoire diversity. From the TCR side, we speculate that some V βA gene may have a higher intrinsic affinity for some HLA alleles but not others. The key requirement for positive selection is the interaction between the CDR1 and CDR2 regions and the selected MHC class I molecule. 40-50 V β The genes differ in their CDR1 and CDR2 regions and the MHC class I genes are highly polymorphic. β The intrinsic affinity of the gene segment is high for some MHC I alleles but low for others, and the MHC and TCR loci co-evolve to ensure more efficient positive selection. This hypothesis is supported by Chen et al., who studied human CD4 in mice selected on either a single mouse or a single human MHC class II molecule. + The TCR repertoire was sequenced. They found that the species-incompatible mouse MHC molecule IA b Compared to species-compatible human MHC class II, a broader CD4 + This can be explained by the fact that on average human TCRs have an increased intrinsic affinity for human MHC class II molecules.
[0524] Similarly, it can be assumed that some V β The gene segment has a higher intrinsic affinity for HLA-A2, while other V β The gene segments then have a lower intrinsic affinity for HLA-A2, but then have a higher intrinsic affinity for any of the other six MHC class I alleles in ABab.I mice. This then means that some TCRs can only be poorly selected by HLA-A2, but then be more effectively selected by other MHC I alleles in ABab.I mice.
[0525] Chen et al. also observed that TCRs selected on mouse MHC II had shorter CDR3 sequences on average compared to human TCRs selected on human MHC II molecules. β The different intrinsic affinities of gene segments for MHC are modulated by the length of the CDR3, i.e., a particular V segment with a shorter CDR3 will have a relatively low intrinsic MHC affinity. β We extend these findings by showing that the TCR repertoire selected on multiple class I alleles contains on average slightly larger CDR3 regions than the TCR repertoire selected on only a single MHC class I allele (in our case HLA-A2). The best explanation is that some V βThe segments have increased intrinsic affinity for any of the six new MHC class I alleles in ABab.I mice, which allows the selection of TCRs with slightly larger CDR3 regions. This not only explains the diversity of ABab.I compared to ABabDII mice, but also can produce TCRs with higher specificity. This hypothesis is based on studies in mice deficient in terminal deoxynucleotidyl transferase (TdT) expression, which results in TCRs with short CDR3s. These TCRs tend to be more promiscuous and cross-reactive. Despite the fact that the TCR repertoire in ABabDII is relatively diverse, we speculate that the TCR repertoire in ABabDII mice is not optimal because the CDR3 region is relatively short. 21 In contrast, thymocytes in ABab.I mice can choose one of six additional class I alleles for selection. Therefore, we hypothesize that different MHC alleles in the thymus compete with each other to select a given T cell clone. If this is correct, T cell clones that cannot be selected by HLA-A2 can be selected by any of the other six MHC class I alleles, for which they have increased intrinsic affinity and then also allow longer CDR3s to be accepted, thereby not hindering positive selection.
[0526] However, it should be noted that the hypothesis that T cells in ABab.I mice find their HLA match with the best intrinsic affinity at the expense of reduced HLA-A2 selection remains speculative to date. This hypothesis is difficult to prove because it is not known whether different MHC class I alleles can select for similarly diverse TCR repertoires.
[0527] Therefore, we are in the process of generating and characterizing mice with a single HLA allele from the HLA alleles contained in the ABab.I mouse. By sequencing the TCR repertoire of mice expressing a single HLA allele in the same background, we can validate certain V β Do segments have different intrinsic affinities for different HLA alleles? 21,248 Therefore, individual ABab-A*03, ABab-A*11, ABab-B*07, ABab-B*15, ABab-C*04, and ABab-C*07 founder lines were generated and require characterization prior to deep sequencing (own data not shown, not published). In these mice, we can prove or disprove certain V β Whether the gene segment is preferentially selected or preferentially ignored by individual MHC I alleles.
[0528] However, mice generally select shorter CDR3 TCRs than humans. The reason for this may be higher TdT and exonuclease activity or a longer expression window in humans compared to mice. The TdT-exonuclease machinery with the recombination activation gene (RAG) evolved to amplify the addition or deletion of nucleotides (more editing); this increased activity produces a higher number of unique TCRs with longer CDR3s, affecting the entire repertoire.
[0529] Because ABab.I mice generate four times more unique clones than ABabDII, they also share more TCRβ clonotypes with the human donor repertoire (about 1000 compared to about 500). The number of clones shared between ABab.I mice is surprisingly high because they are not HLA-matched. The high clonal overlap may be explained by nonrandom V and J usage. In humans, the theoretical number of TCRβ sequences is 5×10 11 If VJ rearrangement is random, it is expected that there will be fewer than five common TCRβ clones between any two individuals, but in reality, about 10,000 common clones have been detected, which is comparable to the theoretical 5×10 in human peripheral blood. 11 Only 0.1% of the detections were consistent. Our data in ABab.I mice support the data in humans and show that the TCRα / TCRβ combination diversity is greater than previously expected. We have also performed deep sequencing of the TCRα repertoires from these two groups of mice. Preliminary data analysis shows that the TCRα repertoire is also more diverse in ABab.I than in ABabDII mice (own data not shown, not published). Detailed analysis is still needed to reveal the combinatorial diversity between these mice.
[0530] In summary, through extended humanization of human TCR locus mouse models, a more diverse and more human-like repertoire can be obtained.
[0531] In vitro and in vivo functional characterization of ABab.I mice
[0532] We show that ex vivo derived APCs from ABab.I mice can efficiently present model epitopes on all six HLA alleles and trigger effector T cells to produce IFN-γ. Due to the lack of HLA-specific antibodies, we designed this in vitro co-culture assay to assess HLA expression and its functionality by activating TCR-modified T cells restricted to model epitopes. APCs from cells of blood, spleen, and lymph nodes are used as targets for effectors because they recapitulate the physiological circulating immune system upon immunization.
[0533] The purpose of generating ABab.I mice is to isolate T cell receptors to treat cancer patients targeting tumor-restricted antigens. Here, we show not only in vitro but also in vivo by immunizing ABab.I mice with multiple model antigens, each of which is known to bind to one of the six HLA alleles presented in mice. These epitopes were selected to cover different antigenic classes, such as frameshift-derived mutants (mCALR on A*03), point mutants (KRAS-G12V on A*11), viruses (CMV-pp65 on B*07 and C*04, HPV-E5 on B*15), and tumor-associated (MAGE-A12 on HLA-C*07:02) epitopes.
[0534] Although most of the epitopes selected in this panel have been shown to be endogenously processed, mice responded more strongly to mutant KRAS and viral epitopes than to other epitopes, regardless of the predicted IC50 nM values. This is not a problem for epitopes that are processed, but for epitopes that have not been shown to be processed, immunization with DNA or adenovirus (encoding the antigen) expressing the complete protein sequence can be used to discover new epitopes using the ABab.I mouse model as a platform.
[0535] In conclusion, the ABab.I mouse model, which expresses six HLA alleles as in the natural human context, may become an unparalleled new tool for isolating novel T cell receptors that will be clinically useful for ATT of cancer.
[0536] Understanding the biology behind fully human HLA haplotypes in mouse models
[0537] The ABab.I model with its diverse TCRβ repertoire has proven to be a valuable tool for isolating unique T cell receptors for therapeutic use. However, understanding the TCRα locus repertoire may determine the combinatorial diversity of the overall TCR combination that the ABab.I mouse can produce. From this, we can also study the theoretically possible combinations of TCR diversity in the ABab.I mouse with TCR diversity (~10 15 clonotypes).
[0538] Different intrinsic V for some human HLA alleles but not others βAffinity may be the next possible step to understand the degree of bias during positive selection in the thymus. To this end, comparing deep sequencing data from ABab.I mice with individual ABab- animals (ABab-A*03, ABab-A*11, ABab-B*07, ABab-B*15, ABab-C*04, and ABab-C*07 mice) in the context of humanized TCRs will allow us to clearly understand whether there is a bias in TCR affinity for HLA, and whether different HLA alleles can select similar or dissimilar TCR repertoires.
[0539] Knockout of HLA-A2 should be the next event from the individual ABab- and ABab.I mice to generate a pure strain lacking the A2 gene; an ideal representation of the normal HLA class I locus in humans.
[0540] Epitope discovery of non-HLA-A*02:01-restricted antigens using ABab.I mice
[0541] Reverse immunology based on epitope prediction is a concern. Therefore, ABab.I mice provide the opportunity to simultaneously identify immunogenic epitopes and isolate T cell receptors. Direct immunology by immunizing ABab.I mice with DNA, adenovirus, or mRNA encoding the complete protein for epitope discovery will generate TCRs restricted to these newly discovered epitopes for use in ATT.
[0542] ABab..I mice as a new tool to isolate human TCRs for cancer ATT
[0543] Predictive screening indicates the number of individuals with mutations per year. In principle, ABab.I mice immunized with these mutated epitopes will generate a range of TCRs with high to optimal affinity for clinical use, however, information on endogenous is required.
[0544] Therefore, the ABab.I mouse is not only qualified to understand the human repertoire shaped in the context of natural class I HLA but also a new model for isolating T cell receptors against multiple antigens for adoptive T cell therapy.
[0545] Example 2: Unbiased discovery of a new MAGE-A1 epitope GTLEEVPTA (SEQ ID NO: 200)
[0546] In this example, novel MAGE-A1 epitopes were screened in ABab.I mice.
[0547] First, the HLA-A*02-restricted immune response to MAGE-A1 was investigated in ABab-I mice after vaccination ( Fig.21A). ABab.I mice were immunized with full-length MAGE-A1 mutated (V→D) at position 279 to disrupt the dominant HLA-A*02-restricted epitope KVLEYVIKV (278-286) (SEQ ID NO: 199). On day 7 after the third immunization, peripheral blood was stimulated with cells expressing MAGE-A1 and IFNγ intracellular staining was performed ( Fig.21 A).
[0548] Then, the epitope of MAGE-A1 was located and one of the TCRs called TCR1 isolated from the respective ABab.I mice bound to it. For this purpose (localization of the epitope), human T cells transduced with TCR1 were co-cultured with K562-A2 cells expressing MAGE-A1, MAGE-A1 fragments (F1-F3) or loaded with KVLEYVIKV (KVL). F1-F3 spans the fragments of MAGE-A1 as follows: F11-97, F2 98-222, F3 223-309. It was found that TCR1 recognizes the HLA-A*02-restricted MAGE-A1 epitope, which is located in the N-terminal fragment formed by amino acid residues 1-97 of MAGE-A1 ( Fig.21 B).
[0549] Finally, to determine the exact epitope, TCR1-transduced human T cells were co-cultured with K562-A2 cells loaded with predicted 9-mer binders (Table 15) or KVLEYVIKV (KVL). It was found that MAGE-A1-reactive TCR1 recognized the 9-mer GTLEEVPTA (SEQ ID NO: 200) ( Fig.21 C). It should be noted here that in the US patent application US2003 / 0148973A1, the nonamer GTLEEVPTA is predicted to be a MAGE-A1 epitope, however, in US2003 / 0148973, no HLA-A2 restricted TCRs could be generated against this epitope, but only TCRs against the four epitopes shown in Table IV of US2003 / 0148973A1 could be generated. It is worth noting that in US2003 / 0148973A, genetically modified mice expressing human HLA-A2 MHC molecules were immunized with mature MAGE-A1 proteins, which means that substantially the same method as the MAGE-A1 immunization used herein was also used in US2003 / 0148973. This clearly shows that the non-human mammals of the present invention, such as the mice of the present invention, allow the generation of CD8 + TCR, for which no TCR has yet been generated.
[0550] Table 15: Predicted 9-mer binders
[0551]
[0552] In summary, a new MAGE-A1 epitope was identified in an unbiased manner that is distinct from the known dominant HLA-A*02-restricted epitope KVL 278-286. This further demonstrates that the ABab.I mouse allows for the identification of new epitopes and suggests that the ABab.I mouse of the present invention can generate TCRs against epitopes that have not been generated by other means (e.g., US2003 / 0148973A1).
[0553] Example 3: Immunization experiment (in vivo immune response analysis)
[0554] To analyze in vivo CD8 + Killer T cell responses We immunized poly-HLA mice with the described model epitopes as peptides (given in the table, 9- and 10-mers). All six model epitopes were predicted in silico (using software) to bind strongly to their respective HLA alleles.
[0555] Table 16: Model peptides presented by HLA alleles present in poly-HLA ABab.I mice for immunization
[0556]
[0557] Procedure: Young mice were immunized with peptides (minimum two times) with an interval of at least 4 weeks between injections. Seven days after the booster injection, PBMCs from poly-HLA mice were stimulated in vitro with the same peptide used for immunization (right) or with nonspecific peptide (left) or CD3 / CD28 beads (center, positive control). Intracellular flow cytometric staining measured the expression of CD8 + The amount of IFN-γ cytokine released by T cells after reacting with their respective epitopes. CD8 + T cell CD3, CD8 and intracellular IFN-γ expression. The dot plots in the figure depict CD8 + IFN-γ + T cells (gated on CD3+ lymphocytes). As a non-specific peptide, NY-ESO peptide (APRGPHGGAASGL) was used only for in vitro stimulation (as a negative control).
[0558] One flow cytometry graph of multiple responders is given. Of the 6-7 mice / epitope, 6 mice responded to KRAS (HLA-A*11:01 restricted) peptides, 3 mice responded to MAGE-A1 (HLA-A*02:01 restricted, as explained in Example 2 above) and HPV (HLA-B*07:02 and / or HLA-B*15:01 restricted) peptides, and 1 mouse responded to mCALR (HLA-A*03:01 restricted), CMV (HLA-C*04:01 restricted), and MAGE-A12 (HLA-C*07:02 restricted) peptides. The immune responses were analyzed by flow cytometry in the blood (PBMCs) of the immunized mice. For this, intracellular IFN-γ cytokine protein staining was performed using antibodies together with CD3 and CD8 antibodies. When the PBMCs were restimulated in vitro in the blood with the respective peptides originally used for immunization, responses to the specific peptides were seen, and no responses to the non-specific peptides were seen. The beads were used as a positive control to show the fitness of our T cells in the blood of our poly-HLA mice.
[0559] Example 4: Analysis of T cell responses of HuTCR mice to single HLA class I alleles
[0560] In this example, the T cell response of ABab.I mice to a single HLA class I allele integrated into their genome was analyzed.
[0561] For this purpose, 11 ABab.I mice were immunized several times with DNA encoding full-length MAGE-A1 mutated (V→D) at position 279 to disrupt the dominant HLA-A*02-restricted epitope KVLEYVIKV (278-286) (SEQ ID NO: 199), see Example 2 in this regard. Blood T cells obtained from the mice were then co-cultured with cell lines expressing different single or double HLAs and MAGE-A1. CD8 + Interferon gamma secreting cells (IFNg + Thus, the T cell responses of HLA-A*02:01, HLA-A*03:01, and HLA-A*11:01 were analyzed separately, and the combined T cell responses of HLA-B*07:02 and HLA-B*15:01 alleles and HLA-C*04:01 and HLA-C*07:02 alleles were analyzed simultaneously.
[0562] The results of this experiment are shown in Fig.25 Mice with a positive T cell response are represented by circles above the background dashed line, while mice with a negative T cell response are represented by circles below the background dashed line. Fig.25It can be seen that for all HLA class I alleles tested individually (HLA-A*02:01, HLA-A*03:01, HLA-A*11:01), as well as for the HLA class I alleles tested together (HLA-B*07:02 and HLA-B*15:01 and HLA-C*04:01 and HLA-C*07:02, respectively), ABab.I mice were found to have active T cell responses against MAGE-A1-derived epitopes in the blood.
[0563] Therefore, this experiment also confirmed that the ABab.I mice of the present invention can induce CD8 + T cell response. In this context, it should also be noted that the amount of active T cells in the blood is generally lower than the amount of active T cells found in the mouse spleen. Therefore, based on the results of T cell counts in the blood, it can be safely assumed that the spleen of immunized ABab.I mice has active CD8 + T cell numbers, and therefore active T cell responses, are even higher.
[0564] also, Fig.25 The results described in show that transgenic animals carrying multiple human HLA class I alleles allow direct comparison of the magnitude of T cell responses associated with each human allele. In the presence of MAGE-A1 as antigen, HLA-A*02:01-restricted CD8 + The T cell response was the strongest, both in terms of number (7 out of 11 immunized mice showed a positive T cell response) and biological activity (IFNg + Response), see Example 2. Thus, the transgenic animals of the present invention allow for direct comparison of the magnitude of T cell responses and simultaneous assessment of T cell responses associated with multiple human HLA alleles. This "multiplexing" is another advantage of the present invention.
[0565] Those skilled in the art will readily appreciate that the present invention is well suited for achieving the stated objectives and obtaining the stated results and advantages, as well as those inherent therein. In addition, it will be apparent to those skilled in the art that various substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention. The compositions, methods, procedures, treatments, molecules and specific compounds described herein currently represent certain exemplary embodiments and are not intended to be limiting of the scope of the invention. Those skilled in the art may envision variations and other uses therein, which are contained within the spirit of the invention as defined by the scope of the claims. The listing or discussion of previously disclosed documents in this specification should not necessarily be considered as an admission that the document is part of the prior art or is common knowledge.
[0566] The present invention exemplarily described herein can be suitably implemented in the absence of any elements or limitations, which are not specifically disclosed herein. Therefore, for example, the terms "include", "comprise", "contain", etc. should be understood broadly and not restrictively. In addition, the terms and expressions adopted herein have been used as descriptive terms rather than restrictive terms, and when using these terms and expressions, it is not intended to exclude any equivalents of the features shown and described or parts thereof, but it should be recognized that various modifications are possible within the scope of the claimed invention. Therefore, it should be understood that although the present invention is specifically disclosed by exemplary embodiments and optional features, modifications and variations of the present invention implemented herein may be adopted by those skilled in the art, and such modifications and variations are considered to be within the scope of the present invention.
[0567] The invention has been described broadly and generically herein. Each of the narrower species and subgeneric groupings falling within the generic disclosure also forms a part of the invention. This includes the generic description of the invention, with a proviso or negative limitation removing any subject matter from the genus, regardless of whether the removed material is specifically recited herein.
[0568] Other embodiments are within the following claims.In addition, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group.
Claims
1. A non-human mammal comprising in its genome at least two (e.g., at least three, at least four, at least five, at least six, or at least seven) human leukocyte antigen (HLA) class I alleles, wherein the at least two human HLA alleles are functionally expressed in that the corresponding MHC I polypeptides are expressed on the surface of cells of the mammal and present MHC antigens to which the non-human mammal provides an antigen-specific CD8+ T cell response, wherein the at least two human HLA class I alleles comprise: a) at least one human HLA-A allele; and b) at least one human HLA-B allele; and / or c) at least one human HLA-C allele; and / or d)(a) and (b); and / or e)(a) and (c); and / or f)(b) and (c); and / or g) (a), (b) and (c).
2. The non-human mammal of claim 1, wherein the mammal further comprises at least one human HLA class II allele in its genome.
3. The non-human mammal of claim 1 or 2, wherein the mammal comprises at least 4, 5, 6 or 7 human HLA class I alleles in its genome.
4. A non-human mammal according to any one of the preceding claims 1 to 3, wherein the mammal comprises in its genome: a) at least two different human HLA-A alleles, preferably at least three different human HLA-A alleles; and / or b) at least two different human HLA-B alleles; and / or c) at least two different human HLA-C alleles.
5. A non-human mammal according to any one of the preceding claims 1 to 4, wherein the at least two human HLA I class alleles comprise one or more HLA-A class I alleles selected from the group consisting of: HLA-A*03 (e.g., HLA-A*03:01), HLA-A*11 (e.g., HLA-A*11:01), HLA-A*01 (e.g., HLA-A*01:01), HLA-A*26 (e.g., HLA-A*26:01), HLA-A*24 (e.g., HLA-A*24:02), HLA-A*32 (e.g., HLA-A*32:01) and HLA-A*02 (e.g., HLA-A*02:01), preferably, the three HLA-A class I alleles are selected from the group of human HLA alleles consisting of: HLA-A*03, HLA-A*11 and HLA-A*02.
6. A non-human mammal according to any one of the preceding claims 1 to 4, wherein the at least two human HLA I class alleles comprise one or more HLA-A class I alleles selected from the group consisting of: HLA-A*11 (e.g., HLA-A*11:01), HLA-A*24 (e.g., HLA-A*24:02) and HLA-A*33 (e.g., HLA-A*33:03), preferably HLA-A*24 (e.g., HLA-A*24:02) and HLA-A*33 (e.g., HLA-A*33:03).
7. A non-human mammal according to any one of the preceding claims 1 to 4, wherein the at least two human HLA I class alleles comprise one or more HLA-A class I alleles selected from the group consisting of (Japan): HLA-A*24 (e.g., HLA-A*24:02), HLA-A*02 (e.g., HLA-A*02:01), HLA-A*11 (e.g., HLA-A*11:01), and HLA-A*31 (e.g., HLA-A*31:01), preferably HLA-A*24 (e.g., HLA-A*24:02) and HLA-A*31 (e.g., HLA-A*31:01).
8. A non-human mammal according to any one of the preceding claims 1 to 4, wherein the at least two human HLA I class alleles comprise one or more HLA-A class I alleles selected from the group consisting of: HLA-A*01 (e.g., HLA-A*01:01), HLA-A*11 (e.g., HLA-A*11:01), and HLA-A*24 (e.g., HLA-A*24:02), preferably HLA-A*01 (e.g., HLA-A*01:01) and HLA-A*24 (e.g., HLA-A*24:02).
9. A non-human mammal according to any one of the preceding claims 1 to 8, wherein the at least three HLA-A class I alleles are selected from a human HLA allele group consisting of: HLA-A*03 (e.g., HLA-A*03:01), HLA-A*11 (e.g., HLA-A*11:01), HLA-A*01 (e.g., HLA-A*01:01), HLA-A*26 (e.g., HLA-A*26:01), HLA-A*24 (e.g., HLA-A*24:02), HLA-A*32 (e.g., HLA-A*32:01) and HLA-A*02 (e.g., HLA-A*02:01), preferably, the three HLA-A class I alleles are selected from a human HLA allele group consisting of: HLA-A*03, HLA-A*11 and HLA-A*02.
10. A non-human mammal according to any one of the preceding claims 1 to 9, wherein the at least two HLA class I alleles comprise one or more HLA-B class I alleles selected from the group consisting of (European / American) HLA-B*07 (e.g. HLA-B*07:02), HLA-B*15 (e.g. HLA-B*15:01), HLA-B*58 (e.g. HLA-B*58:01), HLA-B*40 (e.g. HLA-B*40:01), HLA-B*35 (e.g. HLA-B*35:01) and HLA-B*08 (e.g. HLA-B*08:01), preferably, the at least two HLA-B class I alleles are selected from the group of human HLA alleles consisting of: HLA-B*07 and HLA-B*15.
11. A non-human mammal according to any one of the preceding claims 1 to 10, wherein the at least two HLA class I alleles comprise one or more HLA-B class I alleles selected from the group consisting of (China): HLA-B*40 (e.g., HLA-B*40:01), HLA-B*46 (e.g., HLA-B*46:01), HLA-B*58 (e.g., HLA-B*58:01), and HLA-B*15 (e.g., HLA-B*15:02), preferably HLA-B*40 (e.g., HLA-B*40:01) and HLA-B*46 (e.g., HLA-B*46:01).
12. A non-human mammal according to any one of the preceding claims 1 to 11, wherein the at least two HLA class I alleles comprise one or more HLA-B class I alleles selected from the group consisting of HLA-B*52 (e.g., HLA-B*52:01), HLA-B*51 (e.g., HLA-B*51:01), HLA-B*35 (e.g., HLA-B*35:01), HLA-B*15 (e.g., HLA-B*15:01), and HLA-B*40 (e.g., HLA-B*40:02), preferably HLA-B*52 (e.g., HLA-B*52:01) and HLA-B*51 (e.g., HLA-B*51:01).
13. A non-human mammal according to any one of the preceding claims 1 to 12, wherein the at least two HLA class I alleles comprise one or more HLA-B class I alleles selected from the group consisting of: HLA-B*40 (e.g., HLA-B*40:06), HLA-B*51 (e.g., HLA-B*51:01), HLA-B*52 (e.g., HLA-B*52:01) and HLA-B*44 (e.g., HLA-B*44:03), preferably HLA-B*40 (e.g., HLA-B*40:06) and HLA-B*51 (e.g., HLA-B*51:01).
14. A non-human mammal according to any one of the preceding claims 1 to 12, wherein the at least two HLA-BI class alleles are selected from a human HLA allele group consisting of: HLA-B*07 (e.g., HLA-B*07:02), HLA-B*15 (e.g., HLA-B*15:01), HLA-B*58 (e.g., HLA-B*58:01), HLA-B*40 (e.g., HLA-B*40:01), HLA-B*35 (e.g., HLA-B*35:01), and HLA-B*08 (e.g., HLA-B*08:01, preferably, the at least two HLA-BI class alleles are selected from a human HLA allele group consisting of: HLA-B*07 and HLA-B*15.
15. A non-human mammal according to any one of the preceding claims 1 to 12, wherein the at least two HLA class I alleles comprise one or more HLA-C class I alleles selected from the group consisting of: HLA-C*04 (e.g., HLA-C*04:01), HLA-C*07 (e.g., HLA-C*07:02), HLA-C*16 (e.g., HLA-C*16:01), HLA-C*03 (e.g., HLA-C*03:04), HLA-C*07 (e.g., HLA-C*07:01) and HLA-C*06 (e.g., HLA-C*06:02), preferably, the two HLA-C class I alleles are selected from the group of human HLA alleles consisting of: HLA-C*04 and HLA-C*07.
16. A non-human mammal according to any one of the preceding claims 1 to 12, wherein the at least two HLA class I alleles comprise one or more HLA-C class I alleles selected from the group consisting of: HLA-C*07 (e.g., HLA-C*07:02), HLA-C*01 (e.g., HLA-C*01:02), and HLA-C*03 (e.g., HLA-C*03:04), preferably HLA-C*01 (e.g., HLA-C*01:02) and HLA-C*03 (e.g., HLA-C*03:04).
17. A non-human mammal according to any one of the preceding claims 1 to 12, wherein the at least two HLA class I alleles comprise one or more HLA-C class I alleles selected from the group consisting of: HLA-C*01 (e.g., HLA-C*01:02), HLA-C*03 (e.g., HLA-C*03:03) and HLA-C*03 (e.g., HLA-C*03:04), preferably HLA-C*01 (e.g., HLA-C*01:02) and HLA-C*03 (e.g., HLA-C*03:03).
18. A non-human mammal according to any one of the preceding claims 1 to 12, wherein the at least two HLA class I alleles comprise one or more HLA-C class I alleles selected from the group consisting of: HLA-C*06 (e.g., HLA-C*06:02), HLA-C*04 (e.g., HLA-C*04:01), HLA-C*07 (e.g., HLA-C*07:02), and HLA-C*15 (e.g., HLA-C*15:02), preferably HLA-C*06 (e.g., HLA-C*06:02) and HLA-C*15 (e.g., HLA-C*15:02).
19. A non-human mammal according to any one of the preceding claims 1 to 12, wherein the at least two HLA-C I class alleles are selected from a human HLA allele group consisting of: HLA-C*04 (e.g., HLA-C*04:01), HLA-C*07 (e.g., HLA-C*07:02), HLA-C*16 (e.g., HLA-C*16:01), HLA-C*03 (e.g., HLA-C*03:04), HLA-C*07 (e.g., HLA-C*07:01) and HLA-C*06 (e.g., HLA-C*06:02), preferably, the two HLA-C I class alleles are selected from a human HLA allele group consisting of: HLA-C*04 and HLA-C*07.
20. The non-human mammal of any one of the preceding claims 1 to 19, wherein the mammal comprises in its genome six or seven human leukocyte antigen (HLA) class I alleles, the HLA class I alleles being selected from the group of human HLA alleles comprising or consisting of: a) HLA-A*03, b) HLA-A*11, c) HLA-B*07, d) HLA-B*15, e) HLA-C*04, f) HLA-C*07 and g) HLA-A*02.
21. The non-human mammal of any one of claims 1 to 20, wherein the seven human HLA alleles comprise or consist of: a) HLA-A*03:01, b) HLA-A*11:01, c) HLA-B*07:02, d) HLA-B*15:01, e) HLA-C*04:01, f) HLA-C*07:02 and g) HLA-A*02:
01.
22. The non-human mammal of any one of the preceding claims 1 to 21, wherein the at least two human HLA alleles are functionally expressed in that the corresponding MHC I polypeptides are expressed on the surface of cells of the mammal.
23. The non-human mammal of any one of the preceding claims 1 to 22, wherein the corresponding MHC I polypeptide is expressed on the surface of peripheral blood cells of the mammal.
24. A non-human mammal according to any one of the preceding claims 1 to 23, wherein the corresponding MHC I polypeptide expressed on the surface of cells of the mammal presents an MHC antigen to which the non-human mammal provides an antigen-specific CD8+ T cell response (e.g., wherein the antigen-specific CD8+ T cell response is measured by any suitable means such as FACS).
25. The non-human mammal of any one of the preceding claims 1 to 24, wherein the at least two human HLA alleles encode chimeric human / non-human mammal MHC molecules.
26. A non-human mammal according to any one of the preceding claims 1 to 25, wherein the at least two HLA alleles encode a chimeric human / non-human mammal MHC I polypeptide, wherein the human portion of the chimeric polypeptide comprises the α1 and α2 domains of a human MHC I polypeptide, wherein the non-human mammal portion of the chimeric polypeptide comprises the α3 domain, transmembrane and cytoplasmic domains of an endogenous non-human mammal MHC I polypeptide, and wherein the non-human mammal expresses the chimeric human / non-human mammal MHC I polypeptide.
27. The non-human mammal of any one of the preceding claims 1 to 26, wherein the at least two HLA alleles encode a chimeric human / non-human MHC I polypeptide, wherein the human portion of the chimeric polypeptide comprises the α1, α2, and α3 domains of a human MHC I polypeptide, wherein the non-human mammal portion of the chimeric polypeptide comprises the transmembrane and cytoplasmic domains of an endogenous non-human mammal MHC I polypeptide, and wherein the non-human mammal expresses the chimeric human / non-human mammal MHC I polypeptide.
28. The non-human mammal according to any one of the preceding claims 1 to 27, wherein each of the at least two HLA alleles is encoded as a monocistronic, preferably, each of the at least two HLA alleles encoded as a monocistronic is selected from the group of human HLA alleles comprising or consisting of: a) HLA-A*03, b) HLA-A*11, c) HLA-B*07, d) HLA-B*15, e)HLA-C*04 and f)HLA-C*07.
29. A non-human mammal according to any one of the preceding claims 1 to 28, wherein each HLA allele is equipped with its mouse endogenous self H-2Db promoter (e.g., having or comprising SEQ ID NO: 227) and polyadenylation signal (e.g., having or comprising SEQ ID NO: 228).
30. A non-human mammal according to any one of the preceding claims 1 to 29, wherein the mammal comprises a complete human T cell receptor (TCR) locus in its genome.
31. A non-human mammal according to any one of the preceding claims 1 to 30, wherein the mammal is deficient in its endogenous T cell receptor (TCR) locus.
32. A non-human mammal according to any one of the preceding claims 1 to 31, wherein the non-human mammal is selected from the group consisting of rodents, dogs, cats, primates, rabbits, pigs and ruminants.
33. The non-human mammal of claim 32, wherein the rodent is a mouse or a rat.
34. A nucleic acid construct comprising a nucleic acid encoding at least two (e.g., at least three, at least four, at least five, at least six, or at least seven, etc.) human HLA class I alleles, wherein the nucleic acid construct is capable of functionally expressing the at least two human HLA alleles (e.g., in a non-human mammal, e.g., as described herein) in that the corresponding MHC I polypeptides are expressed on the surface of a cell of the non-human mammal comprising the nucleic acid construct and present an MHC antigen to which the non-human mammal provides an antigen-specific CD8+ T cell response, wherein the at least two human HLA class I alleles comprise: a) at least one (e.g., at least two or at least three) human HLA-A alleles; or b) at least one (e.g., at least two) human HLA-B alleles; and / or c) at least one (e.g., at least two) human HLA-C alleles; and / or d)(a) and (b); and / or e)(a) and (c); and / or f)(a) and (c); and / or g) (a), (b) and (c).
35. The nucleic acid construct of claim 34, wherein the nucleic acid further encodes at least one human HLA class II allele.
36. The nucleic acid construct of any one of claims 34 or 35, wherein the nucleic acid construct comprises 4, 5, 6 or 7 human HLA class I alleles.
37. according to the nucleic acid construct described in any one in claim 34 to 36, wherein said nucleic acid construct comprises a) at least two different human HLA-A alleles, preferably at least three different human HLA-A alleles; and / or b) at least two different human HLA-B alleles; and / or c) at least two different human HLA-C alleles.
38. The nucleic acid construct of any one of claims 34 to 37, wherein the at least two human HLA class I alleles comprise one or more HLA-A class I alleles selected from the group consisting of HLA-A*03 (e.g., HLA-A*03:01), HLA-A*11 (e.g., HLA-A*11:01), HLA-A*01 (e.g., HLA-A*01:01), HLA-A*26 (e.g., HLA-A*26:01), HLA-A*24 (e.g., HLA-A*24:02), HLA-A*32 (e.g., HLA-A*32:01), and HLA-A*02 (e.g., HLA-A*02:01), preferably, the three HLA-A class I alleles are selected from the group of human HLA alleles consisting of: HLA-A*03, HLA-A*11, and HLA-A*02.
39. The nucleic acid construct of any one of claims 34 to 38, wherein the at least two human HLA class I alleles comprise one or more HLA-A class I alleles selected from the group consisting of HLA-A*11 (e.g., HLA-A*11:01), HLA-A*24 (e.g., HLA-A*24:02), and HLA-A*33 (e.g., HLA-A*33:03), preferably HLA-A*24 (e.g., HLA-A*24:02) and HLA-A*33 (e.g., HLA-A*33:
03.
40. The nucleic acid construct of any one of claims 34 to 38, wherein the at least two human HLA class I alleles comprise one or more HLA-A class I alleles selected from the group consisting of HLA-A*24 (e.g., HLA-A*24:02), HLA-A*02 (e.g., HLA-A*02:01), HLA-A*11 (e.g., HLA-A*11:01), and HLA-A*31 (e.g., HLA-A*31:01), preferably HLA-A*24 (e.g., HLA-A*24:02) and HLA-A*31 (e.g., HLA-A*31:01).
41. The nucleic acid construct of any one of claims 34 to 38, wherein the at least two human HLA class I alleles comprise one or more HLA-A class I alleles selected from the group consisting of HLA-A*01 (e.g., HLA-A*01:01), HLA-A*11 (e.g., HLA-A*11:01), and HLA-A*24 (e.g., HLA-A*24:02), preferably HLA-A*01 (e.g., HLA-A*01:01) and HLA-A*24 (e.g., HLA-A*24:02).
42. The nucleic acid construct of any one of claims 34 to 38, wherein the at least two HLA-A class I alleles are selected from a human HLA allele group consisting of: HLA-A*03 (e.g., HLA-A*03:01), HLA-A*11 (e.g., HLA-A*11:01), HLA-A*01 (e.g., HLA-A*01:01), HLA-A*26 (e.g., HLA-A*26:01), HLA-A*24 (e.g., HLA-A*24:02), HLA-A*32 (e.g., HLA-A*32:01) and HLA-A*02 (e.g., HLA-A*02:01), preferably, the at least three HLA-A class I alleles are selected from a human HLA allele group consisting of: HLA-A*03, HLA-A*11 and HLA-A*02.
43. The nucleic acid construct of any one of claims 34 to 42, wherein the at least two HLA class I alleles comprise one or more HLA-B class I alleles selected from the group consisting of HLA-B*07 (e.g., HLA-B*07:02), HLA-B*15 (e.g., HLA-B*15:01), HLA-B*58 (e.g., HLA-B*58:01), HLA-B*40 (e.g., HLA-B*40:01), HLA-B*35 (e.g., HLA-B*35:01) and HLA-B*08 (e.g., HLA-B*08:01), preferably, the at least two HLA-B I class alleles are selected from the group of human HLA alleles consisting of HLA-B*07 and HLA-B*15.
44. The nucleic acid construct of any one of claims 34 to 42, wherein the at least two HLA class I alleles comprise one or more HLA-B class I alleles selected from the group consisting of HLA-B*40 (e.g., HLA-B*40:01), HLA-B*46 (e.g., HLA-B*46:01), HLA-B*58 (e.g., HLA-B*58:01), and HLA-B*15 (e.g., HLA-B*15:02), preferably HLA-B*40 (e.g., HLA-B*40:01) and HLA-B*46 (e.g., HLA-B*46:01).
45. The nucleic acid construct of any one of claims 34 to 42, wherein the at least two HLA class I alleles comprise one or more HLA-B class I alleles selected from the group consisting of HLA-B*52 (e.g., HLA-B*52:01), HLA-B*51 (e.g., HLA-B*51:01), HLA-B*35 (e.g., HLA-B*35:01), HLA-B*15 (e.g., HLA-B*15:01), and HLA-B*40 (e.g., HLA-B*40:02), preferably HLA-B*52 (e.g., HLA-B*52:01) and HLA-B*51 (e.g., HLA-B*51:01).
46. The nucleic acid construct of any one of claims 34 to 42, wherein the at least two HLA class I alleles comprise one or more HLA-B class I alleles selected from the group consisting of HLA-B*40 (e.g., HLA-B*40:06), HLA-B*51 (e.g., HLA-B*51:01), HLA-B*52 (e.g., HLA-B*52:01), and HLA-B*44 (e.g., HLA-B*44:03), preferably HLA-B*40 (e.g., HLA-B*40:06) and HLA-B*51 (e.g., HLA-B*51:01).
47. The nucleic acid construct of any one of claims 34 to 42, wherein the at least two HLA-B class I alleles are selected from the human HLA allele group consisting of: HLA-B*07 (e.g., HLA-B*07:02), HLA-B*15 (e.g., HLA-B*15:01), HLA-B*58 (e.g., HLA-B*58:01), HLA-B*40 (e.g., HLA-B*40:01), HLA-B*35 (e.g., HLA-B*35:01) and HLA-B*08 (e.g., HLA-B*08:01), preferably, the two HLA-B class I alleles are selected from HLA-B*07 and HLA-B*15.
48. The nucleic acid construct of any one of claims 34 to 47, wherein the at least two HLA class I alleles comprise one or more HLA-C class I alleles selected from the group consisting of HLA-C*04 (e.g., HLA-C*04:01), HLA-C*07 (e.g., HLA-C*07:02), HLA-C*16 (e.g., HLA-C*16:01), HLA-C*03 (e.g., HLA-C*03:04), HLA-C*07 (e.g., HLA-C*07:01) and HLA-C*06 (e.g., HLA-C*06:02), preferably, the two HLA-C class I alleles are selected from the group of human HLA alleles consisting of HLA-C*04 and HLA-C*07.
49. The nucleic acid construct of any one of claims 34 to 47, wherein the at least two HLA class I alleles comprise one or more HLA-C class I alleles selected from the group consisting of HLA-C*07 (e.g., HLA-C*07:02), HLA-C*01 (e.g., HLA-C*01:02), and HLA-C*03 (e.g., HLA-C*03:04), preferably HLA-C*01 (e.g., HLA-C*01:02) and HLA-C*03 (e.g., HLA-C*03:04).
50. The nucleic acid construct of any one of claims 34 to 47, wherein the at least two HLA class I alleles comprise one or more HLA-C class I alleles selected from the group consisting of HLA-C*01 (e.g., HLA-C*01:02), HLA-C*03 (e.g., HLA-C*03:03) and HLA-C*03 (e.g., HLA-C*03:04), preferably HLA-C*01 (e.g., HLA-C*01:02) and HLA-C*03 (e.g., HLA-C*03:03).
51. The nucleic acid construct of any one of claims 34 to 47, wherein the at least two HLA class I alleles comprise one or more HLA-C class I alleles selected from the group consisting of HLA-C*06 (e.g., HLA-C*06:02), HLA-C*04 (e.g., HLA-C*04:01), HLA-C*07 (e.g., HLA-C*07:02), and HLA-C*15 (e.g., HLA-C*15:02), preferably HLA-C*06 (e.g., HLA-C*06:02) and HLA-C*15 (e.g., HLA-C*15:02).
52. The nucleic acid construct of any one of claims 34 to 47, wherein the at least two HLA-C class I alleles are selected from a human HLA allele group consisting of: HLA-C*04 (e.g., HLA-C*04:01), HLA-C*07 (e.g., HLA-C*07:02), HLA-C*16 (e.g., HLA-C*16:01), HLA-C*03 (e.g., HLA-C*03:04), HLA-C*07 (e.g., HLA-C*07:01) and HLA-C*06 (e.g., HLA-C*06:02), preferably, the at least two HLA-C class I alleles are selected from a human HLA allele group consisting of: HLA-C*04 and HLA-C*07.
53. The nucleic acid construct of any one of claims 34 to 52, wherein the mammal comprises seven human leukocyte antigen (HLA) class I alleles in its genome, wherein the seven human HLAs are selected from a human HLA allele group comprising or consisting of: a) HLA-A*03, b) HLA-A*11, c) HLA-B*07, d) HLA-B*15, e) HLA-C*04, f) HLA-C*07 and g) HLA-A*02.
54. The nucleic acid construct of any one of claims 34 to 53, wherein the seven human HLA alleles comprise or consist of: a) HLA-A*03:01, b) HLA-A*11:01, c) HLA-B*07:02, d) HLA-B*15:01, e) HLA-C*04:01, f) HLA-C*07:02 and g) HLA-A*02:
01.
55. The nucleic acid construct of any one of claims 34 to 54, wherein the HLA allele encodes a chimeric human / non-human mammal MHC molecule.
56. The nucleic acid construct of any one of claims 34 to 55, wherein the at least two HLA alleles encode a chimeric human / non-human mammal MHC I polypeptide, wherein the human portion of the chimeric polypeptide comprises the α1 and α2 domains of a human MHC I polypeptide, and wherein the non-human mammal portion of the chimeric polypeptide comprises the α3 domain, transmembrane and cytoplasmic domains of an endogenous non-human mammal MHC I polypeptide.
57. The nucleic acid construct of any one of claims 34 to 56, wherein the at least two HLA alleles encode a chimeric human / non-human MHC I polypeptide, wherein the human portion of the chimeric polypeptide comprises the α1, α2, and α3 domains of a human MHC I polypeptide, and wherein the non-human mammal portion of the chimeric polypeptide comprises the transmembrane and cytoplasmic domains of an endogenous non-human mammal MHC I polypeptide.
58. The nucleic acid construct according to any one of claims 34 to 57, wherein each of the at least two HLA alleles is encoded as a monocistronic, preferably, each of the at least three HLA alleles encoded as a monocistronic is selected from the group of human HLA alleles comprising or consisting of: a) HLA-A*03, b) HLA-A*11, c) HLA-B*07, d) HLA-B*15, e)HLA-C*04 and f)HLA-C*07.
59. The nucleic acid construct according to any one of claims 34 to 58, wherein each HLA allele is equipped with its endogenous own H-2Db promoter and polyadenylation signal, preferably, the at least two HLA alleles are selected from the group of human HLA alleles comprising or consisting of: a) HLA-A*03, b) HLA-A*11, c) HLA-B*07, d) HLA-B*15, e)HLA-C*04 and f)HLA-C*07.
60. The nucleic acid construct of any one of claims 34 to 59, wherein the endogenous self H-2Db promoter is a MHC H-2 type I promoter (eg, having or comprising SEQ ID NO: 227).
61. The nucleic acid construct of any one of claims 34 to 60, wherein the polyadenylation signal (pA) is a bovine growth hormone (bGH) polyadenylation signal (e.g. having or comprising SEQ ID NO: 228), preferably, the at least two HLA alleles are selected from the group of human HLA alleles comprising or consisting of: a) HLA-A*03, b) HLA-A*11, c) HLA-B*07, d) HLA-B*15, e)HLA-C*04 and f)HLA-C*07.
62. A nucleic acid construct according to any one of claims 34 to 62, wherein the nucleic acid construct encodes a 2A peptide linker (e.g., having or comprising SEQ ID NO: 229), such that the encoded at least two human MHC class I molecules are separated by a 2A peptide linker, preferably, the at least two HLA alleles are two or more selected from the following: a) HLA-A*03, b) HLA-A*11, c) HLA-B*07, d) HLA-B*15, e)HLA-C*04 and f)HLA-C*07.
63. according to the nucleic acid construct described in any one in claim 34 to 62, described nucleic acid construct further encodes leader sequence (for example having or comprising SEQ ID NO:230).
64. according to the nucleic acid construct described in any one in claim 34 to 63, wherein said nucleic acid construct is according to any one in Fig. 1 to Figure 22 disclosed herein (for example, described nucleic acid construct is ITR-flank, for example, with 5'-PiggyBac-ITR flank, for example, has or comprises SEQ ID NO:231, and with 3'-PiggyBac-ITR flank, for example, has or comprises SEQ ID NO:232).
65. The nucleic acid construct of any one of claims 34 to 64, wherein the leader sequence is a human β2-microglobulin (β2m) leader sequence (eg, having or comprising SEQ ID NO: 233).
66. according to the nucleic acid construct described in any one in claim 34 to 65, wherein said nucleic acid construct is codon optimized for expression in described non-human mammal.
67. An expression vector comprising the nucleic acid construct according to any one of claims 34 to 66.
68. A host cell (e.g., a recombinant and / or isolated and / or non-human host cell) comprising a nucleic acid construct according to any one of claims 34 to 66 and / or an expression vector according to claim 67.
69. A method for modifying an endogenous HLA allele of a non-human mammal, the method comprising: The non-human mammal is transduced and / or transplanted with the nucleic acid construct according to any one of claims 34 to 66 and / or the expression vector according to claim 67.
70. The method of claim 69, wherein transduction is performed by pronuclear microinjection.
71. A method for producing a non-human mammalian oocyte carrying a modified target sequence in its genome (e.g., by transposon-mediated targeting, e.g., as described in the experimental section of this document), the method comprising the step of introducing a nucleic acid construct according to any one of claims 34 to 66 (e.g., an ITR-flanked targeting vector (e.g., a cassette carrying HLA)) and / or an expression vector according to claim 67 into a non-human mammalian oocyte.
72. according to the described method of claim 71, wherein will be injected into the nucleus / pronucleus of described oocyte or be introduced into described oocyte by electroporation according to the nucleic acid construct described in any one in claim 34 to 66 and / or the expression vector described in claim 67.
73. A method of producing a non-human mammal carrying a modified target sequence in its genome, the method comprising: (a) producing an oocyte as described in any one of claims 71 or 72; (b) analyzing the presence of the modification in offspring born by a non-human female host to which the oocyte obtained in (a) has been transferred.
74. The method of any one of claims 71 to 73, wherein the method comprises a transposon-mediated targeting step.
75. The method of any one of claims 71 to 74, wherein the non-human mammal is selected from the group consisting of a rodent, a dog, a cat, a primate, a rabbit, a pig, and a ruminant.
76. The method of claim 75, wherein the rodent is a mouse or a rat.
77. A non-human mammal produced and / or modified by a method according to any one of claims 71 to 76.
78. A method of producing one or more T cell receptors capable of binding a target antigen, the method comprising administering the target antigen to a non-human animal as defined in any one of claims 1 to 33 or claim 77.
79. The method of claim 78, wherein the target antigen is a full-length polypeptide or a fragment of the full-length polypeptide.
80. The method of any one of claims 78 to 79, wherein the antigen is a tumor-specific antigen (TSA) or a tumor-associated antigen.
81. The method of any one of claims 78 to 80, further comprising isolating T cells that bind the target antigen from cells of the non-human animal.
82. The method of any one of claims 78 to 81, further comprising isolating a nucleic acid encoding the T cell receptor that binds the target antigen from a cell of the non-human animal.
83. The method of any one of claims 78 to 82, wherein the T cell receptor is a human T cell receptor.
84. A T cell receptor obtained or obtainable by a method according to any one of claims 78 to 73.
85. A method of identifying an epitope capable of eliciting an immune response, the method comprising administering to a non-human animal as defined in any one of claims 1 to 33 or claim 76 a target antigen suspected of containing an epitope capable of eliciting an immune response.
86. The method of claim 85, wherein the target antigen is a full-length polypeptide or a fragment of the full-length polypeptide.
87. The method of claim 86, wherein the epitope is selected from a tumor-specific epitope, a viral epitope, a neoantigen epitope, and a human self epitope.
88. The method of any one of claims 85 to 87, further comprising isolating T cells that bind the target antigen from cells of the non-human animal.
89. The method of any one of claims 85 to 88, further comprising isolating a nucleic acid encoding the T cell receptor that binds the target antigen from a cell of the non-human animal.
90. The method of any one of claims 85 to 89, further comprising recombinantly producing the T cell receptor and determining the epitope to which the T cell receptor binds.
91. The method of any one of claims 85 to 90, wherein the method is an unbiased epitope discovery method.
92. The method of any one of claims 85 to 91, wherein the epitope is an MHC I restricted epitope.
93. An epitope for identifying an epitope capable of eliciting an immune response, the epitope being identified or identifiable by the method according to any one of claims 85 to 92, preferably the epitope is the MAGE-A1 epitope GTLEEVPTA (SEQ ID NO: 200).
94. Use of a non-human animal according to any one of claims 1 to 33 or claim 77 for producing one or more T cell receptors capable of binding an antigen of interest.
95. Use of a non-human animal according to any one of claims 1 to 33 or claim 77 for identifying one or more T cell receptors capable of binding an antigen of interest.
96. The use according to claim 94 or 95, wherein the antigen is selected from tumor-specific antigens, viral antigens, new antigenic epitopes and human autoantigens.
97. Use of a non-human animal according to claims 1 to 33 or claim 77 for identifying epitopes capable of eliciting an immune response thereto.
Citation Information
Patent Citations
Tumor specific t-cell receptors
CN104853765A
HLA Class I Expressing Non-Human Animal
CN105578876A
Humanized t cell mediated immune responses in non-human animals
CN107666828A
Transgenic animal expressing hla-a24 and utilization thereof
US20050050580A1
Mouse model for autoimmune disorders
US20060156419A1
